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Zusammenfassung 
 
Abstract 
This thesis deals with the functionalization of pentahalogenated pyridines and 
dihalogenated quinolines through palladium catalyzed cross coupling reactions. This 
includes the synthesis, chemo-selective arylation and alkynylation of 4-bromo-2,3,5-
trichloro-6-iodopyridine using Suzuki-Miyaura and Sonogashira reactions. Synthesized 
pentaalkynylated pyridines show strong fluorescence and were consequently analysed 
by UV/Vis- and fluorescence spectroscopy.   
The chemo-selective arylation of 4,6-dihalogenated-2-(trifluoromethyl) quinoline by 
Suzuki-Miyaura reaction was studied. Obtained derivatives were evaluated for their 
potential to inhibit ecto-5'-nucleotidase for both human and rat.  
Besides, the synthesis of indolo [2,3-c] quinolines was studied by sequential chemo-
selective Suzuki-Miyaura reaction followed by double C-N coupling starting from 3-
bromo-4-iodoquinoline.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Zusammenfassung 
 
Zusammenfassung 
Die vorliegende Arbeit beschäftigt sich mit der Funktionalisierung von 
pentahalogenierten Pyridinen und dihalogenierten Chinolinen mittels Palladium 
katalysierter Kupplungsreaktionen. Dabei wurde eine Synthesemethode für 4-Brom-
2,3,4-trichlor-6-iodpyridin entwickelt und diese Verbindung in chemoselektiven 
Arylierungen sowie Alkinylierung mittels Suzuki-Miyaura- bzw. Sonogashira- 
reaktionen eingesetzt. Die erhaltenden pentaalkinylierten Verbindugnen zeigen eine 
starke Fluoreszenz und wurden folglich mittels UV/Vis und Fluoreszenzspektroskopie 
näher untersucht.  
Weiterhin wurden chemoselektive Arylierungen an zweifach halogenierten 2-
(Trifluomethyl)-chinolinen durch Suzuki-Miyaura Reaktionen untersucht. Diese 
Verbindungen wurden zusätzlich bezüglich ihrer Inhibierungsaktivität hinsichtlich ecto-
5‘-Nukleotidase untersucht.  
Eine Darstellung von Indol[2,3-c]chinolinen unter Anwendung chemoselective Suzuki-
Miyaura Reaktion und anschließender doppelte C-N Kupplung gelang ausgehend von 3-
Brom-4-iodchinolin und bildet den Abschluss dieser Arbeit.  
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1. Introduction 
The synthesis of new molecular entities is of special interest for the development of 
many areas of research ranging from materials science to biological or pharmaceutical 
science. Therefore, the development of more efficient and economical synthetic 
methods is a priority of organic chemistry today. In this sense it is increasingly 
important to decrease the number of synthetic steps, the quantity of starting materials 
required and the formation of side-products.1 Catalysis has proven to be very efficient 
for the development of reactions with high selectivity and high atom economy. 
Catalysis is a phenomenon known since ancient times. Nowadays it plays a fundamental 
role in the manufacture of the vast majority of chemicals used by our society. In 1835 
Berzelius recognized the effect of catalysts and was the first to propose the term 
catalysis. The first and still valid definition comes from Wilhelm Ostwald: "Catalysis is 
the acceleration of a slow chemical process by the presence of a foreign substance". 
Later he could specify it even more: "A catalyst is any substance that, without appearing 
in the final product of a chemical reaction, its speed changes".2 
Presently, most of industrial chemical processes are based on catalysis. The replacement 
of classical stoichiometric methodologies with cleaner catalytic alternatives is promoted 
by a growing environmental awareness to reduce a waste production. Even today, more 
than 90 % of the chemical products are based on at least one catalytic step. For example, 
most of modern petrochemical technologies are catalytic one-step processes with high 
atom utilization.3,4 
Cross-coupling reactions catalyzed by transition metals represent one of the most 
famous methodologies in modern organic chemistry and is becoming an indispensable 
tool for the synthetic organic chemist.5 In recent years the application of this 
methodologies in the synthesis of drugs or products with potential biological activity6 
and new materials7 is very common. 
To carry out this type of couplings, a broad spectrum of transition metals has been used, 
in which undoubtedly, palladium is one of the most used metals in recent years due to 
the high catalytic activity of the complexes formed by this metal. In addition, 
Palladium-catalyzed cross-couplings reactions allows the control of the region-
selectivity,8 chemo-selectivity9 and the possibility for multiple coupling reactions.10 
1. Introduction 
2 
 
Palladium catalysts offer a broad functional group tolerance, low toxicity and low 
sensitivity to air and moisture.11 
The great variety of reactions of coupling C-C and C-Het bonds catalyzed by palladium 
has caused that, in the last century, an enormous quantity of publications in international 
scientific journals has appeared. In 2010, the importance of these processes in all areas 
of science was rewarded with the Nobel Prize in Chemistry to three representative 
researchers in this field: Richard F. Heck, Ei-ichi Negishi and Akira Suzuki.12 
Until now, a wide range of palladium-catalyzed cross-coupling reactions for the 
formation of carbon-carbon bonds have been established. Figure 1 shows the most 
commonly utilized cross-couplings in organic synthesis. 
H
R1
R2
R3
+ R4 X
Cat.(Pd0Ln)
base
R4
R1
R2
R3
R4 = aryl, vinyl, benzyl
X = Cl, Br, I, OTf
Heck Reaction
R1 Sn(alkyl)3 + R
2 X
Cat.(Pd0Ln) R1 R2
Stille Reaction
R1 = alkyl, alkynyl, aryl, vinyl
R2 = alkynyl, acyl, aryl, benzyl, vinyl
X = Br, Cl, I, OP(=O)(OR)2, OTf
R1 B
OH
OH
+ R2 X
Cat.(Pd0Ln)
base
R1 R2
R1 = alkyl, alkynyl, aryl, vinyl
R2 = alkyl, alkynyl, aryl, benzyl, vinyl
X = Br, Cl, I, OP (=O)(OR)2OTf, OTs
Suzuki Reaction
R1 H + R2 X
Cat.(Pd0Ln)
Cat. CuX, base
R1 = alkyl, aryl, vinyl
R2 = aryl, benzyl, vinyl
X = Br, Cl, I, OTf
Sonogashira Reaction
R1 ZnX + R2 X
Cat.(Pd0Ln)
R1 R2
R1 = alkyl, alkynyl, aryl, vinyl
R2 = acyl, aryl, benzyl, vinyl
X = Br, Cl, I, OTf, OAc
Negishi Reaction
R2 X+NH2R1
Cat.(Pd0Ln)
base
H
N R2R1
R1 R2
Buchwald-Hartwig amination Reaction
R1 = alkyl, aryl, vinyl, benzy
R2 = aryl
X = I, OTf, Br, Cl
 
Figure 1. Prominent palladium-catalyzed cross-coupling reactions in organic 
synthesis.13, 14 
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Mechanistically, these reactions are very similar except for the Heck reaction. A general 
mechanism is shown in Figure 2.15 
Pd(II)
Pd(0)
R1 Pd(II) XR1 Pd(II) R2
R2MMX
R1 R2 R1X
 
Figure 2: General mechanism of the cross-coupling reaction 
Generally palladium-catalyzed coupling processes starts from a Pd(0) complex. 
However, as a source of palladium, Pd(0) or Pd(II) complexes can be used. The Pd(II) 
complexes are usually more stable than those of Pd(0). 
The active species of palladium(0) is formed in situ either by dissociation of ligands 
derived from a complex of Pd(0) or by reduction of a Pd(II) precursor. Historically, 
reduction has often been effected by phosphines such as PPh3 which generates the 
palladium(0) complex in addition to oxidized phosphorus by-products .16-20  Afterwards, 
the oxidative addition of the organic electrophile R1-X onto the Pd(0) can occur by 
different ways: associative bimolecular process (SN2 reaction), radicalic or Ionic.  
Due to the different strength of the C-X bond, iodides react faster than bromides, which 
in turn react faster than chlorides. Aryl fluorides are generally not reactive. In the case 
of aryl chlorides and -bromides, the oxidative addition is the rate limiting step. 
The resulting organopalladium(II) complex then reacts in the transmetallation step with 
an organometallic compound. The result is a diorganopalladium(II) complex. When 
highly reactive aryl halides (e.g. iodides) are used, transmetallation is rate-limiting. 
Subsequently, reductive elimination of the desired organic coupling product is produced 
and the palladium(0) catalyst is regenerated (reductive elimination). 
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1.1. Suzuki-Miyaura Reaction 
In 1979 N. Miyaura, A. Suzuki and co-worker were the first to describe a procedure 
about palladium-catalyzed cross-coupling reactions of aryl- or alkenyl halides or -
triflates in the presence of organoboranes, organoboronic acids as well as organoboronic 
esters (cf. Figure 1, 3).21 This popular method is universally known as Suzuki-Myaura 
reaction. In recent years, many papers and patents regarding the Suzuki-Myaura 
reaction were reported to improve site-selectivity, chemo-selectivity, low catalyst 
loading, expansion of substrates scope and applications of greener process-conditions 
(green solvent, low catalyst loading, recycling of catalyst, low temperature, minimizing 
side-products).22, 23 
Pd(0)
Ar1 Pd(II) XAr1 Pd(II) Ar2
Ar1 Pd(II) OH
Ar1X
OH
XAr2B(OH)2
B(OH)3
Ar1 Ar2
 
Figure 3. Possible reaction mechanism for Suzuki-Miyaura coupling 
1.2. Sonogashira Cross-Coupling Reactions 
The Sonogashira reaction was discovered in 1975 based on preliminary studies carried 
out independently by the groups of Cassar24, Heck25 and Sonogashira26. This reaction 
consists of a coupling of terminal alkynes with activated sp2-carbons (halides or 
pseudohalides), using a palladium catalyst and a copper(I) co-catalyst (cf. Figure 1). 
The mechanism of the Sonogashira reaction is based on a Cu/Pd transmetallation 
process in the presence of amines, consisting of two independent catalytic cycles. The 
cycle I contains typical oxidation addition, transmetallation and reductive elimination 
processes and cycle II results in the formation of the alkynyl copper reagent required for 
the transmetallation of cycle I (Figure 4). 
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Pd0L2
R1 Pd(II) XR1 Pd(II)
R1-X
R1
Pd0L4 or Pd2+ +2L
L
L
L
L
R2
Cu R2Cu+X-
R2H
R2H HX-amine
amine
Cycle II
Cycle I
A
B
CD
R2
Cu+X-  
Figure 4. Proposed mechanism for the Sonogashira reaction.27 
The efficiency of Sonogashira reactions are influenced by the steric and electronic 
effects of the employed alkyne and organic electrophile utilized as well as the bases, 
solvents and catalyst systems used. 
1.3. Buchwald-Hartwig amination reaction 
In 1994 the groups of Stephen L. Buchwald and John F. Hartwig independently 
developed the Buchwald-Hartwig amination reactions.28 This important reaction is 
based on the formation of C-N bonds by Pd-catalyzed cross-coupling of amines with 
aryl halides. The efficiency demonstrated by the Buchwald-Hartwig amination reactions 
in the synthesis of aryl amines, mainly replaced conventional methods such as the 
Goldberg reaction, nucleophilic aromatic substitution and reductive amination. 
After intensive studies with different ligand systems, different catalytic cycles for 
Buchwald-Hartwig reactions have been proposed. However, a catalytic cycle which has 
been recently suggested by Buchwald29 for dialkylbiaryl phosphines is depicted in 
1. Introduction 
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Figure 5. After the formation of the catalytic species Pd0Ln (n commonly = 2; 
sometimes n = 1; L = tertiary phosphines) follows an oxidative addition of the aryl 
halide to Pd0Ln and subsequent coordination of the amine to the resulting palladium(II) 
intermediate. Base deprotonates the amine and the arylamine product are formed by 
reductive elimination and the catalyst is regenerated.  
Pd0Ln
Base
Base*HX
Pd(0) or Pd(II)Precatalyst
PdIILn
X(Ar)PdIILn
N(H)(R)RI
PdIILn
ArN(R)RI
HN(R)RI
Oxidative
addition
Reductive
elimination
Amine
bindingDeprotontion
ArX
Ar
X
Ar
RI(R)N
 
Figure 5. Catalytic cycle for palladium-catalyzed amination 
It is important to point out that if amines possess -hydrogen atoms, the 
[PdLnAr((NCH2R)R
I)] complex may undergo a β-hydride elimination reaction to 
generate an imine as side-product (Figure 6). 
LnPd
N
RIH2C
R
ß-hydride elimination LnPd
H
NRI
R
H
+ LnPd +
RIN
R
 
Figure 6. β-hydride elimination in Buchwald-Hartwig amination. 
Pd(OAc)2 and Pd2(dba)3 are common precursors which have been used for Buchwald-
Hartwig reactions.  
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1.4. Purpose and scope of the present work  
Palladium-catalyzed cross-coupling reactions have a growing impact on the 
development of new pharmaceuticals and materials. The application of these methods 
for the selective functionalization of polyhalogenated nitrogen heterocycles is 
increasingly attractive to synthetic chemists. Although aryl chlorides have the advantage 
of being cheaper and more widely available than the corresponding bromides and 
iodides.30 These last ones, have the advantage of being much more reactive especially in 
Suzuki-Miyaura and Sonogashira reactions. Therefore, the presence of the different 
halogens in the same heterocycle makes selective reactions possible at specific positions 
with good yields. 
In this work, simple pentahalogenated pyridine precursors will be studied for use in 
chemo-selective functionalization through Suzuki-Miyaura and Sonogashira reactions. 
In addition, selective arylation of 4,6-dihalogenated-2- (trifluoromethyl) quinoline will 
be developed and tested for their biological activity against ecto-5'-nucleotidase 
enzymes. Finally, the synthesis of indolo[2,3-c]quinolines will be studied by sequential 
chemo-selective Suzuki-Miyaura reaction followed by double C-N coupling starting 
from 3-bromo-4-iodoquinoline. 
2. Synthesis of Functionalized Pyridines 
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2. Synthesis of Functionalized Pyridines by Chemoselective Suzuki-Miyaura and 
Sonogashira Reactions. 
2.1. Chemoselective Suzuki-Miyaura Reaction of 4-bromo-2,3,5-trichloro-6-
iodopyridine  
 
2.1.1. Introduction 
Pyridine was discovered in 1849 by the Scottish chemist Thomas Anderson as one of 
the constituents of bone oil.31 In the following years it was found to be a part of many 
compounds related to life, such as Nicotinic acid (Vitamin B3), Pyridoxine (Vitamin 
B6), and NAD, to mention a few examples.  
Pyridine derivatives are associated with diverse pharmacological properties such as 
antimicrobial,32, 33 anticancer,34 anticonvulsant,35 and anti-HlV36 activities. In the 
pharmaceutical industry, pyridine forms the nucleus of over 7000 existing drugs.37 
Naturally, such diversity in biological properties of pyridine derivatives attracted 
attention of synthetic and pharmaceutical chemists. In 2008 Eung-Seok Lee and co-
workers synthesized 2,6-diaryl-substituted pyridines by modified Kröhnke procedure, 
which showed moderate cytotoxicity against several human cancer cell lines.38 Four 
years later the same research group synthesized 2,4,6-triaryl –substituted pyridines 
which showed better cytotoxicity against several human cancer cell lines than the 
previous series of compounds mentioned above.39 Hence,  polysubstitution of pyridine 
could offer a range of compounds with potential high biological activity against cancer 
cells. 
N
N
S N S
NN
N
HO
OH
ClCl
2-(4-chlorophenyl)-4-(4-hydroxyphenyl)
-6-(phenyl)pyridine
2-(4-chlorophenyl)-4-(3-hydroxyphenyl)
-6-(pyridin-4-yl)pyridine
2-phenyl-6-(thiophen-2-yl)pyridine2-(pyridin-4-yl)-6-(thiophen-2-yl)pyridine
 
Figure 1. Arylated pyridines synthesized by the research group of Eung-Seok Lee with 
cytotoxicity against several human cancer cell lines. 
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Currently there is a wide variety of procedures that describe the synthesis of 
polyfunctionalized pyridines. Most of these are limited by the number of synthetic steps 
required. For example, despite being the first to synthesize the pentaarylpyridine with 
five different aryl groups, the procedure reported by Schmitt et al needed 13 steps to 
achieve the final product.40 Another factor that limits many of new methods reported is 
the low variability of functional groups introduced to the pyridine ring, as is the case of 
the procedures described by Yamaguchi and co-workers41,42 and Nishiwaki and co-
workers.43 
Site-selective Suzuki-Miyaura reactions of pentahalogenated pyridines provide a 
convenient method for the selective synthesis of highly functionalized pyridines, due to 
the broad range of functional groups and facile synthetic accessibility of boronic acids. 
In this sense, my research group has accumulated a great experience in synthesizing 
highly functionalized pyridines by site-selective Suzuki-Miyaura reaction, using 
polyhalogenated pyridine as starting materials.44 However, in case of 
pentachloropyridine electron density distribution of the pyridine core changed by 
introduction of arylrings in position 2 and 6, limiting the selectivity at position 4. 
Hence, selective arylation was impeded to access tri- and tetraarylated pyridines.  
All these results led me to think that 4-bromo-2,3,5-trichloro-6-iodopyridine is an 
interesting starting material to explore the chemoselectivity in Suzuki-Miyaura reaction. 
The presence of bromine and iodine atoms as better leaving groups than chlorine, 
allows changing the regioselectivity of the cross-coupling reaction at the pyridine 
nucleus as compared to pentachloropyridine. Therefore, 4-bromo-2,3,5-trichloro-6-
iodopyridine might guarantee a better selectivity, fundamentally at positions 6 and 4, 
giving rise to the formation of new molecules by the successive introduction of aryl 
substituents to the nucleus of the pyridine. 
2.1.2. Synthesis of 4-bromo-2,3,5-trichloro-6-iodopyridine 
For the synthesis of the novel starting material 4-bromo-2,3,5-trichloro-6-iodopyridine 3 
(Scheme 1), only 2 reaction steps are required, starting from commercially available 
2,3,5-trichloropyridine, adapting a procedure described by Bobbio et al..45 First, 
lithiation of 2,3,5-trichloropyridine occurred selectively at position 4. Further treatment 
with iodine produced 2,3,5-trichloro-4-iodopyridine 2 in 75% yield. In the second 
2. Synthesis of Functionalized Pyridines 
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reaction step, deprotonation of 2,3,5-trichloro-4-iodopyridine 2 was performed with the 
base lithium 2,2,6,6-tetramethylpiperidide (LiTMP). It is important to note that initially 
generated 6-lithiated species 2a instantaneously metamorphosed by migration of the 
heavy halogen to the less basic 4-lithiated isomer 2b. Finally lithiated species 2b was 
quenched by the addition of 1,2-dibromotetrachloroethane giving 4-bromo-2,3,5-
trichloro-6-iodopyridine 3 in 77 % yield.  
N
ClCl
Cl
I
N
ClCl
Cl
I
N
ClCl
Cl
Br
N
ClCl
Cl
Li
2
Li
3
I
I
2a
2b
ii
N
ClCl
Cl
i
1
N
ClCl
Cl
Li
1a
LiTMP
C2Br2Cl4
LDA
I2
 
Scheme 2. Synthesis of starting material 3. i: 1) 1(1.0 equiv.), LDA (1.0 equiv.), THF,  
-78 °C, 2 h; 2) I
2 
(1.2 equiv.), THF, -78 °C, 2 h. ii: 1) 2 (1.0 equiv.), LiTMP (1.0 equiv.), 
THF, -100 °C, 2 h; 2) C
2
Br
2
Cl
4
 (3.3 equiv.), THF, -78 °C, 2 h. 
 
Figure 2. Single crystal structure of compound 3. 
1H-NMR spectroscopic analysis allowed to observe that the only signal in the form of a 
singlet that previously appeared at 8.22 ppm for the proton belonging to compound 2, 
disappeared for new starting material 3. The analysis of the 13C-NMR and DEPT 
spectra allowed identifying that the carbon signal that appeared as CH at 144.3 ppm for 
compound 2, appeared in the starting material 3 as quaternary carbon at 138.9 ppm. The 
spectrum of GC/MS and HR-MS corroborated the presence of bromide as substituent 
2. Synthesis of Functionalized Pyridines 
11 
 
and later the structure of starting material 3 was confirmed by X-ray crystallographic 
analysis (Figure 2). IR and Elemental Analysis were also analyzed. 
2.1.3. Chemoselective monoarylation to position 6 
Having in hand 4-bromo-2,3,5-trichloro-6-iodopyridine 3 as a starting material, I started 
to search for suitable conditions for the monoarylation, using Pd(PPh3)4 (5 mol%) as a 
catalyst, K3PO4 (1.1 equiv) as base, phenylboronic acid (1.1 equiv.) in the presence of 
toluene as solvent at 100 °C for a period of 22 h. Although the desired compound 4a 
was obtained with only 40 % yield (Scheme 2, Table 1, entry 1), these conditions served 
as a reference for the optimization process. The best yield was obtained when the 
amount of arylboronic acid was increased to 1.5 equivalents and a solvent mixture of 
toluene, water and ethanol was employed (entry 3). It is noteworthy, that the use of a 
more active catalyst system based on Pd(OAc)2 and PCy3 led to the formation of 
corresponding diarylated pyridine, exclusively (entry 4). 
NI
Cl
Br
Cl
Cl i N
Cl
Br
Cl
Cl
3 4a
Ph-B(OH)2
 
Scheme 2. Optimization for the synthesis of 4a. Conditions: i, 3 (1.0 equiv.), 
PhB(OH)2, Pd -species, ligand, K3PO4 , solvent, 100 °C, 22 h. 
Table 1. Optimization for Synthesis of 4a. 
Entry Pd source  
(mol%) 
Ligand 
(mol%) 
Base  
(equiv.) 
Solvent PhB(OH)2 
(equiv.) 
4a  
(%)a 
1 Pd(PPh3)4 (5) - K3PO4 (1.1) Toluene 1.1 40 
2 Pd(PPh3)4 (5) - K3PO4 (1.5) Toluene 1.5 60 
3 Pd(PPh3)4 (5) - K3PO4 (1.5) Toluene/H2O/
EtOH (6:1:1) 
1.5 78 
4 Pd(OAc)2 (5)  PCy3 (10) K3PO4 (1.1) Toluene 1.1 - 
a Yield of isolated products. 
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Using optimized conditions a range of 4-bromo-2,3,5-trichloro-6-arylpyridines 4a-k 
was synthesized in 60 – 86 % yield (Scheme 3, Table 2). Electron donating as well as 
electron withdrawing groups resulted in high yields (products 4a-g, and 4i). However, 
reaction of arylboronic acids bearing a trifluoromethyl, cyano or chloro substituent led 
to a decrease in yield (products 4h, 4j and 4k). In all the cases, the reactions were 
developed with high selectivity at position 6, since a reaction at another position was 
not observed. 
Sterical hindrance by a methoxy group might have a negligible effect on the reaction 
outcome as emphasized by the synthesis of compounds 4c, 4e and 4i. In particular the 
highest yield was obtained for compound 4i, consisting of an ortho-methoxy group.  
NI
Cl
Br
Cl
Cl
3
NR
Cl
Br
Cl
Cl
4a-k
i
R-B(OH)2
 
Scheme 3. Synthesis of 4a-k. Reaction conditions i: 3 (1.0 equiv.), R-B(OH)2 (1.5 
equiv.), K3PO4 (1.5 equiv.), Pd(PPh3)4 (5 mol%), Toluene/EtOH/H2O (6:1:1), 22 h, 
100 °C. 
Table 1. Chemoselective synthesis of monoarylated pyridines 4a-k. 
Compound R 4 [%]a 
a C6H5 78 
b 4-MeC6H4 83 
c 4-(MeO)C6H4 73 
d 4-FC6H4 73 
e 3-(MeO)C6H4 77 
f 2-thienyl 81 
g 3-(NO2)C6H4 78 
h 4-CF3C6H4 60 
i 2-(MeO)C6H4 86 
j 4-(CN)C6H4 60 
k 4-ClC6H4 69 
a Yield of isolated products. 
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As expected, the monoarylation of 4-bromo-2,3,5-trichloro-6-iodopyridine 3, allowed to 
achieve singinificantly higher yields than coresponding homologs synthesized by Ehlers 
et al. using Pentachloropyridine as starting material.46 These excellent results are due to 
the fact that iodine in position 6 of the starting material 3 is a better leaving group than 
chlorine in pentachloropyridine. 
The structure of compounds 4k was independently confirmed by X-Ray diffraction 
analysis (Figure 3). The aryl group attached to the pyridine moiety of this compound is 
twisted out of plane and shows a torsion angle of 48.08° (N1-C5-C32-C33). 
4k
 
Figure 3: Single crystal structure of compound 4k, nitrogen atoms blue, chlorine atoms 
green and bromine atom brown. 
2.1.4. Chemoselective diarylation at positions 6 and 4.  
Knowing that in a previous investigation Reimann et al.44 employed 
pentachloropyridine as starting material and achieved selective diarylation at positions 2 
and 6 of the pyridine nucleus. I assumed that 4-bromo-2,3,5-trichloro-6-iodopyridine 3 
could also be an ideal substrate for chemoselective synthesis of 4,6-diarylpyridines 
(Scheme 4), giving access to regioisomeric 2,4-arylated pyridines. 
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Cl
Br
Cl
Cl N
Cl Cl
Cl
3 5a
Me
Me
i
4-TolB(OH)2
 
Scheme 4. Optimization for the synthesis of 5a. Conditions: i, 3 (1.0 equiv.), 4-
TolB(OH)2, Pd -species (5 mol%), ligand (10 mol%), K3PO4, toluene/water/n-butanol 
(6:1:1), T °C, time h. 
Table 2. Optimization for the synthesis of 5a. 
a Yield of isolated products 
In the previous study I have already recognized PCy3 might a good ligand for the 
diarylation of compound 3. Hence, for the optimization of this reaction I selected 
Pd(PPh3)4 and Pd(OAc)2/PCy3 as catalyst (table 3). As expected, the best conditions for 
this chemoselective diarylation was when Pd(OAc)2 (5 mol%) and PCy3  was employed 
in the presence of K3PO4 (2.1 equiv) as base, p-Tolylboronic acid (2.1 equiv), toluene / 
water / n-butanol as solvent mixture at 100 °C, for a period of 19 h (entry 5). Increase in 
temperature, time, amount of base or corresponding arylboronic acid did not improve 
the yield. 
Entry Pd source  
(mol%) 
Ligand 
(mol%) 
Base  
(equiv.) 
4-TolB(OH)2 
(equiv.) 
T 
(°C) 
time  
(h) 
5a  
(%)a 
1 Pd(PPh3)4 (5) - K3PO4 (2.5) 2.5 100 19 50 
2 Pd(PPh3)4 (5) - K3PO4 (2.5) 2.5 130 31 59 
3 Pd(PPh3)4 (5) - K3PO4 (3.0) 3.0 130 31 62 
4 Pd(OAc)2 (5)  PCy3 (10) K3PO4 (2.0) 2.0 100 19 75 
5 Pd(OAc)2 (5)  PCy3 (10) K3PO4 (2.1) 2.1 100 19 81 
6 Pd(OAc)2 (5)  PCy3 (10) K3PO4 (2.5) 2.5 100 19 67 
7 Pd(OAc)2 (5)  PCy3 (10) K3PO4 (3.0) 3.0 100 19 58 
8 Pd(OAc)2 (5)  PCy3 (10) K3PO4 (3.5) 3.5 100 19 38 
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The reaction of 3 with various arylboronic acids, using my optimized conditions (Table 
3, entry 5), afforded 2,3,5-trichloro-6,4-diarylpyridines 5a-h (Table 4) in moderate to 
very good yields (34-81 %). Compounds 5g and 5h were obtained in moderate yields, 
which can be explained by the formation of substantial amounts of triarylated side-
products using electron-poor arylboronic acids, which might electronically activate the 
monoarylated intermediate and diarylated products for further coupling. 
The presence of two methyl groups in meta position of the aryl ring in compound 5e is 
evidence that substituents in this position do not represent an impediment for this 
double coupling. 
NI
Cl
Br
Cl
Cl
3
NR
Cl
R
Cl
Cl
5a-h
i
R-B(OH)2
 
Scheme 5. Synthesis of 5a-h. Reaction conditions i: 3 (1.0 equiv.), R-B(OH)
2 
(2.1 
equiv.), K
3
PO
4 
(2.1 equiv.), Pd(OAc)
2 
(5 mol%), PCy3 (10 mol%), Toluene/nBuOH/H2O 
(6:1:1), 19 h, 100 °C. 
 
Table 3. Synthesis of 4,6-diarylated pyridines 5a-h. 
Compound R 5 [%]a 
a 4-MeC6H4  81 
b 4-ClC6H4 77 
c 4-(MeO)C6H4 54 
d 4-(CN)C6H4 66 
e 3,5-(Me)2C6H4 72 
f 4-EtC6H4 58 
g 3-ClC6H4 34 
h 4-CF3C6H4 35 
a Yield of isolated products 
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2.1.5. Chemoselective arylation at positions 6 and 4 in a two-step 
procedure 
For the chemoselective synthesis of the diarylated pyridines 6a-c (Scheme 6, table 5) 
having two different aryl substituents, the same conditions described for the 
monoarylation were used in each of the two required reaction steps. First, compound 4b 
(table 2) was synthesized, which was used for the next step by reaction with 1.5 
equivalents of the respective arylboronic acid. The yields of 6a-c are not affected by the 
nature of the substituents employed. However, separation problems from corresponding 
triarylated side products are mainly the reason for the moderate isolated yields. 
NR1
Cl
Br
Cl
Cl
4b
NR1
Cl
R2
Cl
Cl
6a-c
i
R2-B(OH)2
 
Scheme 6. Synthesis of 6a-c. Reaction conditions i: 4b (1.0 equiv.), R2-B(OH)2 (1.5 
equiv.), K3PO4 (1.5 equiv.), Pd(PPh3)4 (5 mol%), Toluene/nBuOH/H2O (6:1:1), 19 h, 
100 °C. 
Table 4. Synthesis of 4,6-diarylated pyridines 6a-c. 
Compound R1 R2 6 [%]
a 
a 4-MeC6H4  4-(CN)C6H4 50 
b 4-MeC6H4 3-(NO2)C6H4 55 
c 4-MeC6H4 3-(MeO)C6H4 48 
a Yield of isolated products 
2.1.6. Chemoselective triarylation at positions 6, 4 and 2 
The selective synthesis of triarylated pyridine 7 in a single reaction step, starting from 
starting material 3, was developed in the presence of Pd(OAc)2 using PCy3 or SPhos as 
a ligand, modifying the amount of 4-tolylboronic acid and the temperature in a solvent 
mixture consisting of toluene/water/n-butanol. Unfortunately, in spite of up to 100 % 
conversion of the starting material 3, I obtained an inseparable mixture by column 
chromatography of the expected 3,5-dichloro-2,4,6-triarylpyridine 7 and tetraarylated 3-
chloro-2,4,5,6-tetraarylpyridine 8 (Scheme 7, Table 6). The presence of both 
compounds in the mixture was confirmed by GC-MS analysis. 
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Scheme 7. Optimization for the synthesis of 7 (mixtures7+8): Conditions: i, 3 
(0.26 mmol), 4-TolB(OH)2, Pd -species (5 mol%), ligand (10 mol%), K3PO4 (3 equiv.), 
toluene/water/n-butanol (6:1:1), T °C, 19 h.  
Table 6. Optimization of triple coupling reaction (Mixtures 7/8) 
The conversion was determined from isolated amount of starting material after the 
reaction. 
2.1.7. Chemoselective triarylation at positions 6, 4 and 2 in a two-step 
procedure 
To overcome the separation problems presented in the previous section, I explored the 
possibility of achieving the synthesis of 2,4,6-triarylated pyridines 9 in a stepwise 
procedure, starting from synthesized product 5. To my delight, I obtained triarylated 
priridines 9a-d (Scheme 8, Table 7), starting from 5a, using Pd(PPh3)4 as catalyst in the 
presence of 1.2 equivalents of the respective arylboronic acids for 20 hours at 100 °C. 
The difficulties associated with the process of separation by column chromatography 
Entry Pd source 
(mol%) 
Ligands 
(mol%) 
4-TolB(OH)2 
(equiv.) 
T 
(°C)   
Conversion 
[%] 
1 Pd (OAc)2 (5) PCy3 (10) 2.5 100 91 
2 Pd (OAc)2 (5)  PCy3 (10) 3.0 100 95 
3 Pd (OAc)2 (5)  PCy3 (10) 3.5 100 99 
4 Pd (OAc)2 (5)  PCy3 (10) 4.0 100 100 
5 Pd (OAc)2 (5) PCy3 (10) 4.5 100 100 
6 Pd (OAc)2 (5)  SPhos (10) 3.2 100 100 
7 Pd (OAc)2 (5) SPhos (10) 3.0 100 100 
8 Pd (OAc)2 (5)  SPhos (10) 3.2 70 84 
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were the main reason of obtained moderate yields, independently from the substitution 
pattern of the employed arylboronic acid. 
NR1
Cl
R1
Cl
Cl
5a
NR1
Cl
R1
Cl
R2
9a-d
i
R2-B(OH)2
 
Scheme 8. Synthesis of 9a-d. Reaction conditions i: 5a (1.0 equiv.), R2-B(OH)2 
(1.2 equiv.), K
3
PO
4
 (1.2 equiv.), Pd(PPh
3
)
4
 (5 mol%), Toluene, 20 h, 100 °C. 
 
Table 7. Synthesis of triarylated pyridines 9a-d. 
Compound R1 R2 9 [%]
a 
a 4-MeC6H4  4-( MeO)C6H4 57 
b 4-MeC6H4 2-( MeO)C6H4 49 
c 4-MeC6H4 4-FC6H4 38 
d 4-MeC6H4 4-ClC6H4 50 
a Yield of isolated products 
2.1.8. Chemoselective triarylation at positions 6, 4 and 2 in a three-step 
procedure 
Encouraged by the successful synthesis of compounds 9a-d, I studied the synthesis of 
triarylated pyridines, starting from compound 6a. These triarylated pyridines 10a-c, 
composed of three different aryl substituents and were isolated in good yields ranging 
from 61-77 %. 
NR1
Cl
R2
Cl
Cl
6a
NR1
Cl
R2
Cl
R3
10a-c
i
R3-B(OH)2
 
Scheme 9. Synthesis of 10a-c. Reaction conditions i: 6a (1.0 equiv.), R3-B(OH)2 
(1.2 equiv.), K
3
PO
4
 (1.2 equiv.), Pd(PPh
3
)
4
 (5 mol%), Toluene, 20 h, 100 °C. 
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Table 8. Synthesis of triarylated pyridines 10a-c. 
Compound R1 R2 R
3
 10 [%]
a 
a 4-MeC6H4  4-(CN)C6H4 4-( MeO)C6H4 63 
b 4-MeC6H4 4-(CN)C6H4 4-ClC6H4 77 
c 4-MeC6H4 4-(CN)C6H4 4-CF3C6H4 61 
a Yield of isolated products 
2.1.9.  Chemoselective pentaarylation of 4-Bromo-2,3,5-trichloro-6-
iodopyridine 
Finally, with compounds 6, 9 and 10 in hand, I decided to study the synthesis of 
pentaarylpyridines, using the reaction conditions previously reported by my research 
group.46 The reaction of triarylated pyridine 9a with phenylboronic acid and 4-tert-
butylphenylboronic acid respectively, allowed the synthesis of 11a-b with very good 
yields (Scheme 10, table 9). 
NR1
R3
R1
R3
R2
11a-b
i
R3-B(OH)2
NR1
Cl
R1
Cl
R2
9a  
Scheme 10. Synthesis of 11a-b. Reaction conditions i: 9a (1.0 equiv.), R3-B(OH)2 (4.0 
equiv.), K
3
PO
4
 (4.0 equiv.), PdCl
2
(CH
3
CN)
2
 (5 mol%), SPhos (10 mol%), Toluene, 
20 h, 100 °C. 
 
Table 9. Synthesis of Pentaarylpyridines 11a,b 
Compound R1 R2 R
3
  11[%]
a 
a 4-MeC6H4  4-(MeO)C6H4 C6H5 99 
b 4-MeC6H4 4-(MeO)C6H4 4-tBuC6H4 80 
a Yield of isolated products 
The structure of compound 11a was independently confirmed by X-Ray diffraction 
analysis (Figure 4). The aryl groups attached to the pyridine moiety of this compound 
are twisted out of plane provoking a propeller-type orientation. The aryl substituent 
located in para position shows a torsion angle of 60.74° (C2-C3-C19-C24). The aryl 
moieties attached ortho or meta to the pyridine core are less twisted by 48.15° and 
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50.43° (N1-C1-C6-C11 and N1-C5-C32-C33) as well as 58.02° and 63.45° (C1-C2-
C13-C18 and C5-C4-C26-C27), respectively. 
 
Figure 4: Single crystal structure of compound 11a, oxygen atoms red, and nitrogen 
atoms blue. 
Likewise, pentaarylpyridines 12a and 12b constituting of three different aryl 
substituents were synthesized with good yields starting from product 6a (Scheme 11, 
Table 10). 
NR1
Cl
R2
Cl
Cl
6a
NR1
R3
R2
R3
R3
12a-b
i
R3-B(OH)2
 
Scheme 11. Synthesis of 12a-b. Reaction conditions i: 6a (1.0 equiv.), R3-B(OH)2 
(6.0 equiv.), K
3
PO
4
 (6.0 equiv.), PdCl
2
(CH
3
CN)
2
 (5 mol%), SPhos (10 mol%), Toluene, 
20 h, 100 °C. 
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Table 10. Synthesis of Pentaarylpyridines 12a-b  
Compound R1 R2 R
3
 12 [%]
a 
a 4-MeC6H4 4-(CN)C6H4 4-(MeO)C6H4 93 
b 4-MeC6H4 4-(CN)C6H4 4-tBuC6H4 75 
a Yield of isolated products 
 
Finally, pyridines 13a and 13b, which consist of four different aryl substituents, were 
obtained by arylation of positions 3 and 5 from compounds 10a and 10b, respectively 
(Scheme 12, Table 11). The moderate yield of product 13b may be due to the formation 
of secondary products by reaction of the arylboronic acid with the arylchloride moiety 
in position 2 of the starting material 10b.  
NR1
Cl
R2
Cl
R3
10a, 10b
NR1
R4
R2
R4
R3
13a-b
i
R4-B(OH)2
 
Scheme 12. Synthesis of 13a-b. Reaction conditions i: 10a or 10b (1.0 equiv.), R4-
B(OH)2 (4.5 equiv.), K3PO4 (4.5 equiv.), PdCl2(CH3CN)2 (5 mol%), SPhos (10 mol%), 
Toluene, 20 h, 100 °C. 
 
Table 11. Synthesis of Pentaarylpyridines 13a-b. 
Compound R1 R2 R
3
 R
4
 13 [%]
a 
a 4-MeC6H4 4-(CN)C6H4 4-(MeO)C6H4 C6H5 90 
b 4-MeC6H4 4-(CN)C6H4 4-ClC6H4 4-(MeO)C6H4 50 
a Yield of isolated products 
2.1.10.  Conclusion 
In conclusion, I was able to synthesize novel 4-bromo-2,3,5-trichloro-6-iodopyridine 3 
as starting material, which allowed the development of an efficient method for the 
synthesis of aryl-substituted pyridines, using Suzuki-Miyaura reactions. The 
pentaarylpyridines were synthesized in very good yields by this methodology and shows 
very good functional group tolerance.  
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2.2. Chemoselective Sonogashira reactions of 4-bromo-2,3,5-trichloro-6-
iodopyridine 
2.2.1. Introduction 
The Sonogashira reaction has become one of the most important and widely used 
methods for preparing alkyl and arylacetylenes due to their relatively simple 
implementation and good tolerance to functional groups.47,48 This reaction have been 
part of key steps towards the synthesis of a wide variety of natural products such as the 
synthesis of Terbinafine,49  as an antifungal medication and the chemoselective 
synthesis of Altinicline,50 a medication for the treatment of Parkinson's disease (figure 
5). 
 
NCl
I N
Me
Pd(PPh3)2Cl2 , CuI
Et3N, TIPS-acetyene, 15h
                  99%
NCl
N
Me
TIPS
Zn, AcOH
75 0C, 18h N
N
Me
TIPS
TBAF, THF, rt
N
N
Me
Altinicline  
Figure 5. Synthesis of Altinicline 
The synthesis of polyalkynylated compounds such as polyalkynylated derivatives of 
thiophenes,51 pyrroles,52 cyclobutadienes,53 ferrocenes54 and pyrimidines,55 has gained a 
lot of research interests, due to their particular optical and electronic properties. 
The synthesis of polyalkynylated pyridines has been an objective of special interest in 
my research group studying the synthesis of pentaalkynylpyridines56 using 
pentachloropyridine as starting material, as well as the synthesis of 2,3,5,6–
tetraalkynylpyridines57 from 2,3,5,6-tetrachloropyridine. Despite the fact that electron 
deficient positions 2, 4 and 6 of pentachloropyridine ought to show a higher reactivity 
than positions 3 and 5, a site-selective Sonogashira reaction has not been possible, 
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because the nucleus of pyridine is significantly activated by introducing alkynyl 
substituents, facilitating further Sonogashira coupling reactions. 
It can be expected that use of 4-bromo-2,3,5-trichloro-6-iodopyridine as starting 
material, allows the successive introduction of alkynyl substituents through 
chemoselective Sonogashira reactions, giving rise to new molecules with good emission 
properties including high quantum yields. 
2.2.2. Chemoselective monoalkynylation at position 6 
In order to find suitable conditions, for selective monoalkynylation on 4-bromo-2,3,5-
trichloro-6-iodopyridine 3 by Sonogashira cross coupling reactions, I firstly studied the 
reaction using standard condition (PdCl2(PPh3)2 5 mol%, CuI (5 mol%) in NEt3 with 1.1 
equiv. of Phenylacetylene at room temperature).TLC analysis verified a significant part 
of starting material had been converted into a new product after 4 hours. After 19 hours 
had elapsed, the starting material was converted almost quantitatively and the desired 
product 14a was isolated in 90 % yield and high chemoselectivity. As product 14a was 
obtained in high yield and excellent chemoselectivity, I started to analyze the feasibility 
of these reaction conditions using various acetylenes (Scheme 13, Table 12). The best 
yields were obtained when arylalkynes with electron-donating groups were used (14a-
c), while electron withdrawing groups led to diminished yields. 
NI
Cl
Br
Cl
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3 14a-h
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Scheme 13. Synthesis of 14a-h. Reaction Conditions i: 3 (1.0 equiv.), acetylene 
(1.1 equiv.), Pd(PPh
3
)
2
Cl2 (5 mol%), CuI (5 mol%), NEt3, rt., 19 h. 
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Table 12. Synthesis of 14a-h 
Compound R 14 [%]a 
a C6H5  90 
b 4-tBuC6H4 92 
c 4-(MeO)C6H4 86 
d 4-FC6H4 45 
e nPr 56 
f 3-Pyridyl 35 
g 4-nPrC6H4  73 
h Cyclopentyl 80 
a Yield of isolated products 
2.2.3. Chemoselective dialkynylation at positions 6 and 4 
In the following, the chemoselectivity of Sonogashira reactions of 4-bromo-2,3,5-
trichloro-6-iodopyridine 3 for a double Sonogashira coupling was studied. After some 
experimentation, using phenylacetylene as a model alkyne, it was found that best results 
were obtained using 1,4-dioxane as a solvent and diisopropylamine as a base at 80 °C 
for 20 h. in the presence of 5 mol% of Pd(PPh3)4 and 5 mol% of copper (I) iodide (entry 
1, Scheme 14, Table 13). 
It is important to note that when the reaction was carried out at lower temperatures, the 
yields decreased dramatically, giving substantial amounts of monoalkynylated coupling 
product. Similarly, the yield decreased, when HN(iPr)2 was exchanged by NEt3. 
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Scheme 14. Synthesis of 15a. Optimization. Conditions i: 3 (1.0 equiv.), 
phenylacetylene (2.1 equiv.), Pd(PPh
3
)
4 
(5 mol%),
 
CuI (5 mol%), 1,4-dioxane, Base, 
20 h. 
Table 13. Optimization for the synthesis of 15a 
Entry Temperature (°C) Base  15a [%]a 
1 80 HN(iPr)2  61 
2 40 HN(iPr)2      0
b 
3 60 HN(iPr)2 25 
4 70 HN(iPr)2 46 
5 80 NEt3 45 
a Yield of isolated products; bonly formation of coumpound 14a was observed. 
Using optimized conditions, the reaction of 3 with differently substituted alkynes 
afforded 2,3,5-trichloro-4,6-dialkynyl- pyridines 15a-e in 51-67 % yield and very good 
chemoselectivity. Obtained yields were not affected significantly by the nature of the 
substituents of employed arylacetylene (Scheme 15, Table 14). 
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Scheme 15. Synthesis of 15a-e. Reaction conditions: i, 3 (1.0 equiv.), acetylene 
(2.1 equiv.), Pd(PPh
3
)
4
 (5 mol%), CuI (5 mol%), HN(iPr)2, 1,4-dioxane, 80 °C, 20 h. 
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Table 14. Synthesis of 15a-e 
Compound R 15 [%]a 
a C6H5  61 
b 4-tBuC6H4 67 
c 4-(MeO)C6H4 51 
d 4-nPrC6H4 63 
e 4-FC6H4 54 
a Yield of isolated products 
2.2.4. Chemoselective trialkynylation at position 6, 4 and 2 
Encouraged by the results achieved during the synthesis of dialkynylated products 15, I 
decided to use the same conditions for chemoselective synthesis of 3,5-dichloro-2,4,6-
trialkynyl-substituted pyridines 16a-d, but logically employing increased amount of the 
alkyne. When 3.5 equivalents of phenylacetylene were used, the synthesis of 3,5-
dichloro-2,4,6-tris (phenylethynyl) pyridine 16a was achieved with a 55 % yield, but the 
formation of small quantities of additional side-products  perhaps  derived from tetra- 
and/or pentaalkynylation, were observed by TLC.  Thus in another attempt, I reduced 
the amount of phenylacetylene to 3.1 equivalents, achieving an improved yield of 60 % 
of the desired product. Using these developed conditions several trialkynylated 
pyridines were synthesized with yields in a range of 44-60 % with good 
chemoselectivity (Scheme 16, Table 15). 
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Scheme 16. Synthesis of 16a-d. Reaction conditions: i, 3 (1.0 equiv.), acetylene 
(3.1 equiv.), Pd(PPh
3
)
4
 (5 mol%), CuI (5 mol%), HN(iPr)2, 1,4-dioxane, 80 °C, 20 h. 
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Table 15. Synthesis of 16a-d 
Compound R 16 [%]a 
a C6H5  60 
b 4-FC6H4 44 
c 4-(MeO)C6H4 58 
d 4-MeC6H4 58 
a Yield of isolated products 
2.2.5. Chemoselective pentaalkynylation of 4-Bromo-2,3,5-trichloro-6-
iodopyridine 
For the synthesis of the pentaalkynyl pyridines 17a-c (Scheme 17, Table 16), which 
contain two different alkynyl substituents in their composition, 2,3,5-trichloro-4,6-bis 
(phenylethynyl)pyridine 15a was converted with 5.0 equivalents of three different 
acetylenes, under the conditions described by Ehlers et al.56 All desired products were 
obtained in high yields ranging from 84-96 %. 
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Scheme 17. Synthesis of 17a-c. Reaction conditions: i, 15a (1.0 equiv.), acetylene 
(5.0 equiv.), Pd(CH3CN)2Cl2 (5 mol%), CuI (5 mol%), XPhos (10 mol%), HN(iPr)2, 
1,4-dioxane, 80 °C, 18 h. 
Table 16. Synthesis of 17a-c 
Compound R1 R2 17 [%]
a 
a C6H5  4-(MeO)C6H4 94 
b C6H5 4-FC6H4 96 
c C6H5 4-tBuC6H4 84 
a Yield of isolated products 
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Finally, 3,5-dichloro-2,4,6-tris(phenylethynyl)pyridine 16a was used to obtain 
pentaalkynylpyridines 18a-c with very good yields (Scheme 18, Table 17).  
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Scheme 18. Synthesis of 18a-c. Reaction conditions: i, 16a (1.0 equiv.), acetylene 
(4.0 equiv.), Pd(CH3CN)2Cl2 (5 mol%), CuI (5 mol%), XPhos (10 mol%), HN(iPr)2, 
1,4-dioxane, 80 °C, 18 h. 
Table 17. Synthesis of 18a-c 
Compound R1 R2 18 [%]
a 
a C6H5  4-(MeO)C6H4 95 
b C6H5 4-FC6H4 97 
c C6H5 4-tBuC6H4 65 
a Yield of isolated products 
2.2.6. Absorption and Fluorescence Properties 
The 6 non-symmetrical pentaalkynylpyridines synthesizeds 17a-c and 18a-c were 
investigated by UV-VIS and fluorescence analysis in dichloromethane (Figure 6). Table 
18 summarizes the corresponding spectral data of all analyzed compounds. The UV-
VIS absorption spectra of the compounds exhibit four absorption bands around 324, 
344, 382, and 418 nm. The absorption band of the compounds 17a and 18a containing 
(4-methoxyphenyl)ethynyl substituents, are slightly red-shifted, presumably due to the 
positive mesomeric effect of the methoxy group. The compounds 17b and 18b, 
containing fluoride as electron withdrawing groups,  showed absorption bands shifted to 
shorter wavelengths. 
2. Synthesis of Functionalized Pyridines 
29 
 
 
Figure 6. Normalized absorption and emission spectra of compounds 17a-c and 18a-c 
measured in dichloromethane. 
The fluorescence spectra were measured in dichloromethane at an excitation wavelength 
of 370 nm. The fluorescence quantum yields were determined by comparison to the 
standard quinine hemisulfate salt monohydrate in H2SO4 (0.05M) which exhibits a 
fluorescence yield of 52 %.58 All emission spectra have their maximum around 440 nm. 
Derivatives 17a and 18a containing (4-methoxyphenyl)ethynyl substituents,  exhibits a 
slight red-shift of 456 and 451 nm respectively, while 18b, containing (4-
fluorophenyl)ethynyl substituents, showed the most blue-shifted emission 434 nm. All 
derivatives showed very good quantum yields, while compounds 17c and 18c which 
contain (4-tert-butylphenyl)ethynyl) as substituents, exhibited the highest quantum yield 
in 54,7 % and 54.6 % respectively. 
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Table 18. Absorption and emission spectroscopic data of 17a-c, 18a-c and PPEP. 
Comp. λ1abs 
(nm) 
log  
λ1abs 
λ2abs 
(nm) 
log  
λ2abs 
λ3abs 
(nm) 
log  
λ3abs 
λ4abs 
(nm) 
log  
λ4abs 
λem 
(nm) 
 
fluo  
(%) 
17a 335 4.85 353 4.88 390 4.67 425 4.34 456  49.2 
17b 324 4.88 336 4.93 375 4.52 409 4.15 434  53.4 
17c 327 4.93 344 5.00 382 4.66 418 4.27 442  54.7 
18a 319 4.79 350 4.90 382 4.70 420 4.31 451  49.8 
18b 324 4.84 336 4.89 375 4.49 413 4.09 434  48.2 
18c 322 4.83 343 4.94 382 4.58 416 4.17 440  54.6 
PPEP - - 338 5.04 376 4.66 421 4.15 477  55.0 
 
 
Figure 7. Comparison of normalized absorption and emission spectra of compounds 
18a-c with penta(phenylethynyl)pyridine PPEP. 
In order to analyze the impact of substituents in 3- and 5-position of the pyridine core 
on Absorption and Fluorescence properties, I compared the absorption and emission 
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spectra of synthesized non-symmetrical pentaalkynylpyridines 18a-c with already 
reported penta(phenylethynyl)pyridine PPEP (Figure 7).56 
The UV-Vis spectra showed a great similarity between the compared compounds, 
especially between PPEP and 18b. However, a great difference was observed betwen 
emission spectra of PPEP and pentaalkynylpyridines 18a-c. While the non-symmetrical 
pentaalkynylpyridines 18a-c exhibited emission bands around 440 nm, the compound 
PPEP exhibited a red-shifted band with maximum at 477 nm containing a shoulder at 
around 600 nm. However, determined quantum yields are in the same range.  
2.2.7. Conclusion 
Chemoselective Sonogashira reactions were successfully applied using 4-bromo-2,3,5-
trichloro-6-iodopyridine in order to synthesize polyalkynylated pyridines. For the first 
time, selective synthesis is achieved at position 6 for a simple coupling, in positions 4 
and 6 for double coupling and at positions 2,4,6 for triple coupling of pentahalogenated 
pyridines. In addition, pentaalkynyl pyridines with two different substituents around the 
pyridine nucleus were synthesized for the first time with very good yields. Furthermore, 
absorption and fluorescence properties of the non-symmetrical pentaalkynylpyridines 
17a-c and 18a-c were studied. All compounds exhibit very good quantum yields, 
similar to already reported penta(phenylethynyl)pyridine PPEP. 
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3. Functionalization of Dihalogenated Quinolines 
3.1. Chemoselective reactions of Suzuki-Miyaura on 4,6-dihalogenated-2-
(trifluoromethyl)quinoline 
3.1.1. Introduction 
Quinolines derivatives are an important class of heterocycles that exhibit a wide range 
of biological activities. The quinolines are found as structural key elements in various 
natural products, especially in alkaloids, and used for the construction of many synthetic 
compounds with diverse pharmacological properties,59, 60 such as antiasthmatic, anti-
inflammatory and antimalarial activity,61 anti-cancer62 and antibiotic activity.63 
2-Trifluoromethyl quinolines are important derivatives of quinolines, which constitute 
privileged scaffolds of many pharmaceutical products studied.64 For example, 
Mefloquine (Figure 8, A) is a commercialized antiprotozoal drug that is used in the 
treatment of malaria.65 Quinoline-based compound B (Figure 6), targets DNA 
topoisomerase IV, and DNA gyrase and can be used as antituberculosis agents.66  
 
N CF3
CF3
N
HH
HO
A (Mefloquine)
N CF3
CF3
O
O N O
O
B  
Figure 8. 2-(trifluromethyl) quinoline derivatives with important biological activity. 
Based on the wide spectrum biological activity of trifluoromethylated quinolines huge 
interest arouse by synthetic chemists  for new and efficient methods for the synthesis of 
such derivatives.67 For example; Uneyama et al. reported a one-pot synthesis of 2-
trifluoromethyl quinolines by rhodium(I)-catalyzed cyclization of N-aryl 
trifluoroacetimidoyl chlorides with alkynes.68a Wu and co-workers developed a 
copper(I)-catalyzed coupling reaction and subsequent cyclization to construct 4-
substituted 2-trifluoromethylated quinolines.68b  
Arylated quinoline derivatives are accessable through palladium-catalyzed cross-
coupling reactions, starting from respective halogenated pyridines.69, 70, 71  
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Recently, Professor Langer's research group reported the synthesis of 3,4,8-triarylated 
2-(Trifluoromethyl) quinolines through selective Suzuki-Miyaura cross-coupling 
reactions. These synthesized compounds showed potent activity as nucleotide 
pyrophosphatase (NPPs) inhibitors.72 Diarylation of 2-(trifluoromethyl) quinolines at 
positions 4 and 6 have not been described so far. The selective Suzuki-Miyaura reaction 
of 4,6-dihalogenated-2-(trifluoromethyl)quinoline allows access to novel quinolines 
derivatives that could have interesting biological activity, too. 
3.1.2. Synthesis of 4,6- dihalogenated-2-(trifluoromethyl)quinoline 
For the synthesis of 4,6-dibromo-2-(trifluoromethyl)quinoline 20a and 6-bromo-4-
chloro-2-(trifluoromethyl)quinoline 20b as starting materials, I followed a two-step 
reaction procedure described by M. Schlosser et al.73 In the first step, p-bromoaniline 
reacted with Ethyl-4,4,4-trifluoroacetoacetate affording 6-bromo-2-(trifluoromethyl) 
quinoline-4(1H)-one 19 in 78 % yield (Scheme 19). Intermediate 19 was then treated 
with phosphorus oxybromide or phosphorus oxychloride to obtain the corresponding 
4,6-dibromo-2-(trifluoromethyl)quinoline 20a and 6-bromo-4-chloro-2-
(trifluoromethyl) quinoline 20b in 80 % and 65 % yield, respectively. The first reaction 
step mentioned above corresponds to a modified mechanism of the Combes quinoline 
synthesis as shown in Scheme 20.74 
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20b  
Scheme 19. Synthesis path to 20a and 20b  
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Scheme 20. Combes synthesis for 6-bromo-2-(trifluoromethyl) quinolin-4(1H)-one 
First, a 1,2-condensation reaction between the β-ketone and the aniline gives a Schiff 
base under 2,3-dehydration. The reaction occurs preferentially on β-ketone, because it 
has a higher electrophilic character than β-ketoester, due to β-ketone is directly bonded 
to an electron withdrawing group as -CF3. This is followed by protonation of the ester, 
resulting in an electrophilic aromatic substitution. Concentrated sulfuric acid was used 
in the classic synthesis as the dehydrogenation reagent.75 However, polyphosphoric acid  
provide milder and more effective dehydrogenations and cyclizations.76  Finally, the 
carboxyl group is protonated, whereby a proton shift between the two vicinal hydroxyl 
groups can occur. It comes to the elimination of ethanol, which results in the formation 
of the quinoline-4-ol. By tautomerism, the enol rearranges into the preferred keto form. 
The starting material for the following syntheses was obtained by the reaction with the 
corresponding phosphorus oxyhalide (Scheme 19). 
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3.1.3. Suzuki-Miyaura reactions on 4,6-dibromo-2-(trifluoromethyl) 
quinoline 
3.1.3.1.  Diarylation on 4,6-dibromo-2-(trifluoromethyl)quinoline 
After the successful synthesis of 4,6-dibromo-2-(trifluoromethyl)quinoline 20a as 
starting material. I started the optimization process looking for the most suitable 
conditions to carry out the diarylation by twofold Suzuki-Miyaura reactions. Based on 
the experiences of our research group,77,78 I converted starting material 20a with 2.6 
equivalents of PhB(OH)2, in presence of 5 mol% of Pd(PPh3)4 as catalyst, 2.6 
equivalents of K3PO4 as base, using toluene as solvent at 100 °C for 8 hours. The 
desired product 21a was synthesized in moderate 56 % yield. The use of another 
catalyst system, comprised of Pd(OAc)2 (5 mol%)/P(Cy)3 (10 mol%) gave the increased 
yield of 78 % (Scheme 21, Table 19, entry 2). A change of base and solvent or 
reduction of the amount of the catalytic system did not give any benefit. 
N
Br
Br
CF3
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N CF3
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Ph-B(OH)2
 
Scheme 21. Optimization for the synthesis of 21a. Conditions: i, 20a (1.0 equiv.), 
PhB(OH)2 (2.6 equiv.), base (2.6 equiv.), Pd-source, ligand, Solvent, 100 °C, 8h. 
Table 19. Optimization for the synthesis of 21a. 
Entry Pd source  
(mol%) 
Ligand 
(mol%) 
Base 
 
Solvent 
(4 mL) 
21a [%]a 
1 Pd(PPh3)4 (5) - K3PO4 toluene 56 
2 Pd(OAc)2 (5) PCy3 (10) K3PO4 toluene 78 
3 Pd(OAc)2 (5) PCy3 (10) Cs2CO3 toluene 50 
4 Pd(OAc)2 (5) PCy3 (10) K3PO4 1,4-dioxane 46 
5 Pd(OAc)2 (2.5) PCy3 (5) K3PO4 toluene 71 
a Yield of isolated product. 
The reaction of 4,6-dibromo-2-(trifluoromethyl)quinoline 20a with different arylboronic 
acids, under optimized conditions, allowed the synthesis of nine different 4,6-diarylated 
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quinolines 21a-k in yields between 35 % - 88 % (table 20). In general, good yields were 
obtained for the compounds derived from electron rich and electron poor arylboronic 
acids. However, yields were not very good for the synthesis of 21c and 21i. The 
moderate yields of 21c can be explained by the formation of substantial amounts of 
side-products by further coupling on the C-Cl moiety of the aryl substituent. The 
sterically hindered 2,6-substituted- as well as 3-thienylboronic acid, did not react under 
these reaction conditions. 
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Scheme 22. Synthesis of 21a-j. Reaction conditions i: 20a (1.0 equiv.), R-B(OH)2 
(2.6 equiv.), K3PO4 (2.6 equiv.), Pd(OAc)2 (5 mol%), PCy3(10) (10 mol%), Toluene, 
8 h, 100 °C. 
Table 20. Synthesis of 4,6-diarylated quinolines 21a-k. 
Compound R 21 [%]a 
a C6H5 78 
b 4-MeC6H4 86 
c 4-ClC6H4 35 
d 4-(MeO)C6H4 59 
e 4-(CF3O)C6H4 77 
f 3-thienyl Traces 
g 3-FC6H4 47 
h 2-MeC6H4 73 
i 4-FC6H4 38 
j 4-CF3C6H4 88 
k 2,6-(Me)2C6H3 Traces 
a Yield of isolated products. 
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The structure of compounds 21a was independently confirmed by X-Ray diffraction 
analysis (Figure 9). The aryl groups attached to the 2-(trifluoromethyl)quinoline moiety 
of this compound are twisted out of plane. The aryl substituent located in position 4 
shows a torsion angle of 60.04° (C8-C7-C16-C21) and the aryl substituent located in 
position 6 is less twisted 38.34° (C5-C4-C10-C15). 
21a  
Figure 9. Single crystal structure of compound 21a 
3.1.3.2.  Site-Selective monoarylation on 4,6-dibromo-2-(trifluoromethyl) 
quinoline 
I envisioned that 20a might also be an ideal substrate for site selective arylation by 
Suzuki–Miyaura reactions. Despite testing different reaction conditions using only 1.0 
equivalent of the respective arylboronic acids. In all cases inseparable mixtures of both 
4- and 6-monoarylated isomers were isolated in ratios of 8:1 up 9:1, corroborated by 
19F-NMR and GC-MS analysis (Scheme 23, table 21). 
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Scheme 23. Site-selective synthesis of 22a-b. Conditions: i, 20a (1.0 equiv.), R-B(OH)2 
(1.0 equiv.), Pd-species (5 mol%), ligand (10 mol%), K3PO4 (2.6 equiv.), solvent, 8 h. 
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Table 21. Employed reaction conditions for the synthesis of 22a-b 
Entry R Solvent T [°C] Pd source  
(mol %) 
Ligand 
(mol %) 
22a-b 
[%]a 
1 C6H5 toluene 100 Pd(OAc)2 (5) PCy3 (10) 0 
2 C6H5 toluene 50 Pd(OAc)2 (5)  PCy3 (10) 0 
3 C6H5 toluene 100 Pd(PPh3)4 (5 ) - 46 
4 C6H5 toluene 50 Pd(PPh3)4 (5 ) - 17 
5 C6H5 toluene/H2O 100 Pd(PPh3)4 (5 ) - 56 
6 4-MeC6H4 toluene 100 Pd(PPh3)4 (5 ) - 49 
a In all cases the yields obtained were mixtures of monoarylated isomers. 
3.1.4. Suzuki-Miyaura reaction of 6-bromo-4-chloro-2-(trifluoromethyl) 
quinoline 
3.1.4.1.  Chemoselective monoarylation in position 6 
In order to overcome the inconvenience for the selective arylation of starting material 
20a. I decided to take advantage of the differences in reactivity of bromine as the better 
leaving group with respect to chlorine in Suzuki-Miyaura reactions. Hence, I studied the 
reactivity of 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 20b as new starting 
material in chemoselective Suzuki-Miyaura reactions. 
Initially, the reaction of 20b with 1.2 equivalents of 4-TolB(OH)2 as model arylboronic 
acid in the presence of 5 mol% of Pd(PPh3)4 as a catalyst, 2.6 equivalents of K3PO4 as a 
base and a mixture of toluene/water as solvent at 80 °C for 8 hours was studied and 
allowed the synthesis of the desired product 23a in 69 % yield. The yield was slightly 
improved to 72 %, when Pd(OAc)2 in the presence of PCy3 as a ligand was used as 
catalytic system (Scheme 24, table 22). 
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Scheme 24. Optimization for the synthesis of 23a. Reaction conditions i: 20b 
(1.0 equiv.), 4-TolB(OH)2 (1.2 equiv.), K3PO4 (2.6 equiv.), Pd-species (5 mol%), 
Toluene/H2O (4:1), 8 h, 80 °C. 
Table 22. Optimization for the chemoselective synthesis of 23a. 
Entry Pd source (mol %) Ligand (mol %) 9a [%]a 
1 Pd(PPh3)4 (5) - 69 
2 Pd(OAc)2 (5) PCy3 (10) 72 
a Yield of isolated products. 
Using the developed method I was able to isolate 6-arylated-4-chloroquinolines 23a-g 
in good yields (72 % - 55 %) and high chemoselectivity (Scheme 25, Table 23). 
Obtained yields were not affected significantly by the nature of the substituents of 
employed arylboronic acids. 
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Scheme 25. Synthesis of 23a-g. Reaction conditions i: 20b (1.0 equiv.), R-B(OH)2 
(1.2 equiv.), K3PO4 (2.6 equiv.), Pd(OAc)2 (5 mol%), PCy3 (10 mol%), Toluene/H2O 
(4:1), 8 h, 80 °C. 
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Table 23. Chemoselective synthesis of 23a-g 
Compound R 23 [%]a 
a 4-MeC6H4 72 
b 3-CF3C6H4 63 
c 4-(MeO)C6H4 66 
d 3,5-(Me)2C6H3 58 
e 2-MeC6H4  66 
f 3-FC6H4 55 
g 4-(EtO)C6H4 61 
a Yield of isolated products. 
3.1.4.2. Non-symmetrical diarylation on 6-bromo-4-chloro-2-
(trifluoromethyl) quinoline 
Motivated by the successful synthesis of 23a-g, I thought that 6-bromo-4-chloro-2-
(trifluoromethyl) quinoline 20b could be an ideal substrate for non-symmetrical 
diarylation. The one-pot two-step reaction of 20b with two different arylboronic acids 
was next studied. The reaction of 20b with 1.2 equivalents of an arylboronic acid for 8 
hours at 80 °C and subsequent addition of a second arylboronic acid (1.2 equiv.) for 
another 8 hours to 100 °C afforded the 2-(trifluoromethyl)-4,6-diarylquinolines 24a-g 
containing two different aryl groups in moderate to good yields (Scheme 26, Table 24 ). 
It is important to note that with this procedure (one-pot two-step reaction) the 
compound 24a was obtained in a good 62 % yield (Entry 1, Table 24). It is noteworthy, 
when the reaction was started from the pure compound 23a following the same 
conditions of the last step for the one-pot reaction, the yield of 24a was only 32 %. 
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Scheme 26. Synthesis of 24a-g. Reaction conditions i: 1) 20b (1.0 equiv.), R1-B(OH)2 
(1.2 equiv.), K3PO4 (2.6 equiv.), Pd(OAc)2 (5 mol%), PCy3 (10 mol%), Toluene/H2O 
(4:1), 8 h, 80 °C; 2) R2-B(OH)2 (1.2 equiv.), 100 °C, 8 h. 
Table 24. Non-symmetrical synthesis of 24a-g 
Compound R1 R
2
 24 [%]
a 
a 4-MeC6H4 4-(MeO)C6H4 62 
b 4-MeC6H4 4-(EtO)C6H4 59 
c 4-MeC6H4 4-CF3C6H4 57 
d 4-MeC6H4 4-ClC6H4 46 
e 4-(MeO)C6H4 4-MeC6H4 46 
f 4-(MeO)C6H4 4-CF3C6H4 46 
g 4-(MeO)C6H4 C6H5 56 
a Yield of isolated products. 
 
All products were characterized by 1H and 13C NMR spectroscopy, IR spectroscopy and 
mass spectrometry. Moreover, the structure of compounds 24c was independently 
confirmed by X-Ray diffraction analysis (Figure 10). The aryl groups attached to the 2-
(trifluoromethyl)quinoline of this compound are twisted out of plane. The aryl 
substituent located in position 4 shows a torsion angle of 52.00° (C8-C7-C17-C18). The 
aryl substituent located in position 6 is less twisted by 27.40° (C5-C4-C10-C15). 
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24c  
Figure 10. Single crystal structure of compound 24c 
3.1.5. Biological studies 
3.1.5.1. Ecto-nucleotidases (ecto-5′-nucleotidase) 
Ecto-nucleotidases are a family of nucleotide metabolizing enzymes that are expressed 
on the plasma membrane. Ecto-5′-nucleotidase (e5′NT), a membrane-bound 
glycoprotein, is a particular member of this group, which is responsible for the 
hydrolysis of extracellular mononucleotides, such as adenosine monophosphate (AMP) 
into adenosine.79 At the same time, the extracellular level of adenosine regulates the 
activation of adrenergic receptors stimulating different cell signaling pathways. This 
results in the control of various physiological functions, such as vasodilation, 
angiogenesis, as well as regulation of cell growth and differentiation.80-83 An abnormal 
expression of the e5′NT leads to malfunctions of these physiological processes.  
Interestingly an over-expression of e5′NT, which results in elevated levels of 
extracellular adenosine, has been found in various types of cancer.84 The high levels of 
adenosine has been correlated with tumor proliferation, metastasis and angiogenesis by 
the activation of adenosine receptors.85  For this reason selective inhibitors of e5'NT that 
reduce the hydrolysis of extracellular nucleotides and in this way the concentration of 
adenosine, could be promissory as a new therapeutic alternative against cancer. Various 
ADP analogs86 and some non-nucleotide derived inhibitors, such as sulphonamides, 
anthraquinones, polyoxometallates, methylxanthines and sulfonic acids, have been 
reported as inhibitors of e5'NT.87,88 Some quinolines derivatives have been shown 
potent activity as nucleotide pyrophosphatase (NPPs) inhibitors,72 a related enzymatic 
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family, and therefore could be promising structures for the synthesis of new inhibitors 
of e5'NT. 
3.1.5.2. Selective inhibition study of ecto-5'-nucleotidases (e5'NT) 
The studies were accomplished in the Centre for Advanced Drug Research, COMSATS 
Institute of Information Technology, Abbottabad, Pakistan, as a part of a cooperation 
project. 
All synthesized compounds (arylated-2- (trifluoromethyl) quinolines derivatives, 21a-j; 
23a-g and 24a-g) were studied for their potential to inhibit ecto-5'-nucleotidase, both 
human and rat source. Most derivatives showed selective inhibition on human ecto-5'-
nucleotidases (h-e5'NT) at 100µM (Table 25).  However, none of the derivatives was 
found to act as inhibitor of r-e5'NT at the same concentration. 
In the series of 4,6-diarylated quinolines 21a-j,  the compound 21d which contains  a 
methoxy group in position 4 of the aryl substituents was the most potent inhibitor of h-
e5'NT with an inhibitory value of IC50 ± SEM= 1.13±0.02 µM. The compound 21g, 
containing a 3-fluoroaryl substituent, also resulted in strong inhibition at h-e5'NT (IC50 
± SEM= 1.19±0.03µM). The compound 21h, possessing a ortho-tolyl groups, exhibited 
a lower inhibitory activity (IC50 ± SEM= 2.21±0.17 µM) as compared to 21d. In case of 
derivative 21a containing two phenyl rings, showed a reduced inhibitory response (IC50 
± SEM= 15.3±1.16 µM). Derivative 21e, possessing trifluoromethoxy group located at 
position 4 of the phenyl rings, showed no inhibitory activity on h-e5'NT. 
The bioactivity on 6-arylated-4-chloroquinolines 23a-g was also studied. The compound 
23f containing a 3-fluoroaryl substituent showed the best inhibition of h-e5'NT with 
IC50 ± SEM= 1.78±0.08 µM. Again, the presence of the methoxy group at position 4 of 
the aryl substituent (compound 23c), showed a good inhibition on h-e5'NT with IC50 ± 
SEM = 2.41 ± 0.11μM. However the presence of the ethoxy group at position 4 of the 
aryl substituent (derivative 23g), resulted in loss of the inhibitory effect, with IC50 ± 
SEM= 25.9±2.83 µM. Derivative 23a, possessing methyl group located at position 4 of 
the phenyl ring, showed no inhibitory activity on h-e5'NT. 
Finally, 4,6-diarylated 2-(trifluoromethyl)quinolines 24a-g were evaluated. This study 
identified that derivative 24f, containing a 4-methoxphenyl substituent in position 6 and 
a 4-trifluoromethylphenyl substituent in position 4, as the best inhibitor of h-e5'NT with 
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IC50 ± SEM= 2.24±0.14 µM. For derivatives 24a and 24e, the combined presence of 
electron donating groups as methyl and methoxy resulted in loss of inhibitory activity. 
Table 25. In vitro ecto-5'-nucleotidase (h-e5'NT and r-e5'NT) inhibitory activities  
Sr. No. Codes h-e5'NT r-e5'NT 
IC50±SEM (μM) 
1 19 2.04±0.13 >100 
2 20a 3.82±0.14 >100 
3 20b 1.72±0.05 >100 
4 21a 15.3±1.16 >100 
5 21c 5.52±0.76 >100 
6 21d 1.13±0.02 >100 
7 21e >100 >100 
8 21g 1.19±0.03 >100 
9 21h 2.21±0.17 >100 
10 21i 5.79±0.98 >100 
11 21j 13.1±1.07 >100 
12 23a >100 >100 
13 23b 21.5±2.07 >100 
14 23c 2.41±0.11 >100 
15 23d 12.3±0.91 >100 
16 23e 3.82±0.14 >100 
17 23f 1.78±0.07 >100 
18 23g 25.9±2.89 >100 
19 24a >100 >100 
20 24b 23.7±2.34 >100 
21 24c 9.93±0.89 >100 
22 24d 8.03±0.99 >100 
23 24e >100 >100 
24 24f 2.24±0.14 >100 
25 24g 8.46±0.92 >100 
Sulfamic acid 42.1±5.8 77.3±7.0 
IC50 is the concentration at which 50% of the enzyme activity was inhibited. All the 
values were expressed as IC50±SEM (standard error of mean) n=3. 
3.1.5.3. Molecular docking 
The calculations were accomplished in the Centre for Advanced Drug Research, 
COMSATS Institute of Information Technology, Abbottabad, Pakistan using FlexX 
utility of LeadIT v2.1.8 software from BioSolveIT GmbH, Germany. 
In order to determine the most probable binding interactions between the compound 
with the highest inhibitory activity 21d and the h-e5'NT enzyme, molecular docking 
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studies were carried out. This study revealed that the oxygen atom of the methoxy group 
and the fluorine atoms of the tri-fluoromethyl group are responsible for making two 
hydrogen bonds with amino acid groups within the active site (Figure 11). One 
hydrogen bond was formed by the fluorine atom with ASN499 and the other hydrogen 
bond was formed between the oxygen and the amino group of ARG354. The four rings 
of compound 21d and the amino acid residues PHE417 and PHE500 were coupled 
through eight π-π stacked interactions. In addition, the benzene ring adjacent to the 
methoxy group and amino acid residues PRO498 formed one π-alkyl interaction. 
 
Figure 11. Probable binding interactions between compound 21d with amino acid 
residues of h-e5'NT. Hydrogen bonding interaction is shown as green dashed lines and 
π-π interactions as pink dashed lines. 
3.1.6. Conclusion 
I described a simple method for the synthesis of mono, di and non-symmetrical 
diarylated -2-(trifluoromethyl) quinolines based on chemo-selective Suzuki-Miyaura 
reactions. This reaction was highly selective when applied to 6-bromo-4-chloro-2-
(trifluoromethyl) quinoline as starting material, while application on 4,6-dibromo-2-
(trifluoromethyl) quinoline gave mixtures of regioisomers. Furthermore, synthesized 
compounds were evaluated for their potential to inhibit ecto-5'-nucleotidase, both 
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human and rat source. None of the compounds showed inhibitory activity on rat ecto-5'-
nucleotidase (r-e5'NT). The majority of this series of compound exhibited selective 
inhibitory activity on h-e5'NT enzyme. The compound 21d was found to be most active 
against human ecto-5'-nucleotidase (h-e5'NT). These newly synthesized classes of 
compounds can be used to develop novel drug candidates against cancer. 
3.2. Synthesis of 7-substituted 7H-indolo[2,3-c]quinolines 
3.2.1. Introduction 
During the last 30 years the derivatives of the indoloquinoline alkaloids have attracted 
considerable attention89 due to their wide range of biological activities, such as 
antimalarial,90 anticancer, antimicrobial,91 and antiplasmodial92 to name a few. 
The Cryptolepine (5-methyl-5H-indolo[3,2-b]quinoline) (C) is a derivative of the 
indoloquinoline of great biological importance which has been isolated from 
Cryptolepis sanguinolenta. The decoction of this plant has been used in traditional 
medicine against malaria, hypertension, hepatitis, and inflammation in West and Central 
Africa.93 The ability of this molecule to inhibit DNA replication, transcription, and 
topoisomerase activities, has made it a promising anticancer agents in modern health.94 
Similarly, the isomer isoneocryptolepine (5-methyl-5H-indolo [2,3-c]quinoline) (D), 
although it has never been found in nature, was synthesized and showed much better 
selectivity (cytotoxicity / antiplasmodial activity ratio) than (C), which makes it a 
reference compound to evaluate the potential antiplasmodial activity of 
indoloquinolines. 
 
N
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Cryptolepine (C) Isoneocryptolepine (D)  
Figure 12. Indoloquinoline derivatives with antiplasmodial activity. 
3. Functionalization of Dihalogenated Quinolines 
47 
 
To expand the molecular library of pharmaceutically active compounds, many 
procedures have been developed for the synthesis of indoloquinolines derivatives in 
recent years.95-98 For example, Wang reported an efficient iron-promoted synthesis of 
6H-indolo[2,3-b]quinolines by the reaction of aminophenyl alcohols and indoles.99 
Maes and co-workers developed an efficient synthetic route for 5-methyl-5H-
indolo[2,3-c]quinoline and its 7H-indolo[2,3-c]quinoline skeleton by combination of a 
selective Buchwald–Hartwig amination with a regioselective Pd catalyzed 
intramolecular arylation reaction starting from 3-bromoquinoline and 2-
bromoaniline.100,101 Wang and Li established a fascinating Rh(III)-catalyzed synthetic 
method for 6-(2-pyridinyl/2-pyrimidinyl)-6H-indolo[2,3-b]quinolines from indoles and 
isoxazoles.102 
Despite the potentially high biological and pharmacological activity of these alkaloid 
derivatives only few reports can be found on the synthesis of 7-substituted 7H-
indolo[2,3-c]quinolines. Therefore, it would be interesting to investigate the synthesis of 
new compounds of this family and the scope of palladium catalyzed reactions, through 
sequential chemoselective Suzuki-Miyaura reaction on 3-bromo-4-iodoquinoline 
followed by double Buchwald-Hartwig amination. 
3.2.2. Synthesis of 3-bromo-4-(2-bromophenyl)quinoline 
Initially, 3-bromo-4-iodoquinoline 25 was prepared according to a three-step procedure 
reported by Bogányi et al.103 Subsequently, a chemoselective Suzuki-Miyaura reaction 
on compound 25 was carried out with 2-bromophenylboronic acid (Scheme 27). The 
Suzuki-Miyaura reaction proceeded selectively to position 4 corresponding to the break 
of the C-I bond of 3-bromo-4-iodoquinoline 25, allowing access to desired product 3-
bromo-4-(2-bromophenyl)quinoline 26 in 61 % yield. The good selectivity of this 
reaction is due to the fact that position 4 is less electron rich than position 3 and the 
iodine atom is a better leaving group than the bromine atom. 
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Scheme 27. Synthesis of 26. Reaction conditions i: 25 (1.0 equiv.), 2-BrAr-B(OH)2  
(1.4 equiv.), Na2CO3 (2.0 equiv.), Pd(PPh3)4 (5 mol%), DMF/H2O (10:1), 100 °C, 24 h. 
3.2.3. Double Buchwald-Hartwig amination reactions on 3-bromo-4-(2-
bromophenyl)quinoline 
In order to find the most suitable conditions for the double C-N coupling of 3-bromo-4- 
(2-bromophenyl)quinoline, p-toluidine was selected as the model amine. Initially, the 
double Buchwald-Hartwig amination was studied by variation of ligands, using 
Pd2(dba)3 (5 mol%) as palladium precursor, NaOtBu (2.4 equiv.) as base in presence of 
toluene as solvent at 100 °C for 24 hours (Entry 1-4, Table 26). Although the reactions 
proceeded with 100 % conversion, very low yields were obtained from the desired 
compound. An increase in temperature using xylene as solvent did not offer any 
improvement. However, the use of KOtBu as a base allowed increasing the yield of 
compound 27a to 94 % (Entry 6, Table 26). 
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Scheme 28. Optimization for the synthesis of 27a. Reaction conditions i: 26 
(1.0 equiv.), Tol-NH2 (1.5 equiv.), base (2.4 equiv.), Pd2(dba)3 (5 mol%), ligand, 
solvent, 24 h. 
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Table 26. Optimization for the synthesis of 27a 
Entry Ligand (mol%) Base T (°C) Solvent 27a [%]a 
1 PtBu3
.HBF4 (10) NaOtBu 100 Toluene Traces 
2 BINAP (5) NaOtBu 100 Toluene 15 
3 BINAP (10) NaOtBu 100 Toluene 28 
4 dppf (10) NaOtBu 100 Toluene 11 
5 BINAP (10) NaOtBu 140 Xylene 19 
6 BINAP (10) KOtBu 100 Toluene 94 
a Yield of isolated products. 
With optimized conditions in hand, I studied the scope of the cyclization reaction of 26 
with different amines. The employment of various anilines or benzyl amines afforded 
the corresponding products 27a-m in good to excellent yields (Table 27). However, this 
method failed when it was applied for aliphatic amines 27n and 27o. Only very low 
yields of the desired products were obtained. With further optimization, I found that a 
temperature increase to 140 °C using xylene as the solvent allowed the synthesis of 
products 27n and 27o in very good yields. 
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Scheme 29. Synthesis of 27a-o. Reaction conditions i: 26 (1.0 equiv.), R-NH2 
(1.5 equiv.), KOtBu (2.4 equiv.), Pd2(dba)3 (5 mol%), BINAP (10 mol%), toluene, 
100 °C, 24 h. 
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 Table 27. Synthesis of 27a-o 
Compound R 27 [%]a 
a 4-MeC6H4 94 
b 4-(MeO)C6H4 95 
c 4-FC6H4 95 
d 4-ClC6H4 80 
e 4-EtC6H4 90 
f 4-(EtO)C6H4 76 
g C6H5 88 
h 3,5-(MeO)2C6H3 96 
i 3,4-(MeO)2C6H3 90 
j 4-MeC6H4CH2 92 
k 4-(MeO)C6H4CH2 71 
l 4-FC6H4CH2 89 
m Cyclopentyl 91 
n nC6H13 85
b 
o nC4H9 88
b 
a Yield of isolated products; b Xylene (mixture of isomers) was used instead of toluene 
at 140°C. 
3.2.4. Conclusion 
I described an efficient and convenient procedure for the synthesis of 7-substituted 7H-
indolo[2,3-c]quinolines based on chemoselective Suzuki-Miyaura reaction followed by 
double C-N coupling. The Suzuki-Miyaura reaction of the 2-bromophenylboronic acid 
with 3-bromo-4-(2-bromophenyl)quinoline proceeded with good site-selectivity in 
favour of positions 4. For the double C-N coupling reaction excellent yields were 
obtained, although for employment of n-butylamine and n-hexylamine higher 
temperatures were required. 
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4. Summary 
In the present work, chemoselective cross-coupling reactions of Suszuki and 
Sonogashira on 4-bromo-2,3,5-trichloro-6-iodopyridine were successfully developed. 
After optimized conditions, it was possible to synthesize 35 new derivatives of aryl-
substituted pyridines and 23 of alkynyl-substituted pyridines in good yields. 
The non-symmetrical pentaalkynyl pyridines synthesized were evaluated for their 
optical properties UV/Vis and fluorescence spectroscopy. These compounds generally 
exhibited high quantum yields. Compounds 17c and 18c which contain (4-tert-
butylphenyl) ethynyl) as substituents, were those with the highest quantum yield with 
54.7 % and 54.6 % respectively. 
In another study, the selective Suzuki-Miyaura reaction of 4,6-dibromo-2- 
(trifluoromethyl) quinoline was investigated. Initially, this starting material allowed the 
synthesis of nine new 4,6-diarylated quinolines derivatives with good yields. However, 
selective arylation only led to the synthesis of inseparable mixtures of both 4- and 6-
monoarylated isomers. This problem was solved when 6-bromo-4-chloro-2- 
(trifluoromethyl) quinoline was used as the starting material. In this context, the 
bromine as the best leaving group with respect to chlorine, allowed the selective 
arylation to position 6 of 2- (trifluoromethyl) quinoline. In addition, 7 non-symmetrical 
diarylated derivatives were isolated. All products were evaluated for their potential to 
inhibit ecto-5'-nucleotidase, both human and rat source. The majority of this series of 
compound exhibited good selective inhibitory activity on human ecto-5'-nucleotidase. 
None of the derivatives showed activity against rat ecto-5'-nucleotidase. The compound 
21d was the most active against human ecto-5'-nucleotidase (h-e5'NT) with an 
inhibitory value of IC50 ± SEM= 1.13±0.02 µM. 
Finally a series of 7-substituted 7H indolo [2,3-c] quinolines was obtained in very good 
yields by sequential chemoselective Suzuki-Miyaura reaction followed by double C-N 
coupling on 3-bromo-4-iodoquinoline as selected starting material. 
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Appendix 
5. Experimental Section 
5.1. Materials and Methods 
5.1.1. General Remarks 
All coupling reactions were carried out in oven-dried pressure tubes under argon 
atmosphere (Argon 4.6). Solvents for reactions were dried and distilled by standard 
methods or purchased in extra dry quality from Acros whenever exclusion of water was 
necessary. Solvents for liquid chromatography and extraction were always distilled 
prior to use (n-heptane, EtOAc, DCM). All employed chemicals, if not otherwise stated, 
were purchased from commercial sources and used without further purification. 
5.1.2. Methods for Compound Characterization and Analysis 
1H-NMR-Spectroscopy: Bruker AVANCE 250 (250 MHz), Bruker AVANCE 300 
(300 MHz), Bruker AVANCE 500 (500 MHz). The NMR spectra presented in this work 
were recorded in CDCl3 solution except for some cases in which it was used DMSO-d6. 
All chemical shifts are given in ppm. All coupling constants are indicated as J. 
References: The spectra were calibrated according to the solvent signals: 7.27 ppm for 
CDCl3, 2.54 ppm for DMSO-d6. Peak characterization: s = singlet, brs = broad singlet, 
d = doublet, brd = broad doublet, dpt = dublet of pseudo triplet, t = triplet, pt = pseudo 
triplet, dd = doublet of doublets, ddd = double doublet doublet, q = quartet, 
quin = quintet, m = multiplet. 
13C NMR-Spectroscopy: Bruker AVANCE 250 (250 MHz), Bruker AVANCE 300 
(300 MHz), Bruker AVANCE 500 (500 MHz). The NMR spectra presented in this work 
were recorded in CDCl3 solution except for some cases in which it was used DMSO-d6. 
All chemical shifts are given in ppm. All coupling constants are indicated as J. 
References: The spectra were calibrated according to the solvent signals: 77.00 ppm for 
CDCl3, 39.5 ppm for DMSO-d6. Peak characterization: d = doublet, q = quartet. DEPT 
method was used for determining the presence of primary, secondary, tertiary and 
quaternary carbon atoms. 
19F NMR-Spectroscopy: Bruker AVANCE 300 (282 MHz). All chemical shifts are 
given in ppm.  
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Mass spectrometry (MS): Finnigan MAT 95 XP (electron ionization EI, 70 eV); 6890 
N/5973 (Agilent), 6210 Time-of-Flight LC/MS (Agilent); Gas Chromatography MS 
(GCMS): Agilent HP-5890 with an Agilent HP-5973 Mass Selective Detector (EI) and 
HP-5 capillary column using helium carrier gas. Only the measurements with an 
average deviation from the theoretical mass of ±2 mDa were accounted as correct. High 
resolution MS [HR-MS (ESI)]: Agilent 1969 A TOF. Only the measurements with an 
average deviation from the theoretical mass of ±2 mDa were accounted as correct. 
Infrared spectroscopy (IR): Nicolet 550 FT-IR spectrometer with ATR sampling 
technique for solids as well as liquids. Signal characterization: w = weak, m = medium, 
s = strong. 
X-ray crystallography: Data were collected on a Bruker Kappa APEX II Duo 
diffractometer. The structure was solved by direct methods and refined by full-matrix 
least squares procedures on F2 with the SHELXTL software package (G. M. Sheldrick, 
Acta Crystallogr. 2008, A64, 112.); XP (Bruker AXS) was used for graphical 
representation.  
UV/Vis spectroscopy: Lambda 5 (Perkin Elmer) and Analytic Jena Specord 50 UV/VIS 
spectrometer in Dichloromethane. 
Fluorescence spectroscopy: Varian Cary Eclipse spectrometer in Dichloromethane. 
Quantum yield was determined using quinine hemisulfate salt monohydrate in 0.05M 
H2SO4 as standard.
58 
Elemental analysis (EA): C/H/N – Microanalysator TruSpec CHNS (Leco);  
Melting point determination (mp): Micro-Hot-Stage GalenTM III Cambridge 
Instruments. The melting points have not been corrected. 
Thin layer chromatography (TLC): Merck Silica 60 F254 on aluminum tin foil from 
Macherey–Nagel. Detection with UV light at 254 nm and/or 366 nm without dipping 
reagent. 
Column chromatography: Separation on Fluka silica gel 60 (0.063–0.200 mm, 70 – 
320 mesh); Eluents were distilled before use. 
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5.2. General Procedures and Product Characterizations 
2,3,5-trichloro-4-iodopyridine (2) was prepared according to procedure described by 
Bobbio et al.45 
Synthesis of the starting material 4-bromo-2,3,5-trichloro-6-iodopyridine (3): 
An oven-dried 100 ml Schlenk-Flask was charged with 3 ml n-butyllithium/hexane-
Solution (2.5 M). The hexane was removed under reduced pressure and 7.5 ml of dry 
THF was added. The resulting solution was cooled down to – 40 °C for 15 minutes and 
2,2,6,6-Tetramethylpiperidine (7.41 mmol, 1.25 ml)  was slowly added. Afterwards it 
was allowed to warm to 0 °C (icebath) and stirred for 30 minutes at this temperature. 
The mixture was again cooled to - 78 °C and stirred for 30 minutes at this temperature. 
In another Schlenk-Flask a solution of 2,3,5-trichloro-4-iodopyridine (3.73 mmol, 
1.15 g) in 4 ml THF was prepared and added slowly to the LiTMP solution at - 100 °C . 
The reaction mixture was stirred for 2 h. During this time a suspension appears. In a 
third Schlenk-Flask a solution of 1,2-dibromotetrachloroethane (11.24 mmol, 3.66 g) in 
11.5 ml THF was prepared and cooled to - 78 °C. The reaction mixture was transferred 
into the solution of 1,2-dibromotetrachloroethane by funnel and was stirred for 
additional 2 hours at - 78 °C. The mixture was allowed to warm to room temperature 
overnight. The reaction mixture was diluted with water and extracted with ethyl acetate. 
The combined organic layers were dried with Na2SO4, filtered and concentrated in 
vacuum. The residue was purified by column chromatography using 
heptane/dichloromethane (10/1) as eluent.  
4-bromo-2,3,5-trichloro-6-iodopyridine (3): 
According to the procedure described above 3 was isolated as 
colorless crystalline solid; yield: 1.118 g (77 %); mp. 172 - 173 °C. 
13C-NMR (62.9 MHz, CDCl3): δ = 146.2 (CHetar), 138.9 (CHetar), 134.0 
(CHetar), 132.7 (CHetar), 115.0 (CHetar). IR (ATR, cm
-1): ṽ = 2922 (m), 2794 (m), 2691 
(m), 2598 (m), 2371 (m), 2275 (m), 2082 (m), 1797 (m),  1514 (m), 1481 (s), 1367 (m), 
1307 (m), 1288 (s), 1257 (s), 1209 (s), 1144 (m), 1065 (s), 1001 (m), 958 (m), 880 (m), 
808 (m), 754 (s), 717 (s), 628 (s), 599 (s), 564 (m), 545 (s). MS (EI, 70 eV): m/z 
(%) = 391 (M+, 17), 389 (M+, 65), 387 (M+, 100), 385 (M+, 48), 264 (12), 262 (42), 260 
(65), 258 (34), 183 (12), 181 (40), 179 (38), 146 (13), 144 (21), 127 (77), 120 (12), 118 
NI
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(16), 111 (17), 109 (47), 74 (23), 47 (11). HR-MS (EI): m/z = calcd. for C5NBrCl3I 
(M+H+) 384.73189; found: 384.73204; calcd. for C5NBrCl2
37ClI (M+H+) 386.72894 
found 386.72920; calcd. for C5N
81BrCl3I (M+H
+) 386.72984; found 386.72920; calcd. 
for C5NBrCl
37Cl2I (M+H
+) 388.72599; found 388.72642; calcd. for C5N
81BrCl2
37ClI 
(M+H+) 388.72689 ; found 388.72642; calcd. for C5N
81BrCl37Cl2I (M+H
+) 390.72394; 
found 390.72389; calcd. for C5NBr
37Cl3I (M+H
+) 390.72304; found 390.72389. Anal. 
calcd. for C5NBrCl3I: C, 15.51; N, 3.62; found: C, 15.65; N, 3.71. 
General procedure for the synthesis of compounds 4a–k: 
An oven-dried, argon-flushed sealable glass tube was charged with 4-bromo-2,3,5-
trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg), Pd(PPh3)4 (5 mol%, 17.3 mg), the 
appropriate arylboronic acid (0.45 mmol) and K3PO4 (0.45 mmol, 95.53 mg) followed 
by a mixture of toluene/ water/ ethanol (6:1:1, 4 mL); The tube was sealed with a Teflon 
valve and stirred at 100 °C for 19 h. The cooled reaction mixture was diluted with water 
and extracted with CH2Cl2. The combined organic layers were dried with Na2SO4, 
filtered and concentrated in vacuum. The residue was purified by column 
chromatography using heptane/dichloromethane as eluent. 
4-bromo-2,3,5-trichloro-6-phenylpyridine (4a):  
4a was synthesized according to general procedure using 4-bromo-
2,3,5-trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg) and 
phenylboronic acid (0.45 mmol, 54.9 mg) and was purified via 
column chromatography (heptane/dichloromethane). White solid; 
yield: 79 mg (78 %). mp. 111-112 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.67 - 7.69 (m, 
2H, CHAr), 7.47-7.49 (m, 3H, CHAr). 
13C-NMR (75.0 MHz, CDCl3): δ = 154.9 
(CAr/Hetar), 146.9 (CAr/Hetar), 137.0 (CAr/Hetar), 136.7 (CAr), 131.0 (CAr/Hetar), 130.7 
(CAr/Hetar), 129.7 (2CHAr), 129.4 (2CHAr), 128.2 (CHAr). IR (ATR, cm
-1): ṽ = 3056 (w), 
2960 (w), 2922 (w), 2852 (w), 2321 (w), 1801 (w), 1760 (w), 1598 (w), 1527 (m), 1481 
(s), 1443 (m), 1368 (s), 1321 (s), 1304 (m), 1291 (s), 1276 (s), 1261 (s), 1196 (s), 1160 
(m), 1077 (m), 1059 (m), 1001 (m), 964 (w), 883 (m), 804 (w), 765 (s), 736 (s), 704 (s), 
690 (s), 652 (m), 617 (w), 599 (s), 559 (m). MS (EI, 70 eV): m/z (%) = 341 (M+, 17), 
339 (M+, 63), 338 (M+, 13), 337 (M+, 100), 335 (M+, 51), 304 (37), 303 (11), 302 (82), 
300 (51), 223 (45), 222 (13), 221 (71), 186 (16), 185 (18), 160 (17), 151 (37), 150 (11), 
Cl
N Cl
Br
Cl
5. Experimental Section 
56 
 
120 (18), 118 (23), 111 (10), 110 (11), 80 (10), 51 (11). HR-MS (ESI): m/z = calcd. for 
C11H5BrCl3N (M+H
+) 335.87437; found: 335.87405; calcd. for C11H5BrCl2
37ClN 
(M+H+) 337.87191; found 337.87132; calcd. for C11H5
81BrCl3N (M+H
+) 337.87191; 
found 337.87132; calcd. for C11H5BrCl
37Cl2N (M+H
+) 339.86925; found 339.86946; 
calcd. for C11H5
81BrCl2
37ClN (M+H+) 339.86925; found 339.86946. Anal. calcd. for 
C11H5BrCl3N: C, 39.15; H, 1.49; N, 4.15 found: C, 39.22; H, 1.60; N, 4.19  
4-bromo-2,3,5-trichloro-6-p-tolylpyridine (4b): 
4b was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg) 
and 4-methylphenylboronic acid (0.45 mmol, 61.2 mg) and 
was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 87 mg (83 %). mp. 113 - 114 °C. 1H-
NMR (300 MHz, CDCl3): δ = 7.57 (d, 
3J = 8.1 Hz, 2H, CHAr), 7.26 (d, 
3J = 8.1 Hz, 2H, 
CHAr), 2.40 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): δ = 154.9 (CAr/Hetar), 146.8 
(CAr/Hetar), 140.0 (CAr/Heta), 140.0 (CAr), 136.9 (CAr), 133.9 (CAr/Hetar), 130.6 (CAr/Hetar), 
129.3 (2CHAr), 128.9 (2CHAr), 21.4 (CH3). IR (ATR, cm
-1): ṽ = 3058 (w), 2912 (m), 
2853 (m), 2726 (w), 2677 (w), 2633 (w), 1908 (w), 1612 (m), 1576 (w), 1533 (m), 1513 
(m), 1480 (s), 1436 (m), 1372 (s), 1323 (s), 1298 (s), 1275 (s), 1262 (s), 1197 (s), 1185 
(s), 1159 (m), 1059 (m), 1022 (m), 963 (w), 884 (m), 820 (s), 799 (m), 760 (s), 749 (s), 
717 (s), 672 (s), 659 (m), 603 (s), 566 (s), 559 (s), 540 (s). MS (EI, 70 eV): m/z 
(%) = 355 (M+, 16), 354 (M+, 13), 353 (M+, 66), 352 (M+, 30), 351 (M+, 100), 350 (M+, 
29), 349 (M+, 52), 348 (M+, 13), 318 (15), 316 (29), 314 (19), 237 (10), 235 (17), 200 
(12), 164 (20), 118 (12). HR-MS (ESI): m/z = calcd. for C12H7NBrCl3 (M+H
+) 
348.88220; found: 348.88204; calcd. for C12H7NBrCl2
37Cl (M+H+) 350.87925, found 
350.87956; calcd. for C12H7N
81BrCl3 (M+H
+) 350.88015, foud 350.87956; calcd. for 
C12H7NBr
37Cl2Cl (M+H
+) 352.87630, found 352.87636; calcd. for C12H7N81Br
37ClCl2 
(M+H+) 352.87720, found 352.87636. Anal. calcd. for C12H7NBrCl3: C, 41.01; H, 2.01; 
N, 3.99 found: C, 41.19; H, 2.16; N, 4.09. 
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4-bromo-2,3,5-trichloro-6-(4-methoxyphenyl)pyridine (4c):  
4c was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg) 
and 4-methoxyphenylboronic acid (0.45 mmol, 68.4 mg) and 
was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 80 mg (73 %). 
mp. 143 - 144 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.70 (d, 
3J = 8.9 Hz, 2H, CHAr), 
7.00 (d, 3J = 8.9 Hz, 2H, CHAr), 3.88 (s, 3H, OCH3). 
13C-NMR (75.0 MHz, CDCl3): 
δ = 161.1 (C-OCH3), 154.8 (CAr/Hetar), 146.9 (CAr/Hetar), 137.2 (CAr), 131.3 (2CHAr), 
130.6 (CAr/Hetar), 130.5 (CAr/Hetar), 129.3 (CAr/Hetar), 113.9 (2CHAr), 55.7 (OCH3). IR 
(ATR, cm-1): ṽ = 3051 (w), 3018 (w), 2964 (m), 2923 (m), 2841 (m), 1858 (w), 1606 
(s), 1578 (w), 1511 (s), 1481 (s), 1437 (m), 1371 (s), 1326 (s), 1303 (s), 1286 (s), 1279 
(s), 1255 (s), 1199 (s), 1176 (s), 1113 (m), 1105 (s), 1061 (s), 1030 (s), 1010 (s), 954 
(m), 883 (m), 828 (s), 799 (s), 764 (s), 752 (s), 671 (s), 658 (m), 627 (m), 602 (s), 572 
(s), 559 (s). MS (EI, 70 eV): m/z (%) = 371 (M+, 17), 370 (M+, 8), 369 (M+, 65), 368 
(M+, 14), 367 (M+, 100), 365 (M+, 52), 354 (5), 352 (7), 326 (11), 324 (16), 322 (8), 317 
(5), 289 (10), 287 (6), 253 (5), 251 (7), 210 (7), 208 (11), 181 (5), 138 (7), 118 (5). HR-
MS (ESI): m/z = calcd. for C12H7ONBrCl3 (M+H
+) 364.87711; found: 364.87736; 
calcd. for C12H7ONBrCl2
37Cl (M+H+) 366.87416; found 366.87499; calcd. for 
C12H7ON
81BrCl3 (M+H
+) 366.87506; found 366.87499; calcd. for C12H7ON
81BrCl2
37Cl 
(M+H+) 368.87211; found 368.87229; calcd. for C12H7ONBrCl
37Cl2 (M+H
+) 
368.87121; found 368.87229; calcd. for C12H7ON
81BrCl37Cl2 (M+H
+) 370.86916; found 
370.86951; calcd. for C12H7ONBr
37Cl3 (M+H
+) 370.86826; found 370.86951. Anal. 
calcd. for C12H7BrCl3NO: C, 39.22; H, 1.92; N, 3.81 found: C, 39.35; H, 2.01; N, 4.02. 
4-bromo-2,3,5-trichloro-6-(4-fluorophenyl)pyridine (4d):  
4d was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg) 
and 4-fluorophenylboronic acid (0.45 mmol, 63.0 mg) and was 
purified via column chromatography (heptane/dichloromethane). 
White solid; yield: 78 mg (73 %). mp. 148 - 149 °C. 1H-NMR (300 MHz, CDCl3): 
δ = 7.67-7.74 (m, 2H, CHAr), 7.13 - 7.21 (m, 2H, CHAr). 
13C-NMR (75.0 MHz, CDCl3): 
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δ = 163.5 (d, 1J = 250.6 Hz, CAr-F), 153.8 (CHetar), 147.0 (CHetar), 137.1 (CHetar), 132.7 
(d, 4J = 3.3 Hz, CAr), 131.5 (d, 
3J = 8.5 Hz, 2CHAr), 131.1 (CHetar), 130.6 (CHetar), 115.3 
(d, 2J = 21.9 Hz, 2CHAr). 
19F-NMR (282 MHz, CDCl3): δ = -110.49. IR (ATR, cm
-1): 
ṽ = 3111 (w), 3063 (m), 2923 (m), 2853 (w), 1775 (w), 1603 (s), 1514 (s), 1483 (s), 
1413 (w), 1381 (s), 1371 (s), 1323 (s), 1308 (s), 1296 (s), 1277 (s), 1262 (s), 1227 (s), 
1201 (s), 1162 (s), 1101 (s), 1062 (s), 962 (m), 888 (m), 837 (s), 815 (s), 765 (s), 752 
(s), 672 (s), 659 (s), 602 (s), 568 (s), 561 (s), 548 (m). MS (EI, 70 eV): m/z (%) = 359 
(M+, 17), 358 (M+, 8), 357 (M+, 61), 356 (M+, 12), 355 (M+, 100), 353 (M+, 50), 322 
(20), 320 (44), 318 (26), 241 (29), 240 (8), 239 (46), 204 (10), 178 (13), 169 (22), 120 
(13), 118 (16). HR-MS (ESI): m/z = calcd. for C11H4NBrCl3F (M+H
+) 352.85712, 
found: 352.85730; calcd. for C11H4NBrCl2
37ClF (M+H+) 354.85417; found 354.85455; 
calcd. for C11H4N
81BrCl3F (M+H
+) 354.85508, found 354.85455; calcd. for 
C11H4N
81BrCl2
37ClF (M+H+) 356.85213; found 356.85190; calcd. for 
C11H4NBrCl
37Cl2F (M+H
+) 356.85122; found 356.85190; calcd. for 
C11H4N
81BrCl37Cl2F (M+H
+) 358.84918; found 358.84890; calcd. for C11H4NBr
37Cl3F 
(M+H+) 358.84827; found 358.84890. Anal. calcd. for C11H4BrCl3FN: C, 37.17; H, 
1.13; N, 3.94 found: C, 37.14; H, 1.23; N, 4.16. 
4-bromo-2,3,5-trichloro-6-(3-methoxyphenyl)pyridine (4e):  
4e was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg) 
and 3-methoxyphenylboronic acid (0.45 mmol, 68.4 mg) and 
was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 85 mg (77 %). mp. 128 - 129 °C. 1H-
NMR (250 MHz, CDCl3): δ = 7.40 (pt, 
3J = 7.9 Hz, 3J = 7.8 Hz, 1H, CHAr), 7.25 (ddd, 
3J = 6.67 Hz, 4J = 1.6 Hz, 4J = 1.0 Hz, 1H, CHAr), 7.18 (dd, 
4J = 2.6 Hz, 4J = 1.6 Hz, 
1H, CHAr), 7.02 (ddd, 
3J = 8.2 Hz, 4J = 2.6 Hz, 4J = 1.0 Hz, 1H, CHAr), 3.87 (s, 3H, 
OCH3). 
13C-NMR (63 MHz, CDCl3): δ = 159.3 (C-OCH3), 154.8 (CAr/Hetar), 146.9 
(CAr/Hetar), 137.9 (CAr), 137.0 (CAr/Hetar), 131.1 (CAr/Hetar), 130.8 (CAr/Hetar), 129.3 (CHAr), 
121.7 (CHAr), 115.5 (CHAr), 114.8 (CHAr), 55.4 (OCH3). IR (ATR, cm
-1): ṽ = 3061 (w), 
3001 (m), 2962 (m), 2939 (m), 2835 (m), 1790 (w), 1745 (w), 1593 (s), 1526 (m), 1487 
(s), 1466 (s), 1372 (s), 1320 (s), 1300 (s), 1283 (s), 1265 (s), 1231 (vs), 1200 (s), 1185 
(s), 1161 (s), 1076 (s), 1067 (s), 1030 (s), 993 (s), 926 (s), 873 (s), 833 (m), 795 (s), 761 
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(s), 749 (s), 702 (s), 689 (s), 658 (m), 602 (s), 553 (s). MS (EI, 70 eV): m/z (%) = 371 
(M+, 18), 370 (M+, 19), 369 (M+, 65), 368 (M+, 61), 367 (M+, 100), 366 (M+, 79), 365 
(M+, 51), 364 (M+, 37), 341, 340 (14), 339 (15), 338 (23), 337 (20), 336 (13), 302 (18), 
300 (12), 289 (10), 223 (10), 221 (15), 210 (13), 208 (18), 138 (10), 118 (10). HR-MS 
(ESI): m/z = calcd. for C12H7ONBrCl3 (M+H
+) 364.87711, found: 364.87699; calcd. for 
C12H7ONBrCl2
37Cl (M+H+) 366.87416; found 366.87451; calcd. for C12H7ON
81BrCl3 
(M+H+) 366.87506, found 366.87451; calcd. for C12H7ON
81BrCl2
37Cl (M+H+) 
368.87211; found 368.87179; calcd. for C12H7ONBrCl
37Cl2 (M+H
+) 368.87121; found 
368.87179; calcd. for C12H7ON
81BrCl37Cl2 (M+H
+) 370.86916, found 370.86922; calcd. 
for C12H7ONBr
37Cl3 (M+H
+) 370.86826; found 370.86922. Anal. calcd. for 
C12H7BrCl3NO: C, 39.22; H, 1.92; N, 3.81 found: C, 39.40; H, 2.03; N, 3.99. 
4-bromo-2,3,5-trichloro-6-(thiophen-2-yl)pyridine (4f): 
4f was synthesized according to general procedure using 4-bromo-
2,3,5-trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg) and 2-
Thienylboronic acid (0.45 mmol, 57.6 mg) and was purified via 
column chromatography (heptane/dichloromethane). White solid; 
yield: 83 mg (81 %). mp. 98 - 99 °C. 1H-NMR (300 MHz, CDCl3): δ = 8.08 (dd, 
4J = 3.0 Hz, 4J = 1.3 Hz, 1H, CHHetar), 7.69 (dd, 
3J = 5.1 Hz, 4J = 1.3 Hz, 1H, CHHetar), 
7.40 (dd, 3J = 5.1 Hz, 4J = 3.0 Hz, 1H, CHHetar). 
13C-NMR (75 MHz, CDCl3): δ = 149.5 
(CHetar), 146.6(CHetar), 137.4(CHetar), 137.1(CHetar), 130.2(CHetar), 129.7(CHetar), 128.8 
(CHHetar), 128.7(CHHetar), 125.2(CHHetar). IR (ATR, cm
-1): ṽ = 3145 (w), 3095 (w), 2957 
(w), 2923 (w), 1793 (w), 1518 (m), 1493 (m), 1475 (m), 1413 (m), 1337 (s), 1300 (s), 
1284 (s), 1262 (m), 1192 (s), 1177 (m), 1081 (s), 1054 (m), 927 (m), 890 (m), 810 (s), 
790 (s), 751 (s), 735 (s), 686 (s), 663 (s), 648 (s), 608 (s), 596 (s), 585 (s). MS (EI, 
70 eV): m/z (%) = 347 (M+, 19), 346 (M+, 9), 345 (M+, 70), 344 (M+, 15), 343 (M+, 
100), 341 (M+, 49), 310 (19), 308 (40), 306 (24), 229 (13), 227 (19), 157 (12), 118 (12), 
45 (12). HR-MS (ESI): m/z = calcd. for C9H3NBrCl3S (M+H
+) 340.82297; found 
340.82284; calcd. for C9H3N
81BrCl3S (M+H
+) 342.82092; found 342.82059; calcd. for 
C9H3NBrCl2
37ClS (M+H+) 342.82002; found 342.82059; calcd. for C9H3N
81BrCl2
37ClS 
(M+H+) 344.81797; found 344.81780; calcd. for C9H3NBrCl
37Cl2S (M+H
+) 344.81707; 
found 344.81780; calcd. for C9H3N
81BrCl37Cl2S (M+H
+) 346.81502; found 346.81466; 
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calcd. for C9H3NBr
37Cl3S (M+H
+) 346.81412; found 346.81466. Anal. calcd. for 
C9H3BrCl3NS: C, 31.47; H, 0.88; N, 4.08 found: C, 31.60; H, 1.20; N, 4.29. 
4-bromo-2,3,5-trichloro-6-(3-nitrophenyl)pyridine (4g):  
4g was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg) 
and 3-nitrophenylboronic acid (0.45 mmol, 75.1 mg) and was 
purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 89 mg (78 %). mp. 166 - 167 °C. 1H-
NMR (250 MHz, CDCl3): δ = 8.60 (pt, 
4J = 1.7 Hz, 1H, CHAr), 8.34 (ddd, 
3J = 8.3 Hz, 
4J = 2.3 Hz, 4J = 1.1 Hz, 1H, CHAr), 8.05 (ddd, 
3J = 7.8 Hz, 4J = 1.7 Hz, 4J = 1.1 Hz, 
1H, CHAr), 7.68 (pt, 
3J = 8.0 Hz, 1H, CHAr). 
13C-NMR (63 MHz, CDCl3): δ = 152.0 
(CAr/Hetar), 148.0 (CAr/Hetar), 147.5 (CAr), 138.0 (CAr), 137.5 (CAr/Hetar), 135.4 (CHAr), 
132.4 (CAr/Hetar), 130.9 (CAr/Hetar), 129.4 (CHAr), 124.7 (CHAr), 124.5 (CHAr). IR (ATR, 
cm-1): ṽ = 3102 (m), 3077 (m), 2961 (w), 2924 (w), 2858 (w), 1810 (w), 1746 (w), 1580 
(w), 1536 (s), 1525 (s), 1494 (s), 1479 (s), 1369 (m), 1351 (s), 1327 (s), 1313 (s), 1304 
(s), 1294 (s), 1272 (s), 1259 (s), 1201 (s), 1174 (m), 1095 (m), 1082 (s), 1066 (s), 1002 
(m), 904 (s), 855 (s), 806 (s), 783 (s), 757 (m), 728 (s), 685 (s), 669 (s), 651 (m), 603 
(s), 564 (s). MS (EI, 70 eV): m/z (%) = 386 (M+, 19), 385 (M+, 10), 384 (M+, 66), 383 
(M+, 14), 382 (M+, 100), 380 (M+, 54), 340 (12), 338 (46), 337 (10), 336 (70), 334 (35), 
324 (10), 301 (16), 299 (10), 257 (27), 255 (26), 220 (15), 187 (11), 185 (32), 118 (11). 
HR-MS (ESI): m/z = calcd. for C11H4O2N2BrCl3 (M+H
+) 379.85162; found: 
379.85154; calcd. for C11H4O2N2BrCl2
37Cl (M+H+) 381.84867; found 381.84911; calcd. 
for C11H4O2N2
81BrCl3 (M+H
+) 381.84958; found 381.84911; calcd. for 
C11H4O2N2BrCl
37Cl2 (M+H
+) 383.84572; found 383.84618; calcd. for 
C11H4O2N2
81BrCl2
37Cl (M+H+) 383.84663; found 383.84618; calcd. for 
C11H4O2N2Br
37Cl3 (M+H
+) 385.81277, found 385.84350; calcd. for 
C11H4O2N2
81BrCl37Cl2 (M+H
+) 385.84368; found 385.84350. Anal. calcd. for 
C11H4BrCl3N2O2: C, 34.55; H, 1.05; N, 7.33 found: C, 34.36; H, 1.15; N, 7.19. 
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4-bromo-2,3,5-trichloro-6-(4-(trifluoromethyl)phenyl)pyridine (4h):  
4h was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg) 
and 4-(trifluoromethyl)phenylboronic acid (0.45 mmol, 
85.5 mg) and was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 73 mg (60 %). 
mp. 123 - 124 °C. 1H-NMR (250 MHz, CDCl3): δ = 7.82 (d, 
3J = 8.5 Hz, 2H, CHAr), 
7.75 (d, 3J = 8.5 Hz, 2H, CHAr). 
13C-NMR (63 MHz, CDCl3): δ = 153.3 (CAr/Hetar), 
147.3 (CAr/Hetar), 140.0 (q, 
5J  = 1.1 Hz, CAr), 137.3 (CAr/Hetar), 132.0 (CAr/Hetar), 131.6 (q, 
2J = 32.7 Hz, (CAr), 130.9 (CAr/Hetar), 129.8 (2CHAr), 125.3 (q, 
3J = 3.7 Hz, 2CHAr), 
123.8 (q, 1J = 272.8 Hz, CF3). 
19F-NMR (235 MHz, CDCl3): δ = - 62.89 (ArCF3). IR 
(ATR, cm-1): ṽ = 3118 (w), 2939 (w), 2641 (w), 1805 (w), 1621 (m), 1581 (w), 1532 
(m), 1489 (s), 1409 (m), 1325 (s), 1307 (s), 1283 (s), 1263 (s), 1200 (s), 1163 (s), 1105 
(s), 1069 (s), 1061 (s), 1018 (s), 970 (s), 956 (s), 883 (m), 844 (s), 789 (s), 764 (s), 738 
(s), 704 (s), 631 (s), 619 (s), 581 (s), 562 (s). MS (EI, 70 eV): m/z (%) = 409 (M+, 17), 
408 (M+, 9), 407 (M+, 63), 406 (M+, 14), 405 (M+, 100), 404 (M+, 7), 403 (M+, 53), 386 
(8), 372 (33), 371 (10), 370 (74), 368 (47), 291 (41), 290 (14), 289 (64), 257 (12), 255 
(18), 254 (19), 253 (13), 228 (19), 219 (24), 218 (14), 200 (11), 193 (14), 185 (12), 169 
(11), 155 (17), 153 (18), 145 (11), 123 (12), 122 (11), 121 (10), 75 (17), 74 (10), 69 
(18). HR-MS (EI): m/z = calcd. for C12H4NBrCl3F3  [M]
+: 402.85393; found: 
402.85369; calcd. for C12H4NBrCl2 
37ClF3: 404.85098; found 404.85134; calcd. for 
C12H4N
81BrCl2 
37ClF3: 406.84893; found 406.84873. Anal. calcd. for C12H4BrCl3F3N: C 
35.55, H 0.99, N 3.45; found: C 35.75, H 1.03, N 3.36. 
4-bromo-2,3,5-trichloro-6-(2-methoxyphenyl)pyridine (4i): 
4i was synthesized according to general procedure using 4-bromo-
2,3,5-trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg) and 2-
methoxyphenylboronic acid (0.45 mmol, 68.4 mg) and was purified 
via column chromatography (heptane/dichloromethane). Pink solid; 
yield: 94 mg (86 %). mp. 123 - 124 °C. 1H-NMR (250 MHz, CDCl3): δ = 7.37-7.48 (m, 
1H, CHAr), 7.27 (dd, 
3J = 7.0 Hz, 4J = 2.1 Hz, 1H, CHAr), 6.97-7.09 (m, 2H, CHAr), 3.81 
(s, 3H, OCH3). 
13C-NMR (63 MHz, CDCl3): δ = 156.6 (C-OCH3), 153.9 (CAr/Hetar), 
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146.6 (CAr/Hetar), 135.9 (CAr/Hetar), 133.0 (CAr/Hetar), 131.1 (CH), 131.0 (CAr/Hetar), 130.1 
(CH), 126.5 (CAr), 120.7 (CHAr), 111.0 (CHAr), 55.5 (OCH3). IR (ATR, cm
-1): ṽ = 3001 
(w), 2960 (w), 2942 (w), 2922 (w), 2841 (w), 1601 (m), 1531 (w), 1488 (s), 1462 (s), 
1437 (m) , 1372 (s), 1327 (m), 1281 (s), 1260 (s), 1240 (s), 1167 (m), 1097 (s), 1062 (s), 
1041 (s), 1016 (s), 942 (w), 884 (w), 796 (s), 779 (m), 760 (s), 733 (s), 696 (s), 655 (m), 
613 (m), 604 (s), 572 (s), 561 (s), 528 (m). MS (EI, 70 eV): m/z (%) = 369 (M+, 15), 
367 (M+, 23), 365 (M+, 12), 334 (46), 333 (15), 332 (100), 331 (13), 330 (64), 317 (10), 
304 (21), 302 (21), 273 (11), 271 (12), 253 (37), 252 (12), 251 (57), 225 (11), 223 (27), 
222 (10), 221 (22), 216 (16), 210 (15), 208 (20), 201 (11), 188 (11), 187 (13), 185 (12), 
151 (15), 147 (12), 138 (18), 120 (14), 118 (20), 111 (11), 63 (12), 62 (6), 39 (8). HR-
MS (EI): m/z = calcd. for C12H7ONBrCl3 [M]
+: 364.87711; found: 364.87695; calcd. 
for C12H7ONBrCl2
37Cl: 366.87416; found 366.87456; calcd. for C12H7ON 
81BrCl2
37Cl: 
368.87211; found 368.87198. Anal. calcd. for C12H7BrCl3NO: C 39.22, H 1.92, N 3.81; 
found: C 39.52, H 2.45, N 3.46. 
4-bromo-2,3,5-trichloro-6-(4-cyanophenyl)pyridine (4j):  
4j was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg) 
and 4-cyanophenylboronic acid (0.45 mmol, 66.1 mg) and was 
purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 64 mg (60 %). mp. 195 - 196 °C. 1H-
NMR (250 MHz, CDCl3): δ = 7.74-7.84 (m, 4H, CHAr). 
13C-NMR (63 MHz, CDCl3): 
δ = 152.6 (CAr/Hetar), 147.4 (CAr/Hetar), 140.7 (CAr/Hetar), 137.5 (CAr/Hetar), 132.3 (CAr/Hetar), 
132.0 (2CHAr), 130.9 (CAr/Hetar), 130.2 (2CHAr), 118.2 (C≡N), 113.5 (CAr). IR (ATR, 
cm-1): ṽ = 3102 (w), 3082 (w), 3053 (w), 2959 (w), 2922 (w), 2853 (w), 2227 (m), 1937 
(w), 1525 (m), 1480 (m), 1370 (s), 1326 (s), 1302 (s), 1287 (m), 1273 (m), 1262 (s), 
1199 (m), 1179 (m), 1063 (m), 1021 (m), 972 (w), 884 (m), 844 (s), 805 (m), 753 (s), 
663 (m), 653 (s), 604 (s), 550 (m), 541 (s). MS (EI, 70 eV): m/z (%) = 366 (M+, 17), 
365 (M+, 9), 364 (M+, 64), 363 (M+, 14), 362 (M+, 100), 361 (M+, 8), 360 (M+, 52), 329 
(36), 328 (12), 327 (79), 325 (50), 248 (39), 247 (13), 246 (61), 212 (10), 211 (20), 210 
(21), 187 (10), 185 (28), 176 (38), 163 (10), 155 (14), 153 (15), 150 (12), 124 (12), 123 
(19) 122 (11), 120 (34), 118 (49), 110 (10), 99 (15), 92 (12), 76 (10), 75 (19), 74 (12). 
HR-MS (EI): m/z = calcd. for C12H4N2BrCl3 [M]
+: 359.86180; found: 359.86197; 
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calcd. for C12H4N2
81BrCl3: 361.85975; found 361.85963; calcd. for C12H4N2 
81BrCl2
37Cl: 363.85680; found 363.85706; calcd. for C12H4N2
81BrCl37Cl2: 365.85385; 
found 365.85453. Anal. calcd. for C12H4BrCl3N2: C 39.77, H 1.11, N 7.73; found: C 
40.24, H 1.36, N 7.39. 
4-bromo-2,3,5-trichloro-6-(4-chlorophenyl)pyridine (4k): 
4k was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.3 mmol, 115.9 mg) 
and 4-chlorophenylboronic acid (0.45 mmol, 70.4 mg) and was 
purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 77 mg (69 %). mp. 161 - 162 °C. 1H-
NMR (250 MHz, CDCl3): δ = 7.65 (d, 
3J = 8.56 Hz, 2H, CHAr), 7.46 (d, 
3J = 8.56 Hz, 
2H, CHAr). 
13C-NMR (63 MHz, CDCl3): δ = 153.6 (CAr/Hetar), 147.1 (CAr/Hetar), 137.2 
(CAr/Hetar), 136.0 (CAr), 135.0 (CAr/Hetar), 131.3 (CAr/Hetar), 130.8 (2CHAr), 130.7 (CAr), 
128.5 (2CHAr). IR (ATR, cm
-1): ṽ = 3056 (w), 2957 (w), 1911 (w), 1594 (m), 1523 (w), 
1496 (m), 1481 (s), 1371 (s), 1325 (s), 1308 (s), 1293 (s), 1260 (s), 1201 (m), 1182 (m), 
1090 (m), 1059 (m), 1016 (s), 964 (m), 885 (m), 833 (s), 779 (s), 751 (s), 737 (s), 715 
(m), 658 (m), 639 (s), 625 (m), 603 (s), 534 (m). MS (EI, 70 eV): m/z (%) = 377 (M+, 
6), 375 (M+, 32), 374 (M+, 10), 373 (M+, 83), 372 (M+, 13), 371 (M+, 100), 370 (M+, 6), 
369 (M+, 45), 338 (31), 336 (49), 334 (26), 259 (17), 257 (54), 256 (10), 255 (57), 222 
(10), 221 (10), 220 (15), 219 (12), 196 (12), 194 (12), 187 (14), 185 (41), 169 (11), 168 
(15), 155 (12), 153 (12), 150 (12), 123 (14), 120 (25), 118 (33), 111 (13), 110 (12), 109 
(10), 99 (12), 98 (17), 97 (20), 85 (10), 75 (20), 74 (14), 50 (10). HR-MS (EI): 
m/z = calcd. for C11H4NBrCl4 [M]
+: 368.82757; found: 368.82764; calcd. for 
C11H4NBrCl3
37Cl: 370.82462; found 370.82506; calcd. for C11H4N 
81BrCl3
37Cl: 
372.82258; found 372.82230; calcd. for C11H4N
81BrCl2
37Cl2: 374.81963; found 
374.81961. Anal. calcd. for C11H4BrCl4N: C 35.53, H 1.08, N 3.77; found: C 35.67, H 
1.18, N 3.76. 
General procedure for the Synthesis of compounds 5a–h 
An oven-dried, argon-flushed sealable glass tube was charged with 4-bromo-2,3,5-
trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg), Pd(OAc)2 (5 mol%, 2.9 mg), PCy3 
(10 mol%, 7.24 mg), the appropriate arylboronic acid (0.55 mmol) and K3PO4 
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(0.55 mmol, 115.12 mg) followed by a mixture of toluene/water/n-butanol (6:1:1, 
4 mL). The tube was sealed with a Teflon valve and stirred at 100 °C for 19 h. The 
cooled reaction mixture was diluted with water and extracted with CH2Cl2. The 
combined organic layers were dried with Na2SO4, filtered and concentrated in vacuum. 
The residue was purified by column chromatography using heptane/dichloromethane as 
eluent. 
2,3,5-trichloro-4,6-di-p-tolylpyridine (5a):  
5a was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and p-tolylboronic acid (0.55 mmol, 74.8 mg) and was purified 
via column chromatography (heptane/dichloromethane). White 
solid; yield: 76 mg (81 %). mp. 121 - 122 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 7.65 (d, 
3J = 8.2 Hz, 2H, CHAr), 7.35 
(d, 3J = 8.0 Hz, 2H, CHAr), 7.29 (d, 
3J = 8.0 Hz, 2H, CHAr), 7.19 (d, 
3J = 8.1 Hz, 2H, 
CHAr), 2.46 (s, 3H, CH3), 2.43 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): δ = 154.9 
(CAr/Hetar), 150.9 (CAr/Hetar), 147.1(CAr/Hetar), 139.5 (CAr/Hetar), 139.1 (CAr/Hetar), 134.1 
(CAr/Hetar), 133.0 (CAr/Hetar), 129.4 (4CHAr), 129.0 (2CAr/Hetar), 128.8 (2CHAr), 
128.3(2CHAr), 21.5 (CH3), 21.4 (CH3). IR (ATR, cm
-1): ṽ = 3038 (w), 2920 (m), 2853 
(m), 1908 (w), 1614 (m), 1575 (w), 1513 (m), 1500 (s), 1450 (m), 1373 (s), 1316 (m), 
1295 (s), 1267 (s), 1205 (m), 1191 (s), 1168 (m), 1043 (s), 1022 (m), 965 (m), 875 (m), 
836 (m), 819 (s), 793 (m), 767 (s), 758 (s), 729 (s), 719 (s), 670 (s), 643 (m), 618 (s), 
610 (m), 580 (m), 563 (s). MS (EI, 70 eV): m/z (%) = 366 (M+, 7), 365 (M+, 34), 364 
(M+, 24), 363 (M+, 97), 362 (M+, 33), 361 (M+, 100), 360 (M+, 13), 328 (32), 327 (11), 
326 (50), 255 (9), 254 (11), 241 (7), 240 (14), 91 (8). HR-MS (ESI): m/z = calcd. for 
C19H14Cl3N (M+H
+) 361.01863, found: 361.01827. Anal. calcd. for C19H14Cl3N: C, 
62.92; H, 3.89; N, 3.86 found: C, 62.89; H, 3.82; N, 3.95. 
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2,3,5-trichloro-4,6-bis(4-chlorophenyl)pyridine (5b):  
5b was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and 4-chlorophenylboronic acid (0.55 mmol, 86.0 mg) and was 
purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 80 mg (77 %). 
mp. 143 - 144 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.70 (d, 
3J = 8.6 Hz, 2H, CHAr), 7.53 (d, 
3J = 8.5 Hz, 2H, CHAr), 7.46 (d, 
3J = 8.6 Hz, 2H, CHAr), 
7.23 (d, 3J = 8.5 Hz, 2H, CHAr). 
13C-NMR (75 MHz, CDCl3): δ = 153.7 (CAr/Hetar), 
149.9 (CAr/Hetar), 147.5 (CAr/Hetar), 135.8 (CAr/Hetar), 135.4 (CAr/Hetar), 135.0 (CAr/Hetar), 
133.8 (CAr/Hetar), 130.9 (2CHAr), 129.9 (2CHAr), 129.5 (CAr/Hetar), 129.2 (2CHAr), 128.7 
(CAr/Hetar), 128.5 (2CHAr). IR (ATR, cm
-1): ṽ = 3094 (w), 3068 (w), 2953 (w), 2922 (m), 
2852 (m), 1781 (w), 1732 (w), 1593 (m), 1535 (w), 1486 (s), 1402 (m), 1367 (s), 1307 
(m), 1286 (s), 1259 (s), 1180 (m), 1166 (m), 1091 (s), 1041 (s), 1016 (s), 962 (m), 895 
(w), 831 (s), 812 (s), 767 (s), 744 (s), 729 (s), 696 (m), 650 (s), 634 (s), 612 (s), 541 
(m). MS (EI, 70 eV): m/z (%) = 407 (M+, 21), 406 (M+, 12), 405 (M+, 65), 404 (M+, 
19), 403 (M+, 100), 402 (M+, 13), 401 (M+, 63), 370 (26), 369 (11), 368 (54), 366 (42), 
333 (14), 331 (15), 297 (15), 296 (15), 295 (21), 263 (12), 261 (38), 225 (22), 196 (15), 
194 (22), 185 (13), 184 (15), 149 (18), 148 (27), 135 (11), 130 (24), 99 (15), 75 (14). 
HR-MS (ESI): m/z = calcd. for C17H8Cl5N (M+H
+) 401.91721, found: 401.91763; 
calcd. for C17H8 Cl4
35ClN: 403.91436, found: 403.9144; calcd. for C17H8 Cl3
35Cl2N: 
405.91156; found 405.91234. Anal. calcd. for C17H8Cl5N: C, 50.60; H, 2.00; N, 3.47 
found: C, 50.74; H, 2.28; N, 3.54. 
2,3,5-trichloro-4,6-bis(4-methoxyphenyl)pyridine (5c): 
5c was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and 4-methoxyphenylboronic acid (0.55 mmol, 83.6 mg) and 
was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 55 mg (54 %). 
mp. 122 - 123 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.74 (d, 
3J = 8.9 Hz, 2H, CHAr), 7.23 (d, 
3J = 8.9 Hz, 2H, CHAr), 7.06 (d, 
3J = 8.9 Hz, 2H, CHAr), 
6.99 (d, 3J = 8.9 Hz, 2H, CHAr), 3.89 (s, 3H, OCH3), 3.87 (s, 3H, OCH3). 
13C-NMR 
Cl
N Cl
Cl
Cl
Cl
Cl
N Cl
Cl
MeO
OMe
5. Experimental Section 
66 
 
(75 MHz, CDCl3): δ = 160.5 (C-OCH3), 160.0 (C-OCH3), 154.4 (CAr/Hetar), 150.6 
(CAr/Hetar), 147.1(CAr/Hetar), 131.1 (2CHAr), 129.9 (2CHAr), 129.4 (CAr/Hetar), 129.0 
(CAr/Hetar), 128.9 (CAr/Hetar), 128.1 (CAr/Hetar), 114.0 (2CHAr), 113.5(2CHAr), 55.35 
(OCH3), 55.27 (OCH3). IR (ATR, cm
-1): ṽ = 3061 (w), 3010 (w), 2957 (w), 2933 (w), 
2838 (w), 1603 (s), 1576 (w), 1507 (s), 1497 (s), 1461 (m), 1453 (m), 1370 (s), 1357 
(m), 1295 (s), 1271 (m), 1245 (s), 1176 (s), 1115 (m), 1048 (m), 1026 (s), 966 (w), 876 
(w), 839 (s), 833 (s), 826 (s), 794 (s), 760 (m), 739 (s), 641 (m), 616 (m), 608 (m), 576 
(s), 529 (m). MS (EI, 70 eV): m/z (%) = 398 (M+, 7), 397 (M+, 32), 396 (M+, 21), 395 
(M+, 96), 394 (M+, 22), 393 (M+, 100), 352 (8), 350 (8), 315 (7), 272 (7), 237 (8), 202 
(8), 201 (13), 197 (9), 196 (11), 176 (7), 175 (11), 124 (7), 123 (7). HR-MS (EI): 
m/z = calcd. for C19H14O2NCl3 [M]
+: 393.00846; found: 393.00705; calcd. for 
C19H14O2NCl2
37Cl: 395.00551; found 395.00537; calcd. for C19H14O2NCl
37Cl2: 
397.00256; found 397.00288. Anal. calcd. for C19H14Cl3NO2: C 57.82, H 3.58, N 3.55; 
found: C 58.08, H 3.69, N 3.49. 
2,3,5-trichloro-4,6-bis(4-cyanophenyl)pyridine (5d):  
5d was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and 4-cyanophenylboronic acid (0.55 mmol, 80.8 mg) and was 
purified via column chromatography (heptane/dichloromethane). 
White solid; yield: 65 mg (66 %). mp. 232 - 233 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 7.88-7.84 (m, 4H, 4CHAr), 7.79 (d, 
3J = 8.3 Hz, 2H, CHAr), 7.43 (d, 
3J = 8.4 Hz, 2H, CHAr). 
13C-NMR (75 MHz, CDCl3): 
δ = 152.9 (CAr/Hetar), 149.3 (CAr/Hetar), 148.1 (CAr/Hetar), 140.5 (CAr/Hetar), 139.5 (CAr/Hetar), 
132.7 (2CHAr), 132.0 (2CHAr), 130.3 (2CHAr), 130.0 (CAr/Hetar), 129.4 (2CHAr), 128.3 
(CAr/Hetar), 118.2 (C≡N), 118.0 (C≡N), 113.6 (CAr), 113.4(CAr). IR (ATR, cm
-1): 
ṽ = 3101 (w), 3072 (w), 3055 (w), 2954 w), 2921 (m), 2851 (w), 2227 (m), 1814 (w), 
1732 (w), 1608 (w), 1540 (m), 1497 (m), 1405 (m), 1370 (s), 1358 (s), 1325 (m), 1308 
(m), 1293 (s), 1267 (s), 1181 (m), 1163 (m), 1099 (m), 1044 (s), 1018 (m), 968 (m), 878 
(m), 845 (s), 832 (s), 767 (s), 749 (s), 738 (s), 726 (m), 673 (s), 662 (s), 650 (s), 637 (s), 
619 (s), 610 (m), 564 (s), 551 (s). MS (EI, 70 eV): m/z (%) = 388 (M+, 6), 387 (M+, 31), 
386 (M+, 19), 385 (M+, 93), 384 (M+, 22), 383 (M+, 95), 352 (12), 351 (14), 350 (63), 
349 (22), 348 (100), 313 (15), 286 (15), 278 (25), 277 (49), 252 (17), 251 (19), 250 
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(22), 224 (12), 187 (15), 185 (35), 176 (10), 175 (11), 174 (11), 161 (14), 156 (15), 150 
(11), 143 (12), 138 (12), 126 (10), 125 (13), 112 (11), 102 (11), 100 (10), 99 (15), 76 
(11), 75 (18). HR-MS (EI): m/z = calcd. for C19H8N3Cl3 [M]
+: 382.97783; found: 
382.97752; calcd. for C19H8N3Cl2
37Cl: 384.97488; found 384.97485; calcd. for 
C19H8N3Cl
37Cl2: 386.97193; found 386.97304. Anal. calcd. for C19H8Cl3N3: C 59.33, H 
2.10, N 10.92; found: C 59.36, H 2.44, N 10.50. 
2,3,5-trichloro-4,6-bis(3,5-dimethylphenyl)pyridine (5e): 
5e was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and 3,5-dimethylphenylboronic acid (0.55 mmol, 82.5 mg) 
and was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 72 mg (72 %). 
mp. 120 - 121 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.31 (s, 
2H, CHAr), 7.13 (s, 1H, CHAr), 7.10 (s, 1H, CHAr), 6.89 (s, 2H, CHAr), 2.41 (s, 6H, 
2CH3), 2.39 (s, 6H, 2CH3). 
13C-NMR (75 MHz, CDCl3): δ = 155.3 (CAr/Hetar), 151.2 
(CAr/Hetar), 147.0 (CAr/Hetar), 138.3 (2CAr/Hetar), 137.7 (2CAr/Hetar), 136.9 (CAr/Hetar), 135.8 
(CAr/Hetar), 131.0 (CHAr), 130.7 (CHAr), 129.0 (CAr/Hetar), 128.9 (CAr/Hetar), 127.1 (2CHAr), 
125.8 (2CHAr), 21.4 (2CH3), 21.3 (2CH3). IR (ATR, cm
-1): ṽ = 3003 (w), 2953 (w), 
2915 (w), 2858 (w), 1605 (m), 1541 (m), 1434 (m), 1372 (s), 1300 (s), 1291 (s), 1264 
(m), 1229 (m), 1204 (m), 1164 (w), 1078 (m), 1041 (m), 1013 (m), 996 (m), 899 (m), 
882 (w), 850 (s), 770 (m), 709 (s), 691 (m), 654 (m), 625 (m), 535 (m). MS (EI, 70 eV): 
m/z (%) = 394 (M+, 7), 393 (M+, 32), 392 (M+, 25), 391 (M+, 96), 390 (M+, 35), 389 
(M+, 100), 388 (M+, 12), 356 (38), 355 (15), 354 (59), 268 (13), 169 (12), 152 (11), 151 
(9), 133 (17), 77 (10). HR-MS (EI): m/z = calcd. for C21H18NCl3 [M]
+: 389.04993; 
found: 389.04979; calcd. for C21H18NCl2
37Cl: 391.04698; found 391.04716; calcd. for 
C21H18NCl
37Cl2: 393.04403; found 393.04448. Anal. calcd. for C21H18Cl3N: C 64.55, H 
4.64, N 3.58; found: C 64.34, H 4.58, N 3.38. 
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2,3,5-trichloro-4,6-bis(4-ethylphenyl)pyridine (5f):  
5f was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and 4-ethylphenylboronic acid (0.55 mmol, 82.5 mg) and was 
purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 59 mg (58 %). 
mp. 93 - 94 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.68 (d, 
3J = 8.1 Hz, 2H, CHAr), 7.37 (d, 
3J = 8.1 Hz, 2H, CHAr), 7.32 
(d, 3J = 8.1 Hz, 2H, CHAr), 7.21 (d, 
3J = 8.1 Hz, 2H, CHAr), 2.81-2.69 (m, 4H, 
2CH2CH3), 1.33 (t, 
3J = 6.7 Hz, 3H, CH2CH3), 1.29 (t, 
3J = 6.7 Hz, 3H, CH2CH3). 
13C-
NMR (75 MHz, CDCl3): δ = 154.9 (CAr/Hetar), 150.9 (CAr/Hetar), 147.1 (CAr/Hetar), 145.7 
(CAr/Hetar), 145.1 (CAr/Hetar), 134.4 (CAr/Hetar), 133.1 (CAr/Hetar), 129.5 (2CH), 129.0 
(CAr/Hetar), 128.9 (CAr/Hetar), 128.3 (2CHAr), 128.1 (2CHAr), 127.7 (2CHAr), 28.7 
(CH2CH3), 28.6 (CH2CH3), 15.4 (CH2CH3), 15.1(CH2CH3). IR (ATR, cm
-1): ṽ = 2963 
(m), 2929 (m), 2871 (w), 1610 (m), 1571 (w), 1539 (m), 1501 (m), 1464 (m), 1370 (s), 
1303 (s), 1271 (s), 1186 (m), 1167 (w), 1099 (m), 1063 (w), 1043 (s), 968 (w), 876 (w), 
851 (m), 829 (s), 767 (m), 738 (m), 716 (m), 668 (s), 619 (m), 578 (s), 537 (m). MS (EI, 
70 eV): m/z (%) = 394 (M+, 8), 393 (M+, 32), 392 (M+, 31), 391 (M+, 99), 390 (M+, 49), 
389 (M+, 100), 388 (28), 378 (20), 377 (13), 376 (58), 375 (16), 374 (61), 253 (10), 240 
(9), 188 (11), 187 (11), 181 (13), 180 (36), 179 (40), 144 (10), 127 (12), 126 (11), 119 
(12), 105 (14). HR-MS (EI): m/z = calcd. for C21H18NCl3 [M]
+: 389.04993; found: 
389.04880; calcd. for C21H18NCl2
37Cl: 391.04698; found 391.04634; calcd. for 
C21H18NCl
37Cl2: 393.04403; found 393.04394. Anal. calcd. for C21H18Cl3N: C 64.55, H 
4.64, N 3.58; found: C 65.00, H 4.99, N 3.30. 
2,3,5-trichloro-4,6-bis(3-chlorophenyl)pyridine (5g):  
5g was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and 3-chlorophenylboronic acid (0.55 mmol, 86.0 mg) and was 
purified via column chromatography 
(heptane/dichloromethane). Oil colorless; yield: 35 mg (34 %). 
Rf (10 % ethyl acetate/ heptan) = 0.52. 1H-NMR (300 MHz, 
CDCl3): δ = 7.73 (d, 
4J = 1.8 Hz, 1H, CHAr), 7.63 (pdt, 
3J = 6.8, 4J = 1.8 Hz, 1H, CHAr), 
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7.50-7.46 (m, 2H, CHAr), 7.35-7.45 (m, 2H, CHAr), 7.27-7.31 (m, 1H, CHAr), 7.14 - 7.21 
(m, 1H, CHAr). 
13C-NMR (75 MHz, CDCl3): δ = 153.5 (CAr/Hetar), 149.6 (CAr/Hetar), 
147.6 (CAr/Hetar), 138.2 (CAr/Hetar), 137.0 (CAr/Hetar), 134.8 (CAr/Hetar), 134.2 (CAr/Hetar), 
130.2 (CHAr), 129.7 (CAr/Hetar), 129.6 (CHAr), 129.6 (CHAr), 129.5 (CHAr), 129.5 (CHAr), 
128.8 (CAr/Hetar), 128.5 (CHAr), 127.7 (CHAr), 126.6 (CHAr). IR (ATR, cm
-1): ṽ = 3065 
(w), 2922 (w), 2852 (w), 1807 (w), 1762 (w), 1699 (w), 1596 (w), 1539 (w), 1472 (m), 
1419 (w), 1366 (s), 1287 (s), 1256 (m), 1206 (m), 1113 (m), 1095 (m), 1048 (s), 9981 
(w), 974 (w), 896 (m), 790 (m), 757 (s), 705 (s), 692 (s), 660 (m), 635 (w), 608 (m), 535 
(m). MS (EI, 70 eV): m/z (%) = 407 (M+, 21), 406 (M+, 12), 405 (M+, 65), 404 (M+, 
19), 403 (M+, 100), 402 (M+, 12), 401 (M+, 62), 370 (35), 369 (15), 368 (72), 367 (13), 
366 (56), 333 (15), 331 (15), 298 (11), 297 (18), 296 (16), 295 (23), 263 (12), 261 (40), 
225 (25), 200 (10), 196 (15), 194 (21), 185 (12), 184 (12), 166 (13), 165 (12), 149 (20), 
148 (29), 135 (10), 130 (13), 123 (10), 117 (10), 111 (10), 99 (17), 75 (18). HR-MS 
(EI): m/z = calcd. for C17H8NCl5 [M]
+: 400.90939; found: 400.90909; calcd. for 
C17H8NCl4
37Cl: 402.90644; found 402.90615; calcd. for C17H8NCl3
37Cl2: 404.90349; 
found 404.90354. Anal. calcd. for C17H8Cl5N: C 50.60, H 2.00, N 3.47; found: C 50.97, 
H 2.48, N 3.07. 
2,3,5-trichloro-4,6-bis(4-(trifluoromethyl)phenyl)pyridine (5h): 
 5h was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and 4-(trifluoromethyl)phenylboronic acid (0.55 mmol, 
104.5 mg) and was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 43 mg (35 %). 
mp. 156 - 157 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.88 (d, 
3J = 8.3 Hz, 2H, CHAr), 7.83 (d, 
3J = 8.1 Hz, 2H, CHAr), 7.76 
(d, 3J = 8.3 Hz, 2H, CHAr), 7.44 (d, 
3J = 8.1 Hz, 2H, CHAr). 
13C-NMR (75 MHz, 
CDCl3): δ = 153.6 (CAr/Hetar), 149.7 (CAr/Hetar), 147.9 (CAr/Hetar), 139.9 (CAr/Hetar), 138.8 
(CAr/Hetar), 131.5 (q, 
2J = 32.7 Hz, 2CAr), 130.0 (2CHAr), 129.9 (CAr), 129.0 (2CHAr), 
128.6 (CAr), 125.9 (q, 
3J = 3.7 Hz, 2CHAr), 125.3 (q, 
3J = 3.7 Hz, 2CHAr), 123.9 (q, 
1J = 272.3 Hz, CF3), 123.8 (q, 
1J = 272.3 Hz, CF3). 
19F-NMR (282 MHz, CDCl3): δ = -
62.83 (ArCF3), -62.85 (ArCF3). IR (ATR, cm
-1): ṽ = 3072 (w), 2925 (w), 2853 (w), 
1580 (w), 1524 (w), 1508 (w), 1408 (m), 1380 (w), 1319 (s), 1296 (m), 1277 (m), 1189 
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(w), 1161 (m), 1107 (s), 1063 (s), 1018 (m), 981 (w), 909 (w), 880 (w), 841 (m), 827 
(m), 776 (m), 705 (m), 679 (w), 644 (w), 630 (m), 621 (m), 612 (m), 593 (m). MS (EI, 
70 eV): m/z (%) = 473 (M+, 27), 472 (M+, 18), 471 (M+, 83), 470 (M+, 19), 469 (M+, 
85), 452 (12), 450 (13), 438 (11), 437 (14), 436 (66), 435 (22), 434 (100), 400 (10), 364 
(10), 363 (14), 344 (13), 329 (12), 295 (21), 294 (12), 228 (18), 193 (13), 145 (12), 75 
(11), 69 (18). HR-MS (EI): m/z = calcd. for C19H8NCl3F6 [M]
+: 468.96210; found: 
468.96243; calcd. for C19H8NCl2
37ClF6: 470.95915; found 470.95954; calcd. for 
C19H8NCl
37Cl2F6: 472.95620; found 472.95697. Anal. calcd. for C19H8Cl3F6N: C 48.49, 
H 1.71, N 2.98; found: C 48.43, H 1.98, N 2.82. 
General procedure for the synthesis of compounds 6a–c 
An oven-dried, argon-flushed sealable glass tube was charged with 4-bromo-2,3,5-
trichloro-6-p-tolylpyridine 4b (0.29 mmol, 100  mg), Pd(PPh3)4 (5 mol%, 16.5 mg), the 
appropriate arylboronic acid (0.43 mmol) and K3PO4 (0.43 mmol, 91 mg) followed by a 
mixture of toluene/water/n-butanol (6:1:1, 4 mL); The tube was sealed with a Teflon 
valve and stirred at 100 °C for 20 h. The cooled reaction mixture was diluted with water 
and extracted with CH2Cl2. The combined organic layers were dried with Na2SO4, 
filtered and concentrated in vacuum. The residue was purified by column 
chromatography using heptane/ethyl acetate as eluent. 
2,3,5-trichloro-4-(4-cyanophenyl)-6-p-tolylpyridine (6a):  
6a was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-p-tolylpyridine 4b (0.29 mmol, 
100  mg) and 4-cyanophenylboronic acid (0.43 mmol, 63.2 mg) 
and was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 53 mg (50 %). 
mp. 191 - 192 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.85 (d, 
3J = 8.6 Hz, 2H, CHAr), 7.65 (d, 
3J = 8.2 Hz, 2H, CHAr), 7.43 (d, 
3J = 8.6 Hz, 2H, CHAr), 
7.30 (d, 3J = 7.9 Hz, 2H, CHAr), 2.43 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): 
δ = 155.3 (CAr/Hetar), 148.8 (CAr/Hetar), 147.5 (CAr/Hetar), 140.2 (CAr/Hetar), 139.9 (CAr/Hetar), 
133.5 (CAr/Hetar), 132.6 (2CHAr), 129.5 (2CHAr), 129.4 (2CHAr), 128.9 (2CHAr), 128.0 
(CAr/Hetar), 122,2 (CAr/Hetar), 118.2 (C≡N), 113.3 (CAr/Hetar), 21.4 (CH3). IR (ATR, cm
-1): 
ṽ = 3092 (w), 3043 (w), 2955 (w), 2923 (w), 2855 (w), 2228 (m), 1572 (w), 1539 (w), 
1497 (m), 1451 (w), 1366 (s), 1296 (s), 1266 (s), 1202 (m), 1184 (m), 1165 (w), 1096 
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(w), 1043 (s), 970 (w), 958 (w), 877 (w), 823 (s), 766 (m), 738 (m), 680 (s), 667 (m), 
646 (m), 619 (w), 572 (s), 554 (m). MS (EI, 70 eV): m/z (%) = 377 (M+, 7), 376 (M+, 
31), 375 (M+, 24), 374 (M+, 96), 373 (M+, 34), 372 (M+, 100), 371 (14), 339 (29), 338 
(12), 337 (45), 301 (10), 266 (19), 265 (24), 240 (10), 238 (10), 185 (11), 150 (10), 133 
(15), 91 (18). HR-MS (EI): m/z = calcd. for C19H11N2Cl3 [M]
+: 371.99823; found: 
371.99710; calcd. for C19H11N2Cl2
37Cl: 373.99528; found 373.99417; calcd. for 
C19H81N2Cl
37Cl2: 375.99233; found 375.99208. Anal. calcd. for C19H11Cl3N2: C 61.07, 
H 2.97, N 7.50; found: C 61.33, H 3.24, N 7.34. 
2,3,5-trichloro-4-(3-nitrophenyl)-6-p-tolylpyridine (6b):  
6b was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-p-tolylpyridine 4b (0.29 mmol, 
100  mg) and 3-nitrophenylboronic acid (0.43 mmol, 
71.8 mg) and was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 62 mg (55 %). 
mp. 113 - 114 °C. 1H-NMR (300 MHz, CDCl3): δ = 8.38 
(ddd, 3J = 8.2 Hz, 4J = 2.3 Hz, 4J = 1.2 Hz, 1H, CHAr), 8.22 (pt, 
4J = 1.8 Hz, 1H, CHAr), 
7.75 (pt, 3J = 7.9 Hz, 1H, CHAr), 7.67-7.63 (m, 3H, CHAr), 7.30 (d, 
3J = 7.9 Hz, 2H, 
CHAr), 2.43 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): δ = 155.5 (CAr/Hetar), 148.4 
(CAr/Hetar), 148.1 (CAr/Hetar), 147.5 (CAr/Hetar), 139.9 (CAr/Hetar), 137.1 (CAr/Hetar), 134.7 
(CHAr), 133.5 (CAr/Hetar), 129.9 (CHAr), 129.4 (CHAr), 128.9 (CHAr), 128.5 (CAr/Hetar), 
128.3 (CAr/Hetar), 124.1 (CHAr), 123.9 (CHAr), 21.4 (CH3). IR (ATR, cm
-1): ṽ = 3082 (w), 
3033 (w), 2922 (w), 2855 (w), 1581 (w), 1528 (s), 1512 (m), 1480 (w), 1453 (w), 1373 
(m), 1345 (s), 1313 (w), 1295 (m), 1268 (m), 1204 (w), 1186 (w), 1165 (w), 1049 (m), 
1002 (w), 931 (w), 899 (m), 825 (m), 811 (m), 768 (w), 730 (m), 702 (s), 691(s), 668 
(m), 570 (m), 533 (w). MS (EI, 70 eV): m/z (%) = 397 (M+, 6), 396 (M+, 33), 395 (M+, 
20), 394 (M+, 97), 393 (M+, 24), 392 (M+, 100), 348 (25), 346 (26), 311 (13), 276 (19), 
275 (13), 274 (10), 261 (10), 241 (18), 240 (30), 238 (20), 214 (11), 213 (16), 155 (14), 
138 (13), 120 (27), 106 (17), 91 (17). HR-MS (ESI): m/z = calcd. for C18H11Cl3N2O2 
([M+H]+): 392.99589, found: 392.99597, calcd. for C18H11Cl2
37ClN2O2: 394.99315, 
found 394.99326, calcd. for C18H11Cl
37Cl2N2O2 : 396.99061, found 396.99107. Anal. 
calcd. for C18H11Cl3N2O2: C 54.92, H 2.82, N 7.12; found: C 55.04, H 3.27, N 6.86. 
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2,3,5-trichloro-4-(3-methoxyphenyl)-6-p-tolylpyridine (6c): 
6c was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-p-tolylpyridine 4b (0.29 mmol, 
100  mg) and 3-methoxyphenylboronic acid (0.43 mmol, 
65.3 mg) and was purified via column chromatography 
(heptane/dichloromethane). Colorless viscous oil; yield: 
51 mg (48 %). Rf = 0.73 (Heptan/ EA 4:1). 1H-NMR 
(300 MHz, CDCl3): δ = 7.66 (d, 
3J = 8.2 Hz, 2H, CHAr), 7.45 (dd, 
3J = 7.96 Hz, 
3J = 7.96 Hz, 1H, CHAr), 7.29 (d, 
3J = 8.2 Hz, 2H, CHAr), 7.03 (ddd, 
3J = 8.4 Hz, 
4J = 2.6 Hz, 5J = 0.9 Hz, 1H, CHAr), 6.83-6.88 (m, 1H, CHAr), 6.82 (dd, 
4J = 2.6 Hz, 
4J = 1.7 Hz, 1H, CHAr), 3.87 (s, 3H, OCH3), 2.43 (s, 3H, CH3), 
13C-NMR (75 MHz, 
CDCl3): δ = 159.7 (C-OCH3), 154.9 (CAr/Hetar), 150.7 (CAr/Hetar), 147.1 (CAr/Hetar), 139.5 
(CAr/Hetar), 137.0 (CAr/Hetar), 134.0 (CAr/Hetar), 129.9 (2CHAr), 129.4 (2CHAr), 128.8 
(CHAr), 128.8 (2CAr/Hetar), 120.5 (CHAr), 114.5 (CHAr), 114.0 (CHAr), 55.3 (OCH3), 21.4 
(CH3). IR (ATR, cm
-1): ṽ = 3033 (v), 2921 (w), 2853 (w), 1610 (m), 1579 (m), 1541 
(m), 1510 (m), 1485 (m), 1453 (m), 1373 (s), 1314 (m), 1286 (s), 1269 (s), 1237 (s), 
1203 (m), 1148 (m), 1053 (s), 1034 (s), 1020 (m), 994 (w), 907 (m), 877 (m), 822 (s), 
770 (m), 750 (s), 712 (s), 634 (m), 576 (m), 491 (m), 481 (m), 408 (w). MS (EI, 70 eV): 
m/z (%) = 382 (M+, 7), 381 (M+, 33), 380 (M+, 32), 379 (M+, 100), 378 (M+, 57), 377 
(M+, 99), 376 (37), 350 (5), 349 (9), 348 (8), 347 (9), 312 (6), 264 (7), 228 (9), 227 (9), 
91 (5), 63 (5), 39 (5). HR-MS (ESI): m/z = calcd. for C19H14Cl3NO (M+H
+) 378.02137; 
found 378.02176; calcd. for C19H14Cl2
37ClNO (M+H+) 380.01864; found 380.01903; 
calcd. for C19H14Cl
37Cl2NO (M+H
+) 382.01611; found 382.01658; calcd. for 
C19H14Cl3NO (M+Na
+) 400.00332; found 400.00353; calcd. for C19H14Cl2
37ClNO 
(M+H+) 402.00059; found 402.00064. Anal. calcd. for C19H14Cl3NO: C 60.26, H 3.73, 
N 3.70; found: C 60.04, H 3.57, N 3.86. 
General procedure for the synthesis of Triarylpyridine from 3 (mixtures 7/8)  
An oven-dried, argon-flushed sealable glass tube was charged with 4-bromo-2,3,5-
trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg), Pd(OAc)2 (5 mol%, 2.9 mg), PCy3 
(10 mol%, 7.24 mg) or SPhos (10 mol%, 10.6 mg), the appropriate arylboronic acid 
(2.5-4.5 equivalent) and K3PO4 (0.77 mmol, 164.45 mg) followed by a mixture of 
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toluene/water/buthanol (6:1:1, 4 mL); The tube was sealed with a Teflon valve and 
stirred at 100 °C or 70 °C for 19 h. The cooled reaction mixture was diluted with water 
and extracted with CH2Cl2. The combined organic layers were dried with Na2SO4, 
filtered and concentrated in vacuum. The residue was purified by column 
chromatography affording isomeric mixtures of 3,5-dichloro-2,4,6-tri-p-tolylpyridine 7 
and 3-chloro-2,4,5,6-tetrakis-p-tolylpyridine 8 which could not be separated 
preparatively by column chromatography. The products were confirmed by GC-MS und 
HR-MS data.  
General procedure for the synthesis of compounds 9a–d 
An oven-dried, argon-flushed sealable glass tube was charged with 2,3,5-trichloro-4,6-
di-p-tolylpyridine 5a (0.28 mmol, 100 mg), Pd(PPh
3
)
4
 (5 mol%, 16 mg), the appropriate 
arylboronic acid (0.33 mmol) and K3PO4 (0.33 mmol, 70.3 mg) followed by anhydrous 
toluene (3 mL). The tube was sealed with a Teflon valve and stirred at 100 °C for 20 h. 
The cooled reaction mixture was diluted with water and extracted with CH2Cl2. The 
combined organic layers were dried with Na2SO4, filtered and concentrated in vacuum. 
The residue was purified by column chromatography using heptane/dichloromethane as 
eluent. 
3,5-dichloro-2-(4-methoxyphenyl)-4,6-di-p-tolylpyridine (9a):  
9a was synthesized according to general procedure 
using 2,3,5-trichloro-4,6-di-p-tolylpyridine 5a 
(0.28 mmol, 100 mg) and 4-methoxyphenylboronic 
acid (0.33 mmol, 50.1 mg) and was purified via 
column chromatography (heptane/dichloromethane). 
White solid; yield: 68 mg (57 %). mp. 137 - 138 °C. 
1H-NMR (300 MHz, CDCl3): δ = 7.79 (d, 
3J = 8.8 Hz, 2H, CHAr), 7.70 (d, 
3J = 8.1 Hz, 
2H, CHAr), 7.36 (d, 
3J = 7.9 Hz, 2H, CHAr), 7.30-7.23 (m, 4H, CHAr), 6.99 (d, 
3J = 8.8 Hz, 2H, CHAr), 3.87 (s, 3H, OCH3), 2.47 (s, 3H, CH3), 2.42 (s, 3H, CH3). 
13C-
NMR (75 MHz, CDCl3): δ = 160.1 (C-OCH3), 154.6 (CAr/Hetar), 154.2 (CAr/Hetar), 149.4 
(CAr/Hetar), 138.8 (CAr/Hetar), 138.5 (CAr/Hetar), 135.6 (CAr/Hetar), 133.8 (CAr/Hetar), 131.1 
(2CH), 130.8 (CAr/Hetar), 129.5 (2CHAr), 129.3 (2CHAr), 128.7 (2CHAr), 128.6 (2CHAr), 
128.3 (CAr/Hetar), 128.2 (CAr/Hetar), 113.4 (2CHAr), 55.3 (OCH3), 21.5 (CH3), 21.4 (CH3). 
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IR (ATR, cm-1): ṽ = 3034 (w), 3005 (w), 2956 (w), 2921 (w), 2836 (w), 1607 (m), 1504 
(m), 1460 (w), 1453 (w), 1440 (w), 1362 (m), 1306 (w), 1249 (s), 1177 (m), 1155 (w), 
1083 (m), 1037 (m), 1027 (m), 1008 (w), 968 (w), 877 (w), 837 (m), 819 (s), 792 (m), 
778 (s), 756 (m), 737 (w), 722 (m), 673 (m), 643 (m), 621 (m), 602 (m), 578 (w), 539 
(s), 531 (s). MS (EI, 70 eV): m/z (%) = 437 (M+, 11), 436 (M+, 17), 435 (M+, 66), 434 
(M+, 28), 433 (M+, 100), 400 (7), 399 (5), 398 (18), 202 (4). HR-MS (ESI): 
m/z = calcd. for C26H21Cl2NO ([M+H]
+): 434.1073, found: 434.10737, calcd. for 
C26H21Cl
37ClN2O: 436.10493, found 436.10496, calcd. for C26H21
37Cl2N2O: 438.1033, 
found 438.10339. Anal. calcd. for C26H21Cl2NO: C 71.89, H 4.87, N 3.22; found: C 
71.67, H 5.03, N 2.96. 
3,5-dichloro-2-(2-methoxyphenyl)-4,6-di-p-tolylpyridine (9b):  
9b was synthesized according to general procedure using 
2,3,5-trichloro-4,6-di-p-tolylpyridine 5a (0.28 mmol, 
100 mg) and 2-methoxyphenylboronic acid (0.33 mmol, 
50.1 mg) and was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 59 mg 
(49 %). mp. 106 - 107 °C.1H-NMR (300 MHz, CDCl3): 
δ = 7.69 (d, 3J = 8.1 Hz, 2H, CHAr), 7.41 (d, 
3J = 7.4 Hz, 2H, CHAr), 7.35 (d, 
3J = 8.1 Hz, 2H, CHAr), 7.28 (m, 4H, CHAr), 7.10-7.07 (m, 1H, CHAr), 7.00 (d, 
3J = 8.7 Hz, 1H, CHAr), 3.85 (s, 3H, OCH3), 2.46 (s, 3H, CH3), 2.41 (s, 3H, CH3). 
13C-
NMR (75 MHz, CDCl3): δ = 156.9 (C-OCH3), 154.8 (2CAr/Hetar), 153.8 (CAr/Hetar), 148.3 
(CAr/Hetar), 138.6 (CAr/Hetar), 138.5 (CAr/Hetar), 135.6 (CAr/Hetar), 133.5 (CAr/Hetar), 130.6 
(CHAr), 130.2 (CHAr), 129.6 (2CHAr), 129.2 (2CHAr), 128.8 (2CHAr), 128.7 (2CHAr), 
128.1 (2CAr/Hetar), 120.6 (CHAr), 110.9 (CHAr), 55.6 (OCH3), 21.4 (CH3), 21.3 (CH3). IR 
(ATR, cm-1): ṽ = 3029 (w), 2919 (w), 2839 (w), 1603 (m), 1583 (w), 1506 (m), 1493 
(m), 1455 (w), 1365 (s), 1305 (w), 1276 (m), 1246 (s), 1184 (m), 1157 (m), 1083 (m), 
1021 (m), 967 (w), 878 (w), 818 (m), 785 (m), 746 (s), 729 (s), 687 (m), 668 (w), 584 
(w), 548 (w), 536 (m). MS (EI, 70 eV): m/z (%) = 435 (M+, 13), 434 (M+, 11), 433 (M+, 
20), 432 (8), 401 (19), 400 (76), 399 (61), 398 (100), 368 (16), 363 (13), 215 (8), 202 
(8), 158 (9). HR-MS (EI): m/z = calcd. for C26H21ONCl2 [M]
+: 433.09947; found: 
433.09878; calcd. for C26H21ONCl
37Cl: 435.09652; found 435.09638. Anal. calcd. for 
C26H21Cl2NO: C 71.89, H 4.87, N 3.22; found: C 71.78, H 4.83, N 3.00. 
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3,5-dichloro-2-(4-fluorophenyl)-4,6-di-p-tolylpyridine (9c):  
9c was synthesized according to general procedure 
using 2,3,5-trichloro-4,6-di-p-tolylpyridine 5a 
(0.28 mmol, 100 mg) and 4-fluorophenylboronic acid 
(0.33 mmol, 46.2 mg) and was purified via column 
chromatography (heptane/dichloromethane). White 
solid; yield: 44 mg (38 %). mp. 152 - 153 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 7.81 (dd, 
3J = 8.9 Hz, 4J = 2.27 Hz, 2H, CHAr), 7.70 (d, 
3J = 8.2 Hz, 2H CHAr), 7.37 (d, 
3J = 7.9 Hz, 2H, CHAr), 7.30 (d, 
3J = 7.9 Hz, 2H, CHAr), 
7.25 (d, 3J = 8.1 Hz, 2H, CHAr), 7.16 (pt, 
3J = 8.8 Hz, 2H, CHAr), 2.47 (s, 3H, CH3), 
2.43 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): δ = 163.1 (d, 
1J = 249.8 Hz, (CAr-F)), 
154.9 (CAr/Hetar), 153.57 (CAr/Hetar), 149.5 (CAr/Hetar), 138.9 (CAr/Hetar), 138.6 (CAr/Hetar), 
135.3 (CAr/Hetar), 134.4 (d, 
4J = 3.66 Hz, CAr), 133.5 (CAr/Hetar), 131.7 (d, 
3J = 8.24 Hz, 
2CH), 129.5 (2CHAr), 129.3 (2CHAr), 128.8 (CAr/Hetar), 128.7 (2CHAr), 128.5 (2CHAr), 
128.4 (CAr/Hetar), 115 (d, 
2J = 22.0 Hz, 2CHAr), 21.4 (CH3), 21.4 (CH3). 
19F-NMR 
(282 MHz, CDCl3): δ = - 112.42. IR (ATR, cm
-1): ṽ = 3033 (w), 2922 (w), 2864 (w), 
1898 (w), 1603 (m), 1574 (w), 1545 (w), 1502 (s), 1450 (w), 1361 (s), 1309 (m), 1297 
(m), 1277 (w), 1226 (m), 1185 (m), 1155 (s), 1079 (m), 1031 (m), 1013 (m), 968 (w), 
875 (m), 819 (s), 806 (m), 778 (s), 758 (m), 734 (m), 715 (m), 676 (m), 659 (m), 620 
(w), 599 (m), 561 (w). MS (EI, 70 eV): m/z (%) = 425 (M+, 13), 424 (M+, 18), 423 (M+, 
76), 422 (M+, 33), 421 (M+, 100), 406 (6), 388 (22), 387 (17), 386 (69), 350 (6), 234 
(6), 233 (8). HR-MS (EI): m/z = calcd. for C25H18NCl2F [M]
+: 421.07948; found: 
421.07922; calcd. for C25H18NCl
37ClF: 423.07653; found 423.07657. Anal. calcd. for 
C25H18Cl2FN: C 71.10, H 4.30, N 3.32; found: C 71.26, H 4.19, N 3.25. 
3,5-dichloro-2-(4-chlorophenyl)-4,6-di-p-tolylpyridine (9d): 
9d was synthesized according to general procedure 
using 2,3,5-trichloro-4,6-di-p-tolylpyridine 5a 
(0.28 mmol, 100 mg) and 4-chlorophenylboronic acid 
(0.33 mmol, 51.6 mg) and was purified via column 
chromatography (heptane/dichloromethane). White 
solid; yield: 60 mg (50 %). mp. 163 - 164 °C. 1H-NMR 
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(300 MHz, CDCl3): δ = 7.76 (d, 
3J = 9.1 Hz, 2H, CHAr), 7.70 (d, 
3J = 8.1 Hz, 2H, CHAr), 
7.45 (d, 3J = 8.7 Hz, 2H, CHAr), 7.37 (d, 
3J = 7.9 Hz, 2H, CHAr), 7.30 (d, 
3J = 7.9 Hz, 
2H, CHAr), 7.25 (d, 
3J = 8.1 Hz, 2H, CHAr), 2.47 (s, 3H, CH3), 2.43 (s, 3H, CH3). 
13C-
NMR (75 MHz, CDCl3): δ = 154.9 (CAr/Hetar), 153.4 (CAr/Hetar), 149.6 (CAr/Hetar), 139.0 
(CAr/Hetar), 138.7 (CAr/Hetar), 136.7 (CAr/Hetar), 135.3 (CAr/Hetar), 134.9 (CAr/Hetar), 133.4 
(CAr/Hetar), 131.1 (2CHAr), 129.5 (2CHAr), 129.3 (2CHAr), 129.0 (CAr/Hetar), 128.8 
(2CHAr), 128.5 (2CHAr), 128.4 (CAr/Hetar), 128.2 (2CHAr), 21.5 (CH3), 21.4 (CH3). IR 
(ATR, cm-1): ṽ = 3132 (w), 3090 (w), 3056 (w), 3032 (w), 2919 (w), 2864 (w), 1908 
(w), 1595 (w), 1543 (w) 1488 (m), 1447 (w), 1361 (s), 1308 (w), 1298 (w), 1278 (w), 
1186 (m), 1153 (m), 1076 (m), 1031 (w), 1010 (m), 968 (w), 948 (w), 872 (m), 818 (s), 
777 (s), 763 (s), 734 (s), 713 (m), 686 (w), 651 (m), 620 (w), 584 (w), 562 (m). MS (EI, 
70 eV): m/z (%) = 442 (M+, 8), 441 (M+, 30), 440 (M+, 26), 439 (M+, 100), 438 (M+, 
31), 437 (M+, 99), 406 (6), 405 (9), 404 (35), 403 (15), 402 (56), 215 (6.34), 213 (8), 
158 (5). HR-MS (EI): m/z = calcd. for C25H18NCl3 [M]
+: 437.04993; found: 437.04960; 
calcd. for C25H18NCl2
37Cl: 439.04698; found 439.04679. Anal. calcd. for C25H18Cl3N: C 
68.43, H 4.13, N 3.19; found: C 68.42, H 4.11, N 3.18. 
General procedure for the synthesis of compounds 10a–c 
An oven-dried, argon-flushed sealable glass tube was charged with 2,3,5-trichloro-4-(4-
cyanophenyl)-6-p-tolylpyridine 6a (0.27 mmol, 100 mg), Pd(PPh
3
)
4
 (5 mol%, 15.5 mg), 
the appropriate arylboronic acid (0.32 mmol) and K3PO4 (0.32 mmol, 68.4 mg) 
followed by anhydrous toluene (3 mL); The tube was sealed with a Teflon valve and 
stirred at 100 °C for 20 h. The cooled reaction mixture was diluted with water and 
extracted with CH2Cl2. The combined organic layers were dried with Na2SO4, filtered 
and concentrated in vacuum. The residue was purified by column chromatography using 
heptane/ethyl acetate as eluent. 
3,5-dichloro-2-(4-methoxyphenyl)-4-(4-cyanophenyl)-6-p-tolylpyridine (10a):  
10a was synthesized according to general procedure 
using 2,3,5-trichloro-4-(4-cyanophenyl)-6-p-
tolylpyridine 6a (0.27 mmol, 100 mg) and 4-
methoxyphenylboronic acid (0.32 mmol, 48.6 mg) Cl
N
Cl
CN
Me OMe
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and was purified via column chromatography (heptane/ ethyl acetate). White solid; 
yield: 75 mg (63 %). mp. 187 - 188 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.84 (d, 
3J = 8.6 Hz, 2H, CHAr), 7.79 (d, 
3J = 8.9 Hz, 2H, CHAr), 7.70 (d, 
3J = 8.2 Hz, 2H, CHAr), 
7.48 (d, 3J = 8.6 Hz, 2H, CHAr), 7.30 (d, 
3J = 7.9 Hz, 2H, CHAr), 7.00 (d, 
3J = 8.9 Hz, 
2H, CHAr), 3.87 (s, 3H, OCH3), 2.43 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): 
δ = 160.6 (C-OCH3), 155.2 (CAr/Hetar), 154.8 (CAr/Hetar), 147.7 (CAr/Hetar), 141.4 (CAr/Hetar), 
139.5 (CAr/Hetar), 135.2 (CAr/Hetar), 132.7 (2CH), 131.4 (2CH), 130.4 (CAr/Hetar), 130.1 
(2CHAr), 129.7 (2CHAr), 129.0 (2CHAr), 127.5 (CAr/Hetar), 127.4 (CAr/Hetar), 118.7 (C≡N), 
113.7 (2CHAr), 112.9 (CAr/Hetar), 55.6 (OCH3), 21.6 (CH3). IR (ATR, cm
-1): ṽ = 3039 
(w), 2955 (w), 2923 (w), 2840 (w), 2232 (m), 1606 (m), 1576 (w), 1510 (m), 1498 (m), 
1465 (w), 1441 (w), 1364 (s), 1304 (w), 1294 (m), 1281 (w), 1254 (s), 1175 (s), 1153 
(m), 1080 (m), 1038 (w), 1014 (m), 971 (w), 876 (m), 846 (m), 830 (s), 791 (m), 781 
(s), 745 (m), 724 (m), 663 (m), 619 (w), 601 (w), 557 (s). MS (EI, 70 eV): m/z 
(%) = 448 (M+, 12), 447 (M+, 19), 446 (M+, 67), 445 (M+, 31) 444 (M+, 100), 409 (16), 
393 (5), 366 (6), 330 (7), 329 (7), 316 (5), 240 (8), 222 (6), 214 (9). HR-MS (EI): 
m/z = calcd. for C26H18ON2Cl2 [M]
+: 444.07907; found: 444.07896; calcd. for 
C26H18ON2Cl
37Cl: 446.07612; found 446.07673. Anal. calcd. for C26H18Cl2N2O: C 
70.12, H 4.07, N 6.29; found: C 69.91, H 4.20, N 6.49. 
3,5-dichloro-2-(4-chlorophenyl)-4-(4-cyanophenyl)-6-p-tolylpyridine (10b):  
10b was synthesized according to general procedure 
using 2,3,5-trichloro-4-(4-cyanophenyl)-6-p-
tolylpyridine 6a (0.27 mmol, 100 mg) and 4-
chlorophenylboronic acid (0.32 mmol, 50.0 mg) and 
was purified via column chromatography (heptane/ 
ethyl acetate). White solid; yield: 92 mg (77 %). mp. 
164 - 165 °C. 1H-NMR (300 MHz, CDCl3): δ = 
 7.85 (d, 3J = 8.5 Hz, 2H, CHAr), 7.76 
(d, 3J = 8.6 Hz, 2H, CHAr), 7.69 (d, 
3J = 8.2 Hz, 2H, CHAr), 7.48 (d, 
3J = 8.5 Hz, 2H, 
CHAr), 7.45 (d, 
3J = 8.6 Hz, 2H, CHAr), 7.30 (d, 
3J = 8.0 Hz, 2H, CHAr), 2.43 (s, 3H, 
CH3). 
13C-NMR (75 MHz, CDCl3): δ = 155.3 (CAr/Hetar), 153.7 (CAr/Hetar), 147.6 
(CAr/Hetar), 140.8 (CAr/Hetar), 139.4 (CAr/Hetar), 136.1 (CAr/Hetar), 135.3 (CAr/Hetar), 134.7 
(CAr/Hetar), 132.5 (2CHAr), 130.9 (2CHAr), 129.7 (2CHAr), 129.4 (2CHAr), 128.8 (2CHAr), 
128.3 (2CHAr), 128.0 (CAr), 127.4 (CAr), 118,3 (C≡N), 112.9 (CAr), 21.4 (CH3). IR 
Cl
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(ATR, cm-1): ṽ = 3071 (w), 3056 (w), 3041 (w), 2956 (w), 2922 (w), 2853 (w), 1597 
(w), 1511 (w), 1489 (m), 1449 (w), 1364 (s), 1308 (w), 1297 (w), 1269 (w), 1184 (w), 
1155 (m), 1095 (m), 1080 (m), 1044 (w), 1011 (m), 973 (w), 905 (m), 875 (m), 829 (m), 
818 (s), 781 (m), 729 (s), 654 (m), 619 (m), 573 (m), 553 (s). MS (EI, 70 eV): m/z 
(%) = 453 (M+, 8), 452 (M+, 34), 451 (M+, 29), 450 (M+, 99), 449 (M+, 35), 448 (M+, 
100), 447 (8), 416 (11), 415 (36), 414 (18), 413 (55), 377 (11), 342 (9), 341 (9), 261 
(19), 241 (11), 240 (20), 238 (11), 225 (21), 171 (10), 170 (13), 157 (14), 91 (12). HR-
MS (EI): m/z = calcd. for C25H15N2Cl3 [M]
+: 448.02953; found: 448.02876; calcd. for 
C25H15N2Cl2
37Cl: 450.02658; found 450.02618; calcd. for C25H15N2Cl
37Cl2: 452.02363; 
found 452.02238. Anal. calcd. for C25H15Cl3N2: C 66.76, H 3.36, N 6.23; found: C 
66.90, H 3.41 , N 6.09. 
3,5-dichloro-2-(4-(trifluoromethyl)phenyl)-4-(4-cyanophenyl)-6-p-tolylpyridine 
(10c):  
10c was synthesized according to general procedure 
using 2,3,5-trichloro-4-(4-cyanophenyl)-6-p-
tolylpyridine 6a (0.27 mmol, 100 mg) and 4-
(trifluoromethyl)phenylboronic acid (0.32 mmol, 
60.8 mg) and was purified via column 
chromatography (heptane/ ethyl acetate). White solid; 
yield: 79 mg (61 %). mp. 187 - 188 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.92 (d, 
3J = 8.1 Hz, 2H, CHAr), 7.86 (d, 
3J = 8.5 Hz, 2H, CHAr), 7.75 (d, 
3J = 8.2 Hz, 2H, CHAr), 
7.70 (d, 3J = 8.2 Hz, 2H, CHAr), 7.50 (d, 
3J = 8.5 Hz, 2H, CHAr), 7.31 (d, 
3J = 7.9 Hz, 
2H, CHAr), 2.44 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): δ = 155.5 (CAr/Hetar), 153.5 
(CAr/Hetar), 147.8 (CAr/Hetar), 141.2 (CAr/Hetar), 140.6 (CAr/Hetar), 139.6 (CAr/Hetar), 134.6 
(CAr/Hetar), 132.6 (2CHAr), 131.1 (q, 
2J = 32.5 Hz, CAr), 130.0 (2CHAr), 129.8 (2CHAr), 
129.5 (2CHAr), 128.9 (2CHAr), 128.6 (CAr/Hetar), 127.6 (CAr/Hetar), 125.1 (q, 
3J = 3.85 Hz, 
2CHAr), 123.9 (q, 
1J = 272.35 Hz, CF3), 118.3 (C≡N), 113.0 (CAr), 21.4 (CH3). 
19F-
NMR (282 MHz, CDCl3): δ = -62.73 (ArCF3). IR (ATR, cm
-1): ṽ = 3044 (w), 2919 (w), 
2858 (w), 2229 (w), 1811 (w), 1611 (w), 1581 (w), 1524 (w), 1452 (w), 1411 (w), 1369 
(m), 1354 (m), 1322 (s), 1272 (w), 1187 (w), 1166 (m), 1123 (s), 1111 (s), 1088 (m), 
1065 (s), 1018 (m), 960 (w), 877 (m), 854 (m), 845 (m), 828 (s), 780 (m), 742 (m), 724 
(m), 699 (m), 649 (m), 619 (m), 594 (m), 550 (m). MS (EI, 70 eV): m/z (%) = 486 (M+, 
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13), 485 (M+, 19), 484 (M+, 68), 483 (M+, 35), 482 (M+, 100), 481 (14), 449 (19), 448 
(16), 447 (52), 295 (6), 240 (6). HR-MS (ESI): m/z = calcd. for C26H15Cl2F3N2 
([M+H]+): 483.06371, found: 483.06374, calcd. for C26H15Cl
37ClF3N2: 485.06132, 
found 485.06241. Anal. calcd. for C26H15Cl2F3N2: C 64.61, H 3.13, N 5.80; found: C 
64.45, H 3.07, N 5.47. 
General procedure for the synthesis of compounds 11a–b 
An oven-dried, argon-flushed sealable glass tube was charged with 3,5-dichloro-2-(4-
methoxyphenyl)-4,6-di-p-tolylpyridine 9a (0.23 mmol, 100 mg), PdCl
2
(CH
3
CN)
2
 
(5 mol%, 3.0 mg), SPhos (10 mol%, 9.5 mg), the appropriate arylboronic acid 
(0.92 mmol) and K3PO4 (0.92 mmol, 195.5 mg) followed by anhydrous toluene (3 mL); 
The tube was sealed with a Teflon valve and stirred at 100 °C for 20 h. The cooled 
reaction mixture was diluted with water and extracted with CH2Cl2. The combined 
organic layers were dried with Na2SO4, filtered and concentrated in vacuum. The 
residue was purified by column chromatography using heptane/dichloromethane as 
eluent. 
2-(4-methoxyphenyl)-3,5-diphenyl-4,6-di-p-tolylpyridine (11a):  
11a was synthesized according to general procedure 
using 3,5-dichloro-2-(4-methoxyphenyl)-4,6-di-p-
tolylpyridine 9a (0.23 mmol, 100 mg) and 
phenylboronic acid (0.92 mmol, 112.2 mg) and was 
purified via column chromatography (heptane/ 
dichloromethane). White solid; yield: 118 mg (99 %). 
mp. 242 - 243 °C.1H-NMR (300 MHz, CDCl3): δ = 7.37 (d, 
3J = 8.8 Hz, 2H, CHAr), 
7.33 (d, 3J = 8.1 Hz, 2H, CHAr), 7.06 - 6.99 (m, 8H, CHAr), 6.97–6.89 (m, 4H, CHAr), 
6.75-6.70 (m, 4H, CHAr), 6.65 (d, 
3J = 8.1 Hz, 2H, CHAr), 3.77 (s, 3H, OCH3), 2.29 (s, 
3H, CH3), 2.14 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): δ = 158.9 (CAr/Hetar), 156.1 
(CAr/Hetar), 155.7 (CAr/Hetar), 150.2 (CAr/Hetar), 138.9 (CAr/Hetar), 138.9 (CAr/Hetar), 138.2 
(CAr/Hetar), 136.9 (CAr/Hetar), 135.5 (CAr/Hetar), 135.2 (CAr/Hetar), 133.5 (CAr/Hetar),133.1 
(CAr/Hetar), 133.1 (CAr/Hetar), 131.6 (2CHAr), 131.3 (2CHAr), 130.3 (2CHAr), 130.1 
(2CHAr), 128.2 (2CHAr), 127.6 (2CHAr), 127.4 (2CHAr), 127.3 (2CHAr), 126.0 (2CHAr), 
125.9 (2CHAr), 112.9 (2CHAr), 55.1 (OCH3), 21.2 (CH3), 21.1 (CH3). IR (ATR, cm
-1): 
N
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ṽ = 3054 (w), 3029 (w), 2949 (w), 2917 (w), 2866 (w), 1603 (m), 1578 (w), 1504 (m), 
1444 (m), 1389 (m), 1353 (w), 1329 (w), 1297 (w), 1272 (w), 1245 (s), 1173 (m), 1042 
(m), 1029 (m), 1006 (w), 963 (w), 880 (w), 818 (s), 796 (m), 764 (m), 697 (s), 657 (m), 
620 (w), 594 (w), 555 (m), 537 (m). MS (EI, 70 eV): m/z (%) = 518 (M+, 21), 517 (71), 
516 (100), 472 (10), 236 (7), 220 (5), 213 (6), 207 (8), 201 (7), 191 (6), 189 (7), 165 (6). 
HR-MS (ESI): m/z = calcd. for C38H31NO ([M+H]
+): 518.24784, found: 518.24755. 
Anal. calcd. for C38H31NO: C 88.17, H 6.04, N 2.71; found: C 87.81, H 5.94, N 2.52. 
3,5-bis(4-tert-butylphenyl)-2-(4-methoxyphenyl)-4,6-di-p-tolylpyridine (11b):  
11b was synthesized according to general procedure 
using 3,5-dichloro-2-(4-methoxyphenyl)-4,6-di-p-
tolylpyridine 9a (0.23 mmol, 100 mg) and 4-tert-
butylphenylboronic acid (0.92 mmol, 163.8 mg) and 
was purified via column chromatography (heptane/ 
dichloromethane). White solid; yield: 116 mg 
(80 %). mp. 237 - 238 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.36 (d, 
3J = 8.9 Hz, 2H, 
CHAr), 7.32 (d, 
3J = 8.1 Hz, 2H, CHAr), 7.03 (dd, 
3J = 8.5 Hz, 3J = 8.4 Hz, 4H, CHAr), 
6.97 (d, 3J = 8.0 Hz, 2H CHAr), 6.81 (d, 
3J = 7.9 Hz, 4H, CHAr), 6.70 (d, 
3J = 8.7 Hz, 
4H, CHAr), 6.60 (d, 
3J = 8.1 Hz, 2H, CHAr), 3.77 (s, 3H, OCH3), 2.29 (s, 3H, CH3), 2.14 
(s, 3H, CH3), 1.22 (s, 18H, CH3 tBu). 
13C-NMR (75 MHz, CDCl3): δ = 158.7 (CAr/Hetar), 
155.8 (CAr/Hetar), 155.5 (CAr/Hetar), 150.4 (CAr/Hetar), 148.9 (CAr/Hetar), 148.9 (CAr/Hetar), 
136.7 (CAr/Hetar), 135.9 (CAr/Hetar), 135.8 (CAr/Hetar), 135.4 (CAr/Hetar), 135.1 (CAr/Hetar), 
133.1 (CAr/Hetar), 133.1 (CAr/Hetar), 131.6 (2CHAr), 130.9 (4CHAr), 130.4 (2CHAr), 130.2 
(2CHAr), 128.1 (2CHAr), 127.3 (2CHAr), 124.2 (2CHAr), 124.1 (2CHAr), 112.7 (2CHAr), 
55.1 (OCH3), 34.3 (2C tBu), 31.3 (6CH3 tBu), 21.2 (CH3), 20.9 (CH3). IR (ATR, cm
-1): 
ṽ = 3028 (w), 2958 (m), 2903 (m), 2866 (m), 1609 (m), 1512 (m), 1500 (m), 1460 (m), 
1443 (w), 1387 (m), 1361 (m),1297 (w), 1244 (s), 1178 (m), 1171 (m), 1110 (m), 1043 
(m), 1031(m), 1020 (m), 1001 (w), 947 (w), 850 (m), 820 (s), 810 (m), 793 (m), 763 
(m), 718 (m), 699 (w), 673 (m), 666 (m), 585 (m), 552 (m), 531 (m). MS (EI, 70 eV): 
m/z (%) = 630 (32), 629 (M+, 88), 628 (100), 614 (7), 613 (7), 612 (12), 572 (9), 556 
(8), 528 (3), 281 (5), 231 (7), 219 (6), 181 (12), 169 (11), 131 (16), 119 (14), 91 (18), 78 
(6), 69 (50), 57 (9), 44 (20), 43 (6), 41 (13), 40 (44), 39 (10). HR-MS (ESI): 
N
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m/z = calcd. for C46H47NO ([M+H]
+): 630.37304 found: 630.37286. Anal. calcd. for 
C46H47NO: C 87.72, H 7.52, N 2.22; found: C 87.52, H 7.50, N 2.15. 
General procedure for the synthesis of 12a–b 
An oven-dried, argon-flushed sealable glass tube was charged with 2,3,5-trichloro-4-(4-
cyanophenyl)-6-p-tolylpyridine 6a (0.23 mmol, 85 mg), PdCl2(CH3CN)2 (5 mol%, 
3.0 mg), SPhos (10 mol%, 9.4 mg), the appropriate arylboronic acid (1.37 mmol) and 
K3PO4 (1.37 mmol, 291 mg) followed by anhydrous toluene (4 mL); The tube was 
sealed with a Teflon valve and stirred at 100 °C for 20 h. The cooled reaction mixture 
was diluted with water and extracted with CH2Cl2. The combined organic layers were 
dried with Na2SO4, filtered and concentrated in vacuum. The residue was purified by 
column chromatography using heptane/dichloromethane as eluent. 
2,3,5-tris(4-methoxyphenyl)-4-(4-cyanophenyl)-6-p-tolylpyridine (12a):  
12a was synthesized according to general procedure 
using 2,3,5-trichloro-4-(4-cyanophenyl)-6-p-
tolylpyridine 6a (0.23 mmol, 85 mg) and 4-
methoxyphenylboronic acid (1.37 mmol, 208.2 mg) 
and was purified via column chromatography 
(heptane/ dichloromethane). White solid; yield: 
124 mg (93 %). mp. 228 - 229 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.28 (d, 
3J = 8.9 Hz, 2H, CHAr), 7.23 (d, 
3J = 8.2 Hz, 2H, CHAr), 7.18 (d, 
3J = 8.5 Hz, 2H, CHAr), 
6.93 (d, 3J = 8.0 Hz, 2H, CHAr), 6.80 (d, 
3J = 8.5 Hz, 2H, CHAr), 6.70–6.63 (m, 6H, 
CHAr), 6.50 (dd, 
3J = 8.8, 4J = 3.7 Hz, 4H, CHAr), 3.69 (s, 3H, OCH3), 3.64 (s, 3H, 
OCH3), 3.63 (s, 3H, OCH3), 2.21 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): δ = 159.0 
(C-OCH3), 158.1 (C-OCH3), 158.1 (C-OCH3), 156.5 (CAr/Hetar), 156.0 (CAr/Hetar), 148.6 
(CAr/Hetar), 144.2 (CAr/Hetar), 137.8 (CAr/Hetar), 137.2 (CAr/Hetar), 133.1 (CAr/Hetar), 132.2 
(4CHAr), 131.9 (CAr/Hetar), 131.9 (CAr/Hetar), 131.5 (2CHAr), 131.2 (2CHAr), 130.9 
(2CHAr), 130.2 (CAr/Hetar), 130.2 (CAr/Hetar), 130.1 (2CHAr), 128.3 (2CHAr), 118.9 (C≡N), 
113.3 (2CHAr), 113.2 (2CHAr), 113.0 (2CHAr), 109.8 (CAr/Hetar), 55.2 (OCH3), 55.0 
(2OCH3), 21.2 (CH3). IR (ATR, cm
-1): ṽ = 2956 (w), 2931 (w), 2834 (w), 2224 (m), 
1608 (m), 1576 (w), 1529 (w), 1513 (m), 1501 (m), 1460 (w), 1445 (w), 1390 (m), 1353 
(w), 1299 (w), 1287 (m), 1243 (s), 1174 (s), 1109 (m), 1028 (m), 1016 (m), 951 (w), 
N
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852 (w), 843 (m), 823 (m), 805 (m), 761 (m), 732 (w), 683 (w), 671 (w), 655 (m), 632 
(m), 558 (s), 535 (m). MS (EI, 70 eV): m/z (%) = 590 (7), 589 (26), 588 (M+, 84), 587 
(100), 543 (8), 294 (33), 253 (7), 234 (7), 233 (6), 223 (6), 218 (8), 207 (14), 201 (7), 
152 (6), 73 (11). HR-MS (ESI): m/z = calcd. for C40H32N2O3 ([M+H]
+): 589.24857, 
found: 589.24799. Anal. calcd. for C40H32N2O 3: C 81.61, H 5.48, N 4.76; found: C 
81.22, H 5.49, N 4.48. 
2,3,5-tris(4-tert-butylphenyl)-4-(4-cyanophenyl)-6-p-tolylpyridine (12b):  
12b was synthesized according to general procedure 
using 2,3,5-trichloro-4-(4-cyanophenyl)-6-p-
tolylpyridine 6a (0.23 mmol, 85 mg) and 4-tert-
butylphenylboronic acid (1.37 mmol, 243.9 mg) and 
was purified via column chromatography (heptane/ 
dichloromethane). White solid; yield: 114 mg (75 %). 
mp. 256 - 257 °C. 1H-NMR (300 MHz, CDCl3): 
δ = 7.33 (d, 3J = 8.4 Hz, 4H, CHAr), 7.23-7.16 (m, 4H, CHAr), 7.07-6.97 (m, 6H, CHAr), 
6.89 (d, 3J = 8.5 Hz, 2H, CHAr), 6.78 (dd, 
3J = 8.5 Hz, 3J = 8.5 Hz, 4H, CHAr), 2.30 (s, 
3H, CH3), 1.27 (s, 9H, CH3 tBu), 1.22 (s, 9H, CH3 tBu), 1.22 (s, 9H, CH3 tBu). 
13C-NMR 
(75 MHz, CDCl3): δ = 156.5 (CAr/Hetar), 156.2 (CAr/Hetar), 150.2 (CAr/Hetar), 149.7 
(CAr/Hetar), 149.7 (CAr/Hetar), 148.2 (CAr/Hetar), 144.1 (CAr/Hetar), 137.7 (CAr/Hetar), 137.6 
(CAr/Hetar), 137.1 (CAr/Hetar), 134.9 (CAr/Hetar), 134.9 (CAr/Hetar), 132.6 (CAr/Hetar), 132.5 
(CAr/Hetar), 131.3 (2CHAr), 130.8 (2CHAr), 130.8 (2CHAr), 130.5 (2CHAr), 130.1 (2CHAr), 
129.8 (2CHAr), 128.2 (2CHAr), 124.6 (2CHAr), 124.5 (2CHAr), 124.3 (2CHAr), 118.9 
(C≡N), 109.6 (CAr), 34.4 (C tBu), 34.4 (C tBu), 34.3 (C tBu), 31.2 (6CH3 tBu), 31.2 (3CH3 
tBu), 21.2 (CH3). IR (ATR, cm 
- 1): ṽ = 3050(w), 2954 (m), 2904 (m), 2867 (m), 2225 
(m), 1738 (w), 1682 (w), 1608 (w), 1533 (m), 1513 (m), 1496 (m), 1462 (m), 1362 (m), 
1309 (w), 1270 (m), 1242 (m), 1202 (m), 1180 (m), 1109 (m), 1019 (m), 1002 (m), 972 
(w), 884 (w), 852 (s), 831 (s), 820 (s), 809 (s),796 (m), 772 (m), 754 (m), 737 (w), 700 
(m), 664 (m), 629 (m), 578 (s), 562 (m), 551 (s), 532 (m). MS (EI, 70 eV): m/z 
(%) = 666 (M+, 63), 665 (100), 651 (5), 609 (7), 593 (5), 579 (6), 554 (5), 553 (9), 551 
(11), 318 (23), 207 (6), 57 (59), 41(16). HR-MS (ESI): m/z = calcd. for C49H50N2 
([M+H]+): 667.40468, found: 667.40437. Anal. calcd. for C49H50N2: C 88.24, H 7.56, N 
4.20; found: C 88.17, H 7.27, N 3.89 
N
Me
CN
tButBu
tBu
5. Experimental Section 
83 
 
General procedure for the synthesis of compounds 13a–b 
An oven-dried, argon-flushed sealable glass tube was charged with the appropriate tri-
arylated pyridine 10a or 10b (0.22 mmol, 100 mg), PdCl2(CH3CN)2 (5 mol%, 2.9 mg), 
SPhos (10 mol%, 9.22 mg), the appropriate arylboronic acid (0.99 mmol) and K3PO4 
(0.99 mmol, 191 mg) followed by anhydrous toluene (3 mL); The tube was sealed with 
a Teflon valve and stirred at 100 °C for 20 h. The cooled reaction mixture was diluted 
with water and extracted with CH2Cl2. The combined organic layers were dried with 
Na2SO4, filtered and concentrated in vacuum. The residue was purified by column 
chromatography using heptane/ethyl acetate as eluent. 
2-(4-methoxyphenyl)-3,5-diphenyl-4-(4-cyanophenyl)-6-p-tolylpyridine (13a):  
13a was synthesized according to general procedure 
using 3,5-dichloro-2-(4-methoxyphenyl)-4-(4-
cyanophenyl)-6-p-tolylpyridine 10a (0.22 mmol, 
100 mg), and phenylboronic acid (0.99 mmol, 
120.7 mg) and was purified via column 
chromatography (heptane/ ethyl acetate). White solid; 
yield: 107 mg (90 %). mp. 261 - 262 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 7.38 (d,
3J = 8.9 Hz, 2H, CHAr), 7.33 (d,
3J = 8.2 Hz, 2H, CHAr), 
7.23 (d, 3J = 8.5 Hz, 2H, CHAr), 7.08–7.04 (m, 6H, CHAr), 7.01 (d, 
3J = 8.4 Hz, 2H, 
CHAr), 6.94–6.84 (m, 6H, CHAr), 6.73 (d, 
3J = 8.9 Hz, 2H, CHAr), 3.77 (s, 3H, OCH3), 
2.30 (s, 3H, CH3). 
13C-NMR (75 MHz, CDCl3): δ = 159.1 (C-OCH3), 156.4 (CAr/Hetar), 
155.9(CAr/Hetar), 148.3 (CAr/Hetar), 143.8 (CAr/Hetar), 138.0 (CAr/Hetar), 137.9 (CAr/Hetar), 
137.5 (CAr/Hetar), 137.4 (CAr/Hetar), 132.9 (CAr/Hetar), 132.3 (CAr/Hetar), 132.3 (CAr/Hetar), 
131.5 (2CHAr), 131.1 (2CHAr), 131.1 (2CHAr), 130.8 (2CHAr), 130.1 (2CHAr), 128.3 
(2CHAr), 127.8 (2CHAr), 127.8 (2CHAr), 126.7 (2CHAr), 126.6 (2CHAr), 118.7 (C≡N), 
113.0 (2CHAr), 109.9 (CAr), 55.1 (OCH3), 21.2 (CH3). IR (ATR, cm
-1): ṽ = 3045 (w), 
3025 (w), 2951 (w), 2929 (w), 2905 (w), 2832 (w), 1602 (m), 1577 (w), 1534 (m), 1510 
(m), 1503 (m), 1443 (w), 1389 (m), 1309 (w), 1295 (w), 1264 (w), 1244 (s), 1175 (m), 
1157 (w), 1074 (w), 1024 (m), 1006 (w), 969 (w), 880 (w), 848 (m), 816 (m), 767 (m), 
742 (m), 727 (m), 703 (s), 660 (m), 626 (w), 594 (w), 557 (m), 532 (m). MS (EI, 
70 eV): m/z (%) = 529 (21), 528 (M+, 71), 527 (100), 484 (8), 483 (12), 264 (8), 165 
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(5). HR-MS (ESI): m/z = calcd. for C38H28N2O ([M+H]
+): 529.22744, found: 
529.22698. Anal. calcd. for C38H28N2O: C 86.34, H 5.34, N 5.30; found: C 86.12, H 
5.29, N 5.14. 
2-(4-chlorophenyl)-3,5-bis(4-methoxyphenyl)-4-(4-cyanophenyl)-6-p-tolylpyridine 
(13b):  
13b was synthesized according to general procedure 
using 3,5-dichloro-2-(4-chlorophenyl)-4-(4-
cyanophenyl)-6-p-tolylpyridine 10b (0.22 mmol, 
100 mg), and 4-methoxyphenylboronic acid 
(0.99 mmol, 150.4 mg) and was purified via column 
chromatography (heptane/ ethyl acetate). White 
solid; yield: 66 mg (50 %). mp. 246 - 247 °C. 1H-NMR (250 MHz, CDCl3): δ = 7.35 (d, 
3J = 8.7 Hz, 2H, CHAr), 7.30 (d, 
3J = 8.2 Hz, 2H, CHAr), 7.27 (d, 
3J = 8.7 Hz, 2H, CHAr), 
7.18 (d, 3J = 8.7 Hz, 2H, CHAr), 7.03 (d, 
3J = 7.9 Hz, 2H, CHAr), 6.89 (d, 
3J = 8.5 Hz, 
2H, CHAr), 6.75 (dd, 
3J = 8.8 Hz, 3J = 8.8 Hz, 4H, CHAr), 6.59 (dd, 
3J = 8.8 Hz, 
3J = 8.9 Hz, 4H, CHAr), 3.73 (s, 3H, OCH3), 3.72 (s, 3H, OCH3), 2.30 (s, 3H, CH3). 
13C-
NMR (75 MHz, CDCl3): δ = 158.3 (C-OCH3), 158.2 (CAr/Hetar), 156.8 (CAr/Hetar), 155.3 
(CAr/Hetar), 148.8 (CAr/Hetar), 143.9 (CAr/Hetar), 139.1 (CAr/Hetar), 137.5 (CAr/Hetar), 137.4 
(CAr/Hetar), 133.6 (CAr/Hetar), 132.8 (CAr/Hetar), 132.4 (CAr/Hetar), 132.1 (4CHAr), 131.5 
(2CHAr), 131.2 (2CHAr), 130.9 (2CHAr), 129.9 (2CHAr), 129.9 (CAr), 129.6 (CAr), 128.4 
(2CHAr), 127.8 (2CHAr), 118.8 (C≡N), 113.4 (2CHAr), 113.3 (2CHAr), 110.0 (CAr), 55.0 
(2OCH3), 21.2 (CH3). IR (ATR, cm
-1): ṽ = 2933 (w), 2837 (w), 1607 (m), 1533 (w), 
1511 (m), 1488 (w), 1461 (w), 1387 (m), 1305 (w), 1288 (m), 1242 (s), 1174 (m), 1160 
(w), 1089 (w), 1030 (m), 1020 (m), 1011 (m), 999 (w), 963 (w), 880 (w), 803 (m), 760 
(w), 729 (s), 692 (w), 649 (m), 613 (w), 558 (m), 548 (w), 534 (w). MS (EI, 70 eV): 
m/z (%) = 595 (M+, 11), 594 (M+, 32), 593 (M+, 58), 592 (M+, 84), 591 (100), 547 (11), 
297 (7), 296 (11), 227 (5), 220 (5), 207 (7), 199 (6), 190 (13), 178 (6), 164 (5), 163 (6). 
HR-MS (ESI): m/z = calcd. for C39H29ClN2O2 ([M+H]
+): 593.19903, found: 593.199, 
calcd. for C39H29
37ClN2O2: 595.19825, found 595.19807. Anal. calcd. for 
C39H29ClN2O2: C 78.98, H 4.93, N 4.72; found: C 78.78, H 4.59, N 4.84. 
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General procedure for the synthesis of compounds 14a–h 
An oven-dried, argon-flushed sealable glass tube was charged with 4-bromo-2,3,5-
trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg), Pd(PPh
3
)
2
Cl2 (0.013 mmol, 5 mol%), 
and CuI (0.013 mmol, 5 mol%). The solids were diluted with triethylamine (21.5 mmol, 
3 mL). The solution was stirred at ambient temperature for ten minutes. Afterwards, 
0.28 mmol of appropriate acetylene was added. The pressure tube was closed with a 
Teflon cap and the reaction mixture was stirred at room temperature for 19 h. 
Afterwards, the reaction mixture was diluted with distilled water and dichloromethane. 
The aqueous layer was extracted with dichloromethane (three times). The combined 
organic layers were dried with sodium sulfate, filtered and the solvent was evaporated 
under reduced pressure. The residue was purified by column chromatography using 
heptane/dichloromethane as eluent to purify the corresponding monoalkynylpyridines. 
4-bromo-2,3,5-trichloro-6-(2-phenylethynyl)pyridine (14a):  
14a was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and ethynylbenzene (0.28 mmol, 0.031 mL) and was purified 
via column chromatography (heptane/ dichloromethane). White 
solid; yield: 84 mg (90 %). mp. 135 – 136 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 7.67 - 7.60 (m, 2H, CHAr), 7.48-7.37 (m, 3H, CHAr). 
13C-NMR 
(75.0 MHz, CDCl3): δ = 147.1 (CAr/Hetar), 139.3 (CAr/Hetar), 135.8 (CAr/Hetar), 134.6 
(CAr/Hetar), 132.4 (2CHAr), 131.6 (CAr/Hetar), 130.0 (2CHAr), 128.5 (CHAr), 121.1 (CAr), 
97.3 (C≡C), 84.8 (C≡C). IR (ATR, cm-1): ṽ =  3055 (w), 2954 (m), 2922 (m), 2220 (m), 
1519 (s), 1492 (s), 1440 (m), 1386 (s), 1321 (s), 1269 (s), 1217 (s), 1080 (s), 916 (m), 
820 (s), 755 (s), 686 (s), 677 (s), 641 (m), 557 (s), 549 (s), 530 (s). MS (EI, 70 eV): m/z 
(%) = 365 (M+, 17), 363 (M+, 63), 362 (14), 361 (M+, 100), 359 (M+, 52), 247 (15), 245 
(24), 219 (10), 184 (24), 175 (32), 127 (10), 120 (12), 118 (18), 92 (16). HR-MS (EI): 
m/z = calcd. for C13H5NBrCl3 [M]
+: 358.86655, found: 358.86609; calcd. for 
C13H5NBrCl2
37Cl [M]+: 360.86360, found: 360.86361; calcd. For C13H5NBrCl
37Cl2 
[M]+: 362.86065, found: 362.86092; calcd. For C13H5N
81BrCl2
37Cl [M]+: 362.86155, 
found: 362.86092; calcd. For C13H5N
81BrCl37Cl2 [M]
+: 364.85860, found: 364.85840; 
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calcd. For C13H5NBr
37Cl3 [M]
+: 364.85770, found: 364.85840; Anal. calcd. for 
C13H5NBrCl3: C 43.20, H 1.39, N 3.88; found: C 43.11, H 1.24, N 3.94 . 
2-(2-(4-tert-butylphenyl)ethynyl)-4-bromo-3,5,6-trichloropyridine (14b):  
14b was synthesized according to general procedure 
using 4-bromo-2,3,5-trichloro-6-iodopyridine 3 
(0.26 mmol, 100 mg) and 1-tert-butyl-4-ethynylbenzene 
(0.28 mmol, 0.051 mL) and was purified via column 
chromatography (heptane/ dichloromethane). White solid; 
yield: 100 mg (92 %). mp. 107 – 108 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.58 (d, 
3J = 8.6 Hz, 2H, CHAr), 7.43 (d, 
3J = 8.6 Hz, 2H, CHAr), 1.34 (s, 9H, CH3 tBu). 
13C-
NMR 75.0 MHz, CDCl3): 153.7 (CAr/Hetar), 147.0 (CAr/Hetar), 139.6 (CAr/Hetar), 135.7 
(CAr/Hetar), 134.5 (CAr/Hetar), 132.2 (2CHAr), 131.3 (CAr/Hetar), 125.6 (2CHAr), 118.0 (CAr), 
97.9 (C≡C), 84.5 (C≡C), 35.0 (C tBu), 31.1 (3CH3 tBu). IR (ATR, cm
-1): ṽ = 2963 (m), 
2905 (m), 2215 (m), 1515 (m), 1483 (s), 1462 (m), 1383 (s), 1319 (s), 1289 (s), 1271 
(s), 1214 (s), 1196 (m), 1081 (s), 998 (m), 945 (m), 895 (m), 843 (s), 835 (s), 819 (s), 
766 (s), 738 (s), 705 (s), 693 (s), 644 (m), 614 (s), 564 (s). MS (EI, 70 eV): m/z 
(%) = 421 (M+, 5), 419 (M+, 19), 418 (6), 417 (M+, 29), 415 (M+, 14), 406 (17), 405 
(11), 404 (64), 403 (19), 402 (100), 401 (13), 400 (50), 376 (10), 374 (13), 188 (10), 41 
(11). HR-MS (ESI): m/z = calcd. for C17H13BrCl3N [M+Na]
+: 437.91892, found: 
437.91832; calcd. for C17H13BrCl2
37ClN [M+Na]+: 439.91597, found: 439.91607; calcd. 
for C17H13
81BrCl3N [M+Na]
+: 439.91687, found: 439.91607, calcd. for 
C17H13
81BrCl2
37Cl2N [M+Na]
+: 441.91392, found: 441.91327; calcd. for 
C17H13BrCl
37Cl2N [M+Na]
+: 441.91302, found: 441.91327; calcd. for C17H13Br
37Cl3N 
[M+Na]+: 443.91007, found: 443.91174; calcd. for C17H13
81BrCl37Cl2N [M+Na]
+: 
443.91097, found: 443.91174. Anal. calcd. for C17H13BrCl3N: C 48.90, H 3.14, N 3.35; 
found: C 48.81, H 3.21, N 3.26. 
4-bromo-2,3,5-trichloro-6-(2-(4-methoxyphenyl)ethynyl)pyridine, (14c):  
14c was synthesized according to general procedure using 
4-bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 
100 mg) and 1-ethynyl-4-methoxybenzene (0.28 mmol, 
0.036 mL) and was purified via column chromatography 
N
Cl
Br
Cl
Cl
MeO
N
Cl
Br
Cl
Cl
tBu
5. Experimental Section 
87 
 
(heptane/dichloromethane). White solid; yield: 86 mg (86 %). mp. 132 - 133 °C. 1H-
NMR (300 MHz, CDCl3): δ = 7.57 (d, 
3J = 8.88 Hz, 2H, CHAr), 6.90 (d, 
3J = 8.88 Hz, 
2H, CHAr), 3.84 (s, 3H, OCH3). 
13C-NMR (75.0 MHz, CDCl3): δ = 161.0 (CAr/Hetar), 
146.9 (CAr/Hetar), 139.6 (CAr/Hetar), 135.5 (CAr/Hetar), 134.1 (CAr/Hetar), 134.1 (2CHAr), 130.9 
(CAr/Hetar), 114.2 (2CHAr), 113.0 (CAr), 98.0 (C≡C), 84.2 (C≡C), 55.3 (OCH3). IR (ATR, 
cm-1): ṽ = 2922 (w), 2849 (w), 2201 (m), 1602 (m), 1517 (s), 1509 (s), 1442 (m), 1320 
(m), 1272 (s), 1251 (s), 1167 (s), 1077 (m), 1020 (s), 955 (m), 829 (s), 788 (s), 735 (s), 
666 (m), 549 (s), 535 (s). MS (EI, 70 eV): m/z (%) = 395 (M+, 17), 394 (10), 393 (M+, 
63), 392 (15), 391 (M+, 100), 390 (7), 389 (M+, 52), 378 (16), 376 (25), 374 (13), 348 
(11), 234 (30), 232 (43), 205 (12), 171 (12), 162 (21), 120 (11), 118 (14), 114 (15). HR-
MS (ESI): m/z = calcd. for C14H7BrCl3NO [M+H]
+: 389.88494, found: 389.88518; 
calcd. for C14H7
81BrCl3NO [M+H]
+: 391.88289, found: 391.88293; calcd. for 
C14H7
81BrCl2
37ClNO [M+H]+: 393.87994, found: 393.88035; calcd. for 
C14H7
81BrCl37Cl2NO [M+H]
+: 395.87699, found 395.87740. Anal. calcd. for 
C14H7BrCl3NO: C 42.95, H 1.80, N 3.58; found: C 42.90, H 1.88, N 3.56. 
4-bromo-2,3,5-trichloro-6-(2-(4-fluorophenyl)ethynyl)pyridine (14d):  
14d was synthesized according to general procedure using 
4-bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 
100 mg) and 1-ethynyl-4-fluorobenzene (0.28 mmol, 
0.032 mL) and was purified via column chromatography 
(heptane/ dichloromethane). White solid; yield: 44 mg 
(45 %). mp. 136 - 137 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.67 - 7.60 (m, 2H, CHAr), 
7.14 - 7.06 (m, 2H, CHAr). 
13C-NMR (75.0 MHz, CDCl3): δ = 163.0 (d, 
1JC-
F = 255.7 Hz, CAr), 147.2 (CAr/Hetar), 139.2 (CAr/Hetar), 135.8 (CAr/Hetar), 134.5 (CAr/Hetar), 
134.5 (d, 3JC-F = 8.8 Hz, 2CHAr), 131.7 (CAr/Hetar), 117.2 (d, 
4JC-F = 3.5 Hz, CAr), 116.0 
(d, 2JC-F = 22.3 Hz, 2CHAr), 96.1 (C≡C), 84.6 (d, 
5JC-F = 1.6 Hz, C≡C). 
19F -NMR (282 
MHz, CDCl3): δ = - 107.48 (s). IR (ATR, cm-1): ṽ = 3069 (w), 2921 (m), 2215 (m), 
1597 (m), 1505 (s), 1484 (s), 1386 (s), 1320 (s), 1282 (s), 1231 (s), 1220 (s), 1213 (s), 
1155 (s), 1072 (s), 1014 (m), 915 (m), 834 (s), 796 (s), 735 (s), 666 (m), 529 (s). MS 
(EI, 70 eV): m/z (%) = 383 (M+, 17), 382 (9), 381 (M+, 65), 380 (14), 379 (M+, 100), 
377 (M+, 50), 265 (10), 263 (16), 202 (14), 193 (18), 118 (11). HR-MS (EI): 
m/z = calcd. for C13H4NBrCl3F [M]
+: 376.85712, found: 376.85662; calcd. for 
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C13H4NBrCl2
37ClF [M]+: 378.85417, found: 378.8535; calcd. for C13H4N
81BrCl3F: 
378.85508, found: 378.85435; calcd. for C13H4N
81BrCl2
37ClF [M]+: 380.85213, foud: 
380.85190; calcd. for C13H4NBrCl
37Cl2F [M]
+: 380.85122, found: 380.85190; calcd. for 
C13H4N
81BrCl37Cl2F [M]
+: 382.84918, found: 382.84917; calcd. for C13H4NBr
37Cl3F: 
382.84827, found: 382.84917. Anal. calcd. for C13H4NBrCl3: C 41.15, H 1.06, N 3.69; 
found: C 41.10, H 1.11, N 3.60. 
4-bromo-2,3,5-trichloro-6-(pent-1-ynyl)pyridine (14e):  
14e was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and 1-pentyne (0.28 mmol, 0.028 mL) and was purified via 
column chromatography (heptane/ dichloromethane). White 
solid; yield: 47.4 mg (56 %). mp. 52 - 53 °C. 1H-NMR (300 MHz, CDCl3): δ = 2.51 (t, 
3J = 7.0 Hz, 2H, CH2), 1.77 - 1.62 (m, 2H, CH2), 1.08 (t, 
3J = 7.4 Hz, 3H, CH3). 
13C-
NMR (75.0 MHz, CDCl3): δ = 146.8 (CAr/Hetar), 139.6 (CAr/Hetar), 135.6 (CAr/Hetar), 134.4 
(CAr/Hetar), 131.1 (CAr/Hetar), 100.1 (2C≡C), 21.6 (CH2), 21.5 (CH2), 13.5 (CH3). IR 
(ATR, cm-1): ṽ = 2964 (m), 2874 (m), 2229 (s), 1514 (m), 1483 (s), 1425 (m), 1376 (s), 
1317 (s), 1288 (s), 1254 (s), 1203 (s), 1088 (m), 862 (m), 774 (s), 738 (m), 682 (s), 553 
(s). MS (EI, 70 eV): m/z (%) = 331 (M+, 9), 329 (M+, 33), 328 (15), 327 (M+, 51), 326 
(18), 325 (M+, 27), 324 (8), 316 (17), 314 (64), 313 (10), 312 (10), 310 (52), 301 (22), 
300 (21), 299 (34), 233 (10), 231 (11), 184 (21), 182 (30), 155 (13), 122 (10), 121 (20), 
120 (24), 118 (29), 115 (10), 111 (12), 99 (11), 86 (14), 85 (15), 29 (10). HR-MS (EI): 
m/z = calcd. for C10H7NBrCl3 [M]
+: 324.88220, found: 324.88151; calcd. for 
C10H7NBrCl2
37Cl [M]+: 326.87925, found: 326.87936; calcd. for C10H7N
81BrCl3 [M]
+: 
326.88015, found: 326.87936; calcd. for C10H7N
81BrCl2
37Cl [M]+: 328.87720, found: 
328.87681; calcd. for C10H7NBrCl
37Cl2 [M]
+: 328.87720, found: 328.87681; calcd. for 
C10H7N
81BrCl37Cl2 [M]
+: 330.87425, found: 330.87411; calcd. for C10H7NBr
37Cl3 [M]
+: 
330.87335, found: 330.87411. Anal. calcd. for C10H7NBrCl3: C 36.68, H 2.15, N 4.28; 
found: C 36.59, H 2.12, N 4.25. 
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2-(2-(4-bromo-3,5,6-trichloropyridin-2-yl)ethynyl)pyridine, (14f):  
14f was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and 2-ethynylpyridine (0.28 mmol, 0.028 mL) and was purified 
via column chromatography (heptane/ dichloromethane). 
Yellow solid; yield: 32 mg (35 %). mp. 189 – 190 °C. 1H-
NMR (300 MHz, CDCl3): δ = 8.69 (ddd, 
3J = 4.9 Hz, 4J = 1.7 Hz, 5J = 1.1 Hz, 1H, 
Hetar), 7.80 - 7.69 (m, 1H, Hetar), 7.65 (dpt, 3J = 7.8 Hz, 5J = 1.1 Hz, 1H, Hetar), 7.34 
(ddd, 3J = 7.5 Hz, 4J = 4.9 Hz, 5J = 1.4 Hz, 1H, Hetar). 13C-NMR (75.0 MHz, CDCl3): 
δ = 150.4 (CHHetar), 147.3 (CHetar), 141.6 (CHetar), 138.5 (CHetar), 136.4 (CHHetar), 135.9 
(CHetar), 135.3 (CHetar), 132.6 (CHetar), 128.3 (CHHetar), 124.2 (CHHetar), 94.8 (C≡C), 83.5 
(C≡C). IR (ATR, cm-1): ṽ = 3076 (w), 2954 (w), 2850 (m), 2205 (w), 1582 (m), 1488 
(s), 1464 (s), 1431 (s), 1378 (s), 1317 (s), 1287 (s), 1273 (s), 1243 (m), 1190 (s), 1083 
(s), 991 (s), 965 (m), 885 (m), 828 (s), 773 (s), 764 (s), 732 (s), 689 (s), 567 (s), 538 (s). 
MS (EI, 70 eV): m/z (%) = 364 (M+, 65), 363 (15), 362 (M+, 100), 361 (10), 360 (M+, 
53), 329 (7), 327 (15), 248 (11), 246 (17), 220 (11), 211 (13), 185 (18), 176 (17), 155 
(12), 153 (11), 123 (18), 120 (21), 118 (29), 78 (10), 75 (11), 52 (11), 51 (19), 50 (11). 
HR-MS (EI): m/z = calcd. for C12H4N2BrCl3 [M]
+: 359.86180, found: 359.86149; calcd. 
for C12H4N2BrCl2
37Cl [M]+: 361.85885, found: 361.85894; calcd. for C12H4N2
81BrCl3 
[M]+: 361.85975, found: 361.85894; calcd. for C12H4N2BrCl
37Cl2 [M]
+: 363.85590, 
found: 363.85626; calcd. for C12H4N2
81BrCl2
37Cl [M]+: 363.85680, found: 363.85626. 
Anal. calcd. for C12H4N2BrCl3: C 39.77, H 1.11, N 7.73; found: C 39.84, H 1.17, N 
7.68. 
4-bromo-2,3,5-trichloro-6-(2-(4-propylphenyl)ethynyl)pyridine (14g);  
 14g was synthesized according to general procedure 
using 4-bromo-2,3,5-trichloro-6-iodopyridine 3 
(0.26 mmol, 100 mg) and 1-ethynyl-4-propylbenzene 
(0.28 mmol, 0.044 mL) and was purified via column 
chromatography (heptane/ dichloromethane). Yellow 
solid; yield: 76 mg (73 %). mp. 66 – 67 °C.  1H-NMR (300 MHz, CDCl3): δ = 7.56 (d, 
3J = 8.12 Hz, 2H, CHAr), 7.21 (d, 
3J = 8.0 Hz, 2H, CHAr), 2.63 (t, 
3J = 7.36 Hz, 2H, 
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CH2), 1.67 (m, 2H, CH2), 0.96 (t,
 3J = 7.37 Hz, 3H, CH3). 
13C-NMR (75.0 MHz, 
CDCl3): δ = 147.0 (CAr/Hetar), 145.3 (CAr/Hetar), 139.5 (CAr/Hetar), 135.7 (CAr/Hetar), 134.4 
(CAr/Hetar), 132.3 (2CHAr), 131.3 (CAr), 128.7 (2CHAr), 118.2 (CAr), 97.7 (C≡C), 84.5 
(C≡C), 38.1 (CH2), 24.2 (CH2), 13.7 (CH3). IR (ATR, cm
-1): ṽ = 2954 (w), 2865 (w), 
2206 (m), 1520 (m), 1481 (s), 1389 (s), 1319 (s), 1269 (s), 1211 (m), 1186 (m), 1078 
(m), 945 (w), 822 (s), 795 (m), 735 (s), 658 (m), 550 (s), 536 (s). MS (EI, 70 eV): m/z 
(%) = 407 (M+, 6), 405 (M+, 27), 404 (7), 403 (M+, 42), 401 (M+, 22), 378 (17), 377 
(10), 376 (63), 375 (15), 374 (100), 373 (9), 372 (52), 260 (15), 258 (23), 197 (17), 188 
(35), 140 (19), 118 (10). HR-MS (EI): m/z = calcd. for C16H11NBrCl3 [M]
+: 400.91350, 
found: 400.91283; calcd. for C16H11NBrCl2
37Cl [M]+: 402.91055, found 402.91065; 
calcd. for C16H11N 
81BrCl2
37Cl [M]+: 404.90850, found 404.908338; calcd. for 
C16H11N
81BrCl37Cl2 [M]
+: 406.90555; found 406.90612. Anal. calcd. for C16H11NBrCl3: 
C 47.62, H 2.75, N 3.47; found: C 47.58, H 2.78, N 3.50. 
4-bromo-2,3,5-trichloro-6-(2-cyclohexylethynyl)pyridine (14h):  
 14h was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and ethynylcyclohexane (0.28 mmol, 0.037 mL) and was 
purified via column chromatography (heptane/ 
dichloromethane). White solid; yield: 76 mg (80 %). mp. 77 –
 78 °C. 1H-NMR (300 MHz, CDCl3): δ = 2.78 - 269 (m, 1H, CH), 1.94 – 1.86 (m, 2H, 
CH2), 1.82 - 173 (m, 2H, CH2), 1.68 – 1.39 (m, 6H, 3CH2). 
13C-NMR (75.0 MHz, 
CDCl3): δ = 146.7 (CAr/Hetar), 139.8 (CAr/Hetar), 135.5 (CAr/Hetar), 134.5 (CAr/Hetar), 130.9 
(CAr/Hetar), 104.1 (2C≡C), 31.8 (2CH2), 29.8 (CH), 25.8 (CH2), 24.6 (2CH2). IR (ATR, 
cm-1): ṽ = 2941 (w), 2924 (s), 2848 (s), 2218 (s), 1520 (m), 1487 (m), 1375 (s), 1319 
(s), 1288 (m), 1205 (s), 1091 (w), 891 (w), 770 (m), 739 (w), 692 (s), 567 (m), 554 (m). 
MS (EI, 70 eV): m/z (%) =  368 (M+, 14), 367 ( 26), 366 (M+, 19), 341 (20), 340 (66), 
339 (31), 338 (100), 336 (52), 312 (27), 299 (21), 286 (20), 195 (22), 120 (24), 118 
(31), 93 (20), 91 (21), 82 (22), 80 (30), 79 (24), 77 (21), 67 (65), 41 (52), 39 (36). HR-
MS (ESI): m/z = calcd. for C13H11NBrCl2
37Cl [M+H]+: 366.91055; found: 366.91024; 
calcd. for C13H11NBrCl
37Cl2 [M+H]
+: 368.90760 found 368.90775. Anal. calcd. for 
C13H11BrCl 3N: C 42.49, H 3.02, N 3.81; found: C 42.38, H 3.18, N 3.78 
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General procedure for the synthesis of compounds 15a–e 
An oven-dried, argon-flushed sealable glass tube was charged with 4-bromo-2,3,5-
trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg), Pd(PPh
3
)
4 
(0.013 mmol, 5 mol%) and 
CuI (0.013 mmol, 5 mol%). The solids were diluted with 5 ml of dry 1,4-dioxane and 
diisopropylamine (14.3 mmol, 2 mL). The solution was stirred at ambient temperature 
for ten minutes. Afterwards, 0.54 mmol of appropriate acetylene was added. The 
pressure tube was closed with a Teflon cap and the reaction mixture was stirred at 
80 °C. After 20 h the reaction was cooled to room temperature and diluted with distilled 
water and dichloromethane. The aqueous layer was extracted with dichloromethane 
(three times). The combined organic layers were dried with sodium sulfate, filtered and 
the solvent was evaporated under reduced pressure. The residue was purified by column 
chromatography using heptane/dichloromethane as eluent to purify the corresponding 
dialkynylpyridines. 
2,3,5-trichloro-4,6-bis(2-phenylethynyl)pyridine (15a): 
15a was synthesized according to general procedure using 4-
bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg) 
and 1-ethynylbenzene (0.54 mmol, 0.059 mL) and was purified 
via column chromatography (heptane/ dichloromethane). 
Yellow solid; yield: 60 mg (61 %). mp. 171 - 172 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 7.69 - 7.64 (m, 4H, CHAr), 7.51 - 7.36 
(m, 6H, CHAr). 
13C-NMR (75.0 MHz, CDCl3): δ = 147.1 
(CAr/Hetar), 139.2 (CAr/Hetar), 133.9 (CAr/Hetar), 133.6 (CAr/Hetar), 
132.3 (2CHAr), 130.8 (CAr/Hetar), 130.4 (2CHAr), 129.8 (2CHAr), 128.6 (2CHAr), 128.5 
(2CHAr), 121.4 (CAr), 121.2 (CAr), 106.1 (C≡C), 96.8 (C≡C), 84.7 (C≡C), 82.1 (C≡C). 
IR (ATR, cm-1): ṽ = 3054 (w), 2924 (w), 2212 (m), 1531 (m), 1498 (m), 1290 (s), 1259 
(m), 1184 (w), 1095 (m), 1067 (m), 912 (m), 804 (m), 749 (s), 679 (s), 527 (m). MS 
(EI, 70 eV): m/z (%) = 385 (M+, 33), 384 (22), 383 (M+, 99), 382 (24), 381 (M+, 100), 
311 (12), 275 (19), 250 (8), 192 (6), 184 (6). HR-MS (EI): m/z = calcd. for 
C21H10NCl2
37Cl [M]
+: 382.98438; found: 382.98430; calcd. for C21H10NCl
37Cl2 [M]
+: 
384.98143 found: 384.98196. Anal. calcd. for C21H10Cl3N: C 65.91, H 2.63, N 3.66; 
found: C 65.82, H 2.67, N 3.73. 
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2,4-bis(2-(4-tert-butylphenyl)ethynyl)-3,5,6-trichloropyridine (15b);  
15b was synthesized according to general procedure 
using 4-bromo-2,3,5-trichloro-6-iodopyridine 3 
(0.26 mmol, 100 mg) and 1-tert-butyl-4-ethynylbenzene 
(0.54 mmol, 0.097 mL) and was purified via column 
chromatography (heptane/dichloromethane). Yellow 
solid; yield: 85 mg (67 %). mp. 159 – 160 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 7.61 - 7.58 (m, 4H, CHAr), 7.47 -
 7.41 (m, 4H, CHAr), 1.36 (s, 9H, CH3 tBu), 1.35 (s, 9H, 
CH3 tBu). 
13C-NMR (75.0 MHz, CDCl3): δ = 154.1 (CAr), 
153.4 (CAr), 146.9 (CAr/Hetar), 139.4 (CAr/Hetar), 133.8 (CAr/Hetar), 133.7 (CAr/Hetar), 132.1 
(4CH), 130.4 (CAr/Hetar), 125.7 (2CH), 125.5 (2CH), 118.3 (CAr), 118.2 (CAr), 106.5 
(C≡C), 97.3 (C≡C), 84.4 (C≡C), 81.8 (C≡C), 35.0 (C tBu), 34.9 (C tBu), 31.1 (6CH3 tBu). 
IR (ATR, cm-1): ṽ = 2958 (m), 2927 (w), 2213 (m), 1528 (m), 1405 (w), 1383 (m), 
1289 (s), 1198 (w), 1107 (w), 1017 (w), 829 (s), 720 (m), 558 (s). MS (EI, 70 eV): m/z 
(%) = 497 (M+, 15), 496 (14), 495 (M+, 48), 494 (14), 493 (M+, 47), 483 (7), 482 (29), 
481 (24), 480 (100), 479 (26), 479 (26), 478 (99), 231 (10). HR-MS (ESI): m/z = calcd. 
for C29H26NCl3 [M+H]
+: 494.12036; found: 494.12; calcd. for C29H10NCl2
37Cl [M+H]+: 
496.11788 found: 496.11732; calcd. for C29H10NCl
37Cl2 [M+H]
+: 498.11576 found: 
498.11535. Anal. calcd. for C29H26Cl3N: C 70.38, H 5.30, N 2.83; found: C 70.46, H 
5.22, N 2.80.  
2,3,5-trichloro-4,6-bis(2-(4-methoxyphenyl)ethynyl)pyridine, (15c):  
15c was synthesized according to general procedure 
using 4-bromo-2,3,5-trichloro-6-iodopyridine 3 
(0.26 mmol, 100 mg) and 1-ethynyl-4-methoxybenzene 
(0.54 mmol, 0.070 mL) and was purified via column 
chromatography (heptane/dichloromethane). Yellow 
solid; yield: 58 mg (51 %). mp. 157 - 158 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 7.62-7.58 (m, 4H, CHAr), 6.96-
6.90 (m, 4H, CHAr), 3.87 (s, 3H, OCH3), 3.86 (s, 3H, 
OCH3). 
13C-NMR (75.0 MHz, CDCl3): δ = 161.3 (CAr), 
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160.9 (CAr), 146.9 (CAr/Hetar), 139.4 (CAr/Hetar), 134.1 (2CHAr), 134.0 (2CHAr), 133.8 
(CAr/Hetar), 133.3 (CAr/Hetar), 129.8 (CAr/Hetar), 114.3 (2CHAr), 114.2 (2CHAr), 113.4 (CAr), 
113.2 (CAr), 106.8 (C≡C), 97.3 (C≡C), 84.1 (C≡C), 81.7 (C≡C), 55.4 (OCH3), 55.4 
(OCH3). IR (ATR, cm
-1): ṽ = 2922 (w), 2837 (w), 2205 (m), 1602 (m), 1529 (s), 1513 
(s), 1436 (w), 1289 (s), 1248 (s), 1167 (s), 1105 (m), 825 (s), 759 (m), 531 (m), 505 
(m). MS (EI, 70 eV): m/z (%) = 445 (M+, 35), 444 (24), 443 (M+, 98), 442 (26), 441 
(M+, 100), 428 (14), 426 (14), 285 (11), 221 (12). HR-MS (EI): m/z = calcd. for 
C23H14O2NCl3 [M]
+: 441.00846; found: 441.00754; calcd. for C23H14O2NCl2
37Cl [M]+: 
443.00551 found: 443.00431; calcd. for C23H14O2NCl
37Cl2 [M]
+: 445.00256 found: 
445.00323. Anal. calcd. for C23H14Cl3NO2: C 62.40, H 3.19, N 3.16; found: C 62.51, H 
3.26, N 3.19. 
2,3,5-trichloro-4,6-bis(2-(4-propylphenyl)ethynyl)pyridine (15d): 
15d was synthesized according to general procedure 
using 4-bromo-2,3,5-trichloro-6-iodopyridine 3 
(0.26 mmol, 100 mg) and 1-ethynyl-4-propylbenzene 
(0.54 mmol, 0.085 mL) and was purified via column 
chromatography (heptane/dichloromethane).  Yellow 
solid; yield: 76 mg (63 %). mp. 65 - 66 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 7.57 (dd, 
3J = 8.20 Hz, 
4J = 2.52 Hz, 4H, CHAr), 7.26 - 7.19 (m, 4H, CHAr), 
2.68 - 2.60 (m, 4H, 2CH2), 1.71 - 1.59 (m, 4H, 2CH2), 
0.99 - 0.84 (m, 6H, 2CH3). 
13C-NMR (75.0 MHz, CDCl3): δ = 146.9 (CAr/Hetar), 145.7 
(CAr), 145.1 (CAr), 139.3 (CAr/Hetar), 133.7 (CAr/Hetar), 133.7 (CAr/Hetar), 132.3 (2CHAr), 
132.3 (2CHAr), 130.4 (CAr/Hetar), 128.8 (2CHAr), 128.7 (2CHAr), 118.5 (CAr), 118.4 (CAr), 
106.6(C≡C), 97.3 (C≡C), 84.4 (C≡C), 81.9 (C≡C), 38.1 (CH2), 38.1 (CH2), 24.3 (CH2), 
24.3 (CH2), 13.7 (CH3), 13.7 (CH3). IR (ATR, cm
-1): ṽ = 2955 (m), 2925 (m), 2865 (m), 
2211 (m), 1529 (s), 1493 (m), 1463 (m), 1382 (s), 1290 (s), 1215 (m), 1179 (m), 1090 
(w), 912 (m), 837 (m), 812 (s), 773 (m), 557 (s), 529 (s). MS (EI, 70 eV): m/z 
(%) = 469 (35), 468 (29), 467 (M+, 97), 466 (27), 465 (M+, 100), 440 (33), 439 (21), 
438 (86), 437 (22), 436 (88), 409 (22), 407 (27), 301 (10), 204 (24), 203 (26). HR-MS 
(EI): m/z = calcd. for C27H22NCl3 [M]
+: 465.08123; found: 465.08073; calcd. for 
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C27H22NCl2
37Cl [M]+: 467.07828 found: 467.07898. Anal. calcd. for C27H22Cl3N: C 
69.47, H 4.75, N 3.00; found: C 69.56, H 4.65, N 2.92. 
2,3,5-trichloro-4,6-bis(2-(4-fluorophenyl)ethynyl)pyridine (15e): 
15e was synthesized according to general procedure using 
4-bromo-2,3,5-trichloro-6-iodopyridine 3 (0.26 mmol, 
100 mg) and 1-ethynyl-4-fluorobenzene (0.54 mmol, 
0.062 mL) and was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 58 mg 
(54 %). mp. 198 - 199 °C. 1H-NMR (300 MHz, CDCl3): 
δ = 7.69 - 7.62 (m, 4H, CHAr), 7.17 - 7.06 (m, 4H, CHAr). 
13C-NMR (75.0 MHz, CDCl3): δ = 163.8 (d, 
1JCF = 253.64 Hz, CAr), 163.5 (d, 
1JCF = 253.50 Hz, CAr), 
147.2 (CAr/Hetar), 139.1 (CAr/Hetar), 134.5 (d, 
3JCF = 8.20 Hz, 2CHAr), 134.5 (d, 
3JCF = 8.20 Hz, 2CHAr), 133.8 (CAr/Hetar), 133.4 (CAr/Hetar), 130.8 (CAr/Hetar), 117.5 (d, 
4JCF = 3.30 Hz, CAr), 117.3 (d, 
4JCF = 3.85 Hz, CAr), 116.2 (d, 
2JCF = 22.56 Hz, 2CHAr), 
115.9 (d, 2JCF = 22.01 Hz, 2CHAr), 105.0 (C≡C), 95.8 (C≡C), 84.3 (d, 
5JCF = 1.10 Hz, 
C≡C), 81.9 (d,5JCF = 1.60 Hz, C≡C). 
19F -NMR (282 MHz, CDCl3): δ = -106.87 (s, 1F, 
Ar), -107.81 (s, 1F, Ar). IR (ATR, cm-1): ṽ = 3073 (w), 2921 (m), 2215 (m), 1598 (m),  
1513 (m), 1387 (m), 1290 (s), 1227 (s), 1154 (s), 1093 (m), 914 (m), 830 (s), 768 (m), 
551 (w), 528 (s), 497 (m). MS (EI, 70 eV): m/z (%) = 421 (M+, 32), 420 (22), 419 (M+, 
100), 418 (24), 417 (M+, 97), 347 (17), 311 (17), 286 (11), 209 (13), 202 (11), 143 (9). 
HR-MS (EI): m/z = calcd. for C21H8NCl3F2 [M]
+: 416.96849; found: 416.96951; calcd. 
for C21H8NCl2
37ClF2 [M]
+: 418.96554 found: 418.96601; calcd. for C21H8NCl
37Cl2F2 
[M]+: 420.96259 found: 420.96335. Anal. calcd. for C21H8Cl3F2N: C 60.25, H 1.93, N 
3.35; found: C 60.36, H 2.01, N 3.40. 
General procedure for the synthesis of compounds 16a–d 
An oven-dried, argon-flushed sealable glass tube was charged with 4-bromo-2,3,5-
trichloro-6-iodopyridine 3 (0.26 mmol, 100 mg), Pd(PPh
3
)
4 
(0.013 mmol, 5 mol%) and 
CuI (0.013 mmol, 5 mol%). The solids were diluted with 5 ml of dry 1,4-dioxane and 
diisopropylamine (14.3 mmol, 2 mL). The solution was stirred at ambient temperature 
for ten minutes. Afterwards, 0.80 mmol of appropriate acetylene was added. The 
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pressure tube was closed with a Teflon cap and the reaction mixture was stirred at 
80 °C. After 20 h the reaction was cooled to room temperature and diluted with distilled 
water and dichloromethane. The aqueous layer was extracted with dichloromethane 
(three times). The combined organic layers were dried with sodium sulfate, filtered and 
the solvent was evaporated under reduced pressure. The residue was purified by column 
chromatography using heptane/dichloromethane as eluent to purify the corresponding 
trialkynylpyridines. 
3,5-dichloro-2,4,6-tris(2-phenylethynyl)pyridine (16a): 
16a was synthesized according to general procedure 
using 4-bromo-2,3,5-trichloro-6-iodopyridine 3 
(0.26 mmol, 100 mg) and 1-ethynylbenzene 
(0.80 mmol, 0.088 mL) and was purified via column 
chromatography (heptane/ dichloromethane). Yellow 
solid; yield: 69 mg (60 %). mp. 151 - 152 °C. 1H-
NMR (300 MHz, CDCl3): δ = 7.71 - 7.63 (m, 6H, 
CHAr), 7.48 - 7.36 (m, 9H, CHAr). 
13C-NMR (75.0 MHz, CDCl3): δ = 140.4 (CAr/Hetar), 
133.9 (CAr/Hetar), 132.3 (6CHAr), 131.9 (CAr/Hetar), 130.2 (CHAr), 129.6 (2CHAr), 128.6 
(2CHAr), 128.5 (4CHAr), 121.7 (CAr), 121.4 (CAr), 105.3 (C≡C), 95.8 (C≡C), 85.3 
(C≡C), 81.9 (C≡C). IR (ATR, cm-1): ṽ = 3048 (w), 2955 (w), 2216 (m), 1529 (m), 1369 
(m) 1264 (m), 1212 (m), 1097 (m), 1025 (m), 973 (m), 916 (w), 751 (s), 688 (s), 485 
(m), 472 (m). MS (EI, 70 eV): m/z (%) = 451 (12), 450 (21), 449 (M+, 66), 448 (32), 
447 (M+, 100), 376 (7), 375 (14), 250 (15). HR-MS (EI): m/z = calcd. for C29H15NCl2 
[M]+: 447.05761; found: 447.05671; calcd. for C29H15NCl
37Cl [M]+: 449.05466 found: 
449.05489. Anal. calcd. for C29H15Cl2N: C 77.69, H 3.37, N 3.12; found: C 77.73, H 
3.48, N 3.21. 
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3,5-dichloro-2,4,6-tris(2-(4-fluorophenyl)ethynyl)pyridine (16b): 
16b was synthesized according to general 
procedure using 4-bromo-2,3,5-trichloro-6-
iodopyridine 3 (0.26 mmol, 100 mg) and 1-
ethynyl-4-fluorobenzene (0.80 mmol, 
0.092 mL) and was purified via column 
chromatography (heptane/dichloromethane). 
White solid; yield: 57 mg (44 %). mp. 182 -
 183 °C. 1H-NMR (300 MHz, CDCl3): 
δ = 7.70 - 7.56 (m, 6H, CHAr), 7.15 - 7.06 (m, 
6H, CHAr). 
13C-NMR (75.0 MHz, CDCl3): δ = 163.7 (d, 
1JCF = 253.09 Hz, CAr), 163.4 
(d, 1JCF = 252.00 Hz, CAr), 140.3 (CAr/Hetar), 134.5 (d, 
3JCF = 8.80 Hz, 2 or 4 CHAr), 134.4 
(d, 3JCF = 8.80 Hz, 2 or 4 CHAr), 133.8 (CAr/Hetar), 131.8 (CAr/Hetar), 117.7 (d, 
4JCF = 3.30 Hz, CAr), 117.5 (d, 
4JCF = 3.85 Hz, CAr), 116.1 (d, 
2JCF = 22.01 Hz, 2CHAr), 
115.9 (d, 2JCF = 22.01 Hz, 4CHAr), 104.4 (C≡C), 94.8 (C≡C), 84.9 (d, 
5JCF = 1.10 Hz, 
C≡C), 81.7 (d, 5JCF = 1.10 Hz, C≡C). 
19F -NMR (282 MHz, CDCl3): δ = - 107.24 (s, 1F, 
Ar), - 108.20 (s, 2F, Ar). IR (ATR, cm-1): ṽ = 3069 (w), 1599 (m), 1535 (m), 1509 (s), 
1403 (w), 1372 (m), 1227 (s), 1154 (s), 1091 (m), 961 (w), 829 (s), 772 (m), 527 (m), 
461 (m). MS (EI, 70 eV): m/z (%) = 505 (14), 504 (20), 503 (M+, 69), 502 (34), 501 
(M+, 100), 429 (10), 286 (21), 251 (10), 143 (9). HR-MS (EI): m/z = calcd. for 
C29H12NCl2F3 [M]
+: 501.02934; found: 501.02880; calcd. for C29H12NCl
37ClF3 [M]
+: 
503.02639 found: 503.02697. Anal. calcd. for C29H12Cl2F3N: C 69.34, H 2.41, N 2.79; 
found: C 69.43, H 2.36, N 2.70. 
3,5-dichloro-2,4,6-tris(2-(4-methoxyphenyl)ethynyl)pyridine (16c): 
16c was synthesized according to general 
procedure using 4-bromo-2,3,5-trichloro-6-
iodopyridine 3 (0.26 mmol, 100 mg) and 1-
ethynyl-4-methoxybenzene (0.80 mmol, 
0.104 mL) and was purified via column 
chromatography (heptane/dichloromethane). 
Yellow solid; yield: 80 mg (58 %). mp. 143 –
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 144 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.63 - 7.58 (m, 6H, CHAr), 6.96 - 6.89 (m, 
6H, CHAr), 3.87 (s, 3H, OCH3), 3.85 (s, 6H, 2OCH3). 
13C-NMR (75.0 MHz, CDCl3): 
δ = 161.1 (CAr), 160.6 (CAr), 140.4 (CAr/Hetar), 134.0 (CHAr), 133.9 (CHAr), 132.9 
(CAr/Hetar), 131.9 (CAr/Hetar) , 114.3 (CHAr), 114.1 (CHAr), 113.8 (CAr), 113.5 (CAr), 105.8 
(C≡C), 96.0 (C≡C), 84.6 (C≡C), 81.5 (C≡C), 55.4 (OCH3), 55.3 (2OCH3). IR (ATR, 
cm-1): ṽ = 3070 (w), 2919 (m), 2838 (w), 1602 (m), 1507 (s), 1439 (m), 1373 (m), 1290 
(m), 1247 (s), 1168 (m), 1020 (m), 830 (s), 766 (m), 569 (m), 487 (m). MS (EI, 70 eV): 
m/z (%) = 541 (14), 540 (22), 539 (M+, 69), 538 (33), 537 (M+, 100), 522 (9), 169 (2). 
HR-MS (EI): m/z = calcd. for C32H21O3NCl2 [M]
+: 537.08930; found: 537.08800; 
calcd. for C32H21O3NCl
37Cl [M]+: 539.08635 found: 539.08608. Anal. calcd. for 
C32H21Cl2NO3: C 71.38, H 3.93, N 2.60; found: C 71.50, H 4.04, N 2.62. 
3,5-dichloro-2,4,6-tris(2-p-tolylethynyl)pyridine (16d):  
16d was synthesized according to general 
procedure using 4-bromo-2,3,5-trichloro-6-
iodopyridine 3 (0.26 mmol, 100 mg) and 1-
ethynyl-4-methylbenzene (0.80 mmol, 
0.101 mL) and was purified via column 
chromatography (heptane/dichloromethane). 
Yellow solid; yield: 74 mg (58 %). mp. 
177 - 178 °C. 1H-NMR (300 MHz, CDCl3): 
δ = 7.58 - 7.54 (m, 6H, CHAr), 7.25 - 7.19 (m, 6H, CHAr), 2.42 (s, 3H, CH3), 2.40 (s, 6H, 
2CH3). 
13C-NMR (75.0 MHz, CDCl3): δ = 140.7 (CAr/Hetar), 140.4 (CAr) 139.9 (CAr), 
133.5 (CAr/Hetar), 132.2 (2CHAr), 131.9 (CAr/Hetar), 129.3 (CHAr), 129.2 (CHAr), 118.6 
(CAr), 118.4 (CAr), 105.7 (C≡C), 96.1 (C≡C), 84.9 (C≡C), 81.7 (C≡C), 21.7 (CH3), 21.7 
(2CH3). IR (ATR, cm
-1): ṽ = 3026 (w), 2956 (w), 2853 (w), 2212 (m), 1536 (m), 1369 
(m), 1262 (w), 1209 (m), 1177 (m), 1093 (m), 833 (w), 809 (s), 764 (m), 526 (s), 459 
(m), 422 (m); MS (EI, 70 eV): m/z (%) = 493 (18), 492 (M+, 27), 491 (80), 490 (M+, 
40), 489 (100), 403 (7), 402 (9), 135 (7). HR-MS (ESI): m/z = calcd. for C32H21NCl2 
[M+H]+: 490.11238; found: 490.11211; calcd. for C32H21NCl
37Cl [M+H]+: 492.11025 
found: 492.11011. Anal. calcd. for C32H21Cl2N: C 78.37, H 4.32, N 2.86; found: C 
78.48, H 4.19, N 2.80. 
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General procedure for the synthesis of compounds 17a–c 
An oven-dried, argon-flushed sealable glass tube was charged with 2,3,5-trichloro-4,6-
bis(2-phenylethynyl)pyridine 15a (0.21 mmol, 80 mg), Pd(CH3CN)2Cl2 (0.0105 mmol, 
5 mol%), XPhos (0.010 mmol, 10 mol%) and CuI (0.0105 mmol, 5 mol%). The solids 
were diluted with 7 ml of dry 1,4-dioxane and diisopropylamine (28.7 mmol, 4 mL). 
The solution was stirred at ambient temperature for ten minutes. Afterwards, 1.05 mmol 
of appropriate acetylene was added. The pressure tube was closed with a Teflon cap and 
the reaction mixture was stirred at 80 °C. After 18 h the reaction was cooled to room 
temperature and diluted with distilled water and dichloromethane. The aqueous layer 
was extracted with dichloromethane (three times). The combined organic layers were 
dried with sodium sulfate, filtered and the solvent was evaporated under reduced 
pressure. The residue was purified by column chromatography using 
heptane/dichloromethane as eluent to purify the corresponding pentaalkynylpyridines. 
2,3,5-tris(2-(4-methoxyphenyl)ethynyl)-4,6-bis(2-phenylethynyl)pyridine (17a):  
17a was synthesized according to general 
procedure using 2,3,5-trichloro-4,6-bis(2-
phenylethynyl)pyridine 15a (0.21 mmol, 
80 mg) and 1-ethynyl-4-methoxybenzene 
(1.05 mmol, 0.139 mL) and was purified 
via column chromatography (heptane/ 
dichloromethane). Yellow solid; yield: 
132 mg (94 %). mp. 185 – 186 °C. 1H-
NMR (300 MHz, CDCl3): δ = 7.68 - 7.65 (m, 4H, CHAr), 7.62 - 7.56 (m, 6H, CHAr), 
7.43 - 7.35 (m, 6H, CHAr), 6.93 - 6.89 (m, 6H, CHAr), 3.86 (brs, 9H, 3OCH3). 
13C-NMR 
(75.0 MHz, CDCl3): δ = 160.5 (CAr), 160.4 (2CAr), 143.0 (CAr), 142.6 (CAr/Hetar), 134.6 
(CAr/Hetar), 133.8 (2CHAr), 133.3 (4CHAr), 132.2 (2CHAr), 132.1 (2CHAr), 129.5 (CHAr), 
129.2 (CHAr), 128.6 (2CHAr), 128.4 (2CHAr), 122.9 (CAr), 122.8 (CAr/Hetar), 122.5 (CAr), 
122.4 (CAr), 114.9 (CAr), 114.9 (CAr), 114.3 (CAr), 114.2 (4CHAr), 114.1 (2CHAr), 102.1 
(C≡C), 101.3 (2C≡C), 95.3 (C≡C), 94.6 (C≡C), 88.0 (C≡C), 87.1 (C≡C), 85.8 (C≡C), 
84.7 (C≡C), 84.6 (C≡C), 55.4 (2OCH3), 55.3 (OCH3). IR (ATR, cm
-1): ṽ = 3050 (w), 
2929 (w), 2834 (w), 2200 (m), 1602 (m), 1507 (s), 1459 (m), 1398 (m), 1246 (s), 1166 
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(s), 1106 (m), 1025 (s), 976 (m), 827 (s), 806 (m), 752 (s), 686 (s), 592 (m), 529 (s), 496 
(m). MS (EI, 70 eV): m/z (%) = 669 (M+, 37), 335 (7), 151 (17), 44 (100), 43 (10), 40 
(24). HR-MS (EI): m/z = calcd. for C48H31O3N [M]
+: 669.22985; found: 669.22890. 
Anal. calcd. for C48H31N O3: C 86.08, H 4.67, N 2.09; found: C 86.24, H 4.51, N 2.01. 
2,3,5-tris(2-(4-fluorophenyl)ethynyl)-4,6-bis(2-phenylethynyl)pyridine (17b):  
17b was synthesized according to general 
procedure using 2,3,5-trichloro-4,6-bis(2-
phenylethynyl)pyridine 15a (0.21 mmol, 
80 mg) and 1-ethynyl-4-fluorobenzene 
(1.05 mmol, 0.120 mL) and was purified via 
column chromatography 
(heptane/dichloromethane). Brown solid; yield: 
127 mg (96 %). mp 213 – 214 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 7.64 - 7.55 (m, 10H, CHAr), 7.47 - 7.34 (m, 6H, CHAr), 7.10 -
 7.03 (m, 6H, CHAr). 
13C-NMR (75.0 MHz, CDCl3): δ = 163.2 (d, 
1JCF = 252.00 Hz, 
CAr), 163.1 (d, 
1JCF = 252.00 Hz, 2CAr), 143.4 (CAr), 143.1 (CAr/Hetar), 135.3 (CAr/Hetar), 
134.2 (d, 3JCF = 8.80 Hz, 2CHAr), 133.7 (d, 
3JCF = 8.80 Hz, 2CHAr), 133.7 (d, 
3JCF = 8.80 Hz, 2CHAr), 132.2 (2CHAr), 132.0 (2CHAr), 129.8 (CHAr), 129.5 (CHAr), 
128.6 (2CHAr), 128.5 (2CHAr), 122.7 (CAr/Hetar), 122.5 (CAr), 122.2 (CAr), 122.1 
(CAr/Hetar), 118.8 (d, 
4JCF  = 3.30 Hz, CAr),  118.8 (d, 
4JCF = 3.30 Hz, CAr), 118.2 (d, 
4JCF =  3.30 Hz, CAr), 115.9 (d, 
2JCF = 22.01 Hz, 2CHAr), 115.9 (d, 
2JCF = 22.5 Hz, 
2CHAr), 115.9 (d, 
2JCF = 22.01 Hz, 2CHAr), 102.8 (C≡C), 100.1 (C≡C), 99.9 (C≡C), 95.2 
(C≡C), 93.9 (C≡C), 87.7 (C≡C), 87.5 (d, 5JCF = 1.65 Hz, C≡C), 85.4 (C≡C), 85.1 (d, 
5JCF = 1.65 Hz, C≡C), 85.1 (d, 
5JCF = 1.65 Hz, C≡C). 
19F -NMR (282 MHz, CDCl3): 
δ = - 108.56 (s, 1F, Ar), - 108.88 (s, F, Ar), - 108.98 (s, F, Ar). IR (ATR, cm-1): 
ṽ = 3064 (w), 3046 (w), 1598 (w), 1503 (m), 1400 (w), 1215 (m), 1150 (m), 976 (m), 
827 (s), 782 (m), 750 (s), 685 (s), 629 (m), 589 (m), 524 (s), 448 (m). MS (EI, 70 eV): 
m/z (%) = 633 (M+, 100), 632 (10), 316 (6), 44 (15), 40 (18). HR-MS (EI): m/z = calcd. 
for C45H22NF3 [M]
+: 633.16989; found: 633.16885. Anal. calcd. for C45H22F3N: C 
85.30, H 3.50, N 2.21; found: C 85.41, H 3.54, N 2.11. 
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2,3,5-tris(2-(4-tert-butylphenyl)ethynyl)-4,6-bis(2-phenylethynyl)pyridine (17c):  
17c was synthesized according to general 
procedure using 2,3,5-trichloro-4,6-bis(2-
phenylethynyl)pyridine 15a (0.21 mmol, 
80 mg) and 1-tert-butyl-4-ethynylbenzene 
(1.05 mmol, 0.189 mL) and was purified 
via column chromatography (heptane/ 
dichloromethane). Brown solid; yield: 
132 mg (84 %). mp. 90 – 91 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 7.71 - 7.67 (m, 4H, CHAr), 7.64 - 7.58 (m, 6H, CHAr), 7.44 -
 7.39 (m, 12H, CHAr), 1.38 (s, 9H, CH3 tBu ), 1.37 (s, 18H, CH3 tBu). 
13C-NMR 
(75.0 MHz, CDCl3): δ =  152.8 (CAr), 152.6 (CAr), 152.6 (CAr), 143.3 (CAr/Hetar), 143.0 
(CAr/Hetar), 135.1(CAr/Hetar), 132.3 (2CHAr), 132.2 (2CHAr), 132.1 (2CHAr), 131.6 
(2CHAr), 131.6 (2CHAr), 129.5 (CHAr), 129.3 (CHAr), 128.6 (2CHAr), 128.4 (2CHAr), 
125.6 (4CHAr), 125.5 (2CHAr), 122.9 (CAr/Hetar), 122.9 (CAr/Hetar), 122.5 (CAr), 122.3 
(CAr), 119.9 (CAr), 119.8 (CAr), 119.2 (CAr), 102.4 (C≡C), 101.4 (C≡C), 101.4 (C≡C), 
95.4 (C≡C), 94.8 (C≡C), 87.9 (C≡C), 87.5 (C≡C), 85.7 (C≡C), 85.1 (C≡C), 85.0 (C≡C), 
34.9 (3C tBu), 31.2 (9CH3 tBu). IR (ATR, cm
-1): ṽ = 3061 (w), 2958 (m), 2865 (w), 2207 
(m), 1598 (w), 1502 (s), 1400 (s), 1362 (m), 1266 (m), 1106 (m), 1024 (w), 828 (s), 753 
(s), 727 (m), 686 (s), 557 (s), 528 (m). MS (EI, 70 eV): m/z (%) = 747 (M+, 100), 732 
(9), 359 (11), 358 (13), 44 (43), 40 (38). HR-MS (EI): m/z = calcd. for C57H49N [M]
+: 
747.38595; found: 747.38531. Anal. calcd. for C57H49N: C 91.52, H 6.60, N 1.87; 
found: C 91.56, H 6.63, N 1.80. 
General procedure for the synthesis of compounds 18a–c 
An oven-dried, argon-flushed sealable glass tube was charged with 3,5-dichloro-2,4,6-
tris(2-phenylethynyl)pyridine 16a (0.18 mmol, 80 mg), Pd(CH3CN)2Cl2 (0.0089
 mmol, 
5 mol%), Xphos (0.018 mmol, 10 mol%) and CuI (0.0089 mmol, 5 mol%). The solids 
were diluted with 5 mL of dry 1,4-dioxane and diisopropylamine (21.5 mmol, 3 mL). 
The solution was stirred at ambient temperature for ten minutes. Afterwards, 0.71 mmol 
of appropriate acetylene was added. The pressure tube was closed with a Teflon cap and 
the reaction mixture was stirred at 80 °C. After 18 h the reaction was cooled to room 
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temperature and diluted with distilled water and dichloromethane. The aqueous layer 
was extracted with dichloromethane (three times). The combined organic layers were 
dried with sodium sulfate, filtered and the solvent was evaporated under reduced 
pressure. The residue was purified by column chromatography using 
heptane/dichloromethane as eluent to purify the corresponding pentaalkynylpyridines. 
3,5-bis(2-(4-methoxyphenyl)ethynyl)-2,4,6-tris(2-phenylethynyl)pyridine, (18a):  
18a was synthesized according to general 
procedure using 3,5-dichloro-2,4,6-tris(2-
phenylethynyl)pyridine 16a (0.18 mmol, 
80 mg) and 1-ethynyl-4-methoxybenzene 
(0.71 mmol, 0.092 mL) and was purified 
via column chromatography (heptane/ 
dichloromethane). Brown solid; yield: 
108 mg (95 %). mp. 199 - 200 °C. 1H-
NMR (300 MHz, CDCl3): δ = 7.69 - 7.66 (m, 6H, CHAr), 7.58 (d, 
3J = 8.88 Hz, 4H, 
CHAr), 7.44 - 7.37 (m, 9H, CHAr), 6.91 (d, 4H, 
3J = 8.88 Hz, CHAr), 3.86 (s, 6H, OCH3). 
13C-NMR (75.0 MHz, CDCl3): δ = 160.4 (CAr), 142.7 (CAr/Hetar) , 134.7 (CAr/Hetar), 133.4 
(CHAr), 132.2 (CHAr), 132.1 (CHAr), 129.6 (CHAr), 129.3 (CHAr), 128.6 (CHAr), 128.4 
(CHAr), 123.2 (CAr/Hetar), 122.5 (CAr), 122.3 (CAr), 114.9 (CAr), 114.2 (CHAr), 102.3 
(C≡C), 101.6 (C≡C), 94.7 (C≡C), 87.9 (C≡C), 85.7 (C≡C), 84.5 (C≡C), 55.4 (2OCH3). 
IR (ATR, cm-1): ṽ = 3050 (w), 2930 (w), 2200 (m), 1602 (m), 1502 (s), 1440 (m), 1289 
(m), 1244 (s) 1167 (s), 1105 (m), 1025 (m), 827 (s), 805 (m), 754 (s), 687 (s), 645 (m), 
596 (m), 528 (s), 409 (m); MS (EI, 70 eV): m/z (%) = 639 (M+, 100), 319 (8), 275 (8), 
44 (21), 40 (20). HR-MS (EI): m/z = calcd. for C47H29O2N [M]
+: 639.21928; found: 
639.21803. Anal. calcd. for C47H29NO2: C 88.24, H 4.57, N 2.19; found: C 88.19, H 
4.45, N 2.18. 
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3,5-bis(2-(4-fluorophenyl)ethynyl)-2,4,6-tris(2-phenylethynyl)pyridine, (18b):  
18b was synthesized according to general 
procedure using 3,5-dichloro-2,4,6-tris(2-
phenylethynyl)pyridine 16a (0.18 mmol, 
80 mg) and 1-ethynyl-4-fluorobenzene 
(0.71 mmol, 0.081 mL) and was purified via 
column chromatography (heptane/ 
dichloromethane). Brown solid; yield: 107 mg 
(97 %). mp. 205 - 206 °C. 1H-NMR (300 MHz, 
CDCl3): δ = 7.67 - 7.57 (m, 10H, CHAr), 7.46 - 7.35 (m, 9H, CHAr), 7.12 - 7.04 (m, 4H, 
CHAr). 
13C-NMR (75.0 MHz, CDCl3): δ = 163.1 (d, 
1JCF = 250.89 Hz, CAr), 143.4 
(CAr/Hetar), 133.8 (d, 
3JCF = 8.25 Hz, CHAr), 132.2 (CHAr), 132.0 (CHAr), 129.8 (CHAr), 
129.5 (CHAr), 128.7 (CHAr), 128.5 (CHAr), 122.7 (CAr), 122.2 (CAr,) 122.1 (CAr), 118.9 
(d, 4JCF = 3.30 Hz, CAr), 118.9 (CAr), 115.9 (d, 
2JCF = 22.56 Hz, CHAr), 102.7 (C≡C), 
100.1 (C≡C), 95.2 (C≡C), 87.7 (C≡C), 85.4 (C≡C), 85.2 (d, 5JCF = 1.10 Hz, C≡C). 
19F -
NMR (282 MHz, CDCl3): δ = -108.02 (s). IR (ATR, cm
-1): ṽ = 3104 (w), 3062 (w), 
2923 (w), 2205 (m), 1597 (m), 1501 (s), 1400 (m), 1222 (m), 1151 (m), 1069 (w), 921 
(w), 828 (s), 755 (s), 688 (s), 596 (m), 525 (s), 448 (m). MS (EI, 70 eV): m/z (%) = 615 
(M+ 100), 614 (10), 308 (6), 44 (5), 40 (15). HR-MS (EI): m/z = calcd. for C45H23NF2 
[M]+: 615.17931; found: 615.17888. Anal. calcd. for C45H23F2N: C 87.79, H 3.77, N 
2.28; found: C 87.72, H 3.64, N 2.40. 
3,5-bis(2-(4-tert-butylphenyl)ethynyl)-2,4,6-tris(2-phenylethynyl)pyridine, (18c):  
18c was synthesized according to general 
procedure using 3,5-dichloro-2,4,6-tris(2-
phenylethynyl)pyridine 16a (0.18 mmol, 
80 mg) and 1-tert-butyl-4-ethynylbenzene 
(0.71 mmol, 0.128 mL) and was purified 
via column chromatography (heptane/ 
dichloromethane). Yellow solid; yield: 
80 mg (65 %). mp. 226 – 227 °C. 1H-NMR (300 MHz, CDCl3): δ = 7.70 - 7.67 (m, 6H, 
CHAr), 7.59 (d, 
3J = 8.69 HZ, 4H, CHAr), 7.44 - 7.39 (m, 13H, CHAr), 1.36 (s, 18H, CH3 
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tBu). 
13C-NMR (75.0 MHz, CDCl3): δ = 152.7 (CAr), 143.1 (CAr/Hetar), 135.2 (CAr/Hetar), 
132.3 (CHAr), 132.2 (CHAr), 131.6 (CHAr), 129.6 (CHAr), 129.3 (CHAr), 128.6 (CHAr), 
128.4 (CHAr), 125.6 (CHAr), 123.1 (CAr/Hetar), 122.4 (CAr), 122.3 (CAr), 119.8 (CAr), 
102.6 (C≡C), 101.5 (C≡C), 94.9 (C≡C), 87.9 (C≡C), 85.6 (C≡C), 84.9 (C≡C), 34.9 (C 
tBu), 31.2 (CH3 tBu). IR (ATR, cm
-1): ṽ = 3055 (w), 2951 (w), 2864 (w), 2201 (m), 1500 
(m), 1442 (w), 1397 (m), 1266 (w), 1215 (w), 1107 (w), 829 (m), 751 (s), 687 (s), 558 
(m), 527 (m). MS (EI, 70 eV): m/z (%) = 691 (M+, 100), 677 (7), 676 (12), 331 (11), 
330 (14), 44 (13), 40 (49). HR-MS (EI): m/z = calcd. for C53H41N [M]
+: 691.32335; 
found: 691.32469. Anal. calcd. for C53H41N: C 92.00, H 5.97, N 2.02; found: C 92.12, 
H 5.81, N 2.16. 
Procedure for the synthesis of 6-bromo-2-(trifluoromethyl)quinolin-4(1H)-one (19) 
An oven-dried round-bottom flask (250 mL) was charged with polyphosphoric acid 
(0.8 g/mmol of aniline) and ethyl-4,4,4- trifluoroacetoacetate (1 equiv.; 23.25 mmol, 
4.28 g). The mixture was warmed to 75 °C under stirring for 5 minutes. The agitated 
solution was charged with 4-bromoanilin (1 equiv.; 23.25 mmol, 4 g) and the reaction 
mixture was warmed to 150 °C under stirring for two hours. After the reaction mixture 
is cooled to room temperature, NaOH solution (10 %) was added which lead to 
precipitation of a white solid and more NaOH solution (10 %) was added until the solid 
was solved again. The solution was filtered and afterwards acidified with HCl solution 
(10 %) until the white solid precipitates again. The Precipitate was filtered off and dried. 
 
6-bromo-2-(trifluoromethyl)quinolin-4(1H)-one (19): 
According to the procedure described above 19 was isolated as 
white solid; yield: 5.34 g (78 %); mp. 277 – 279 °C. 1H-NMR 
(300 MHz, DMSO-d6): δ = 8.28 (d, 1H, 
4J = 2.46 Hz, CHAr/Hetar), 
7.90 (brs, 2H, CHAr/Hetar), 7.06 (s, 1H, CHAr/Hetar), 3.92 (s, 1H, 
NH). 13C-NMR (75 MHz, DMSO-d6): δ = 164.5 (C=O), 146.4 (q, 
2J = 34.66 Hz, C-
CF3), 145.4 (CAr), 134.5 (CHAr/Hetar), 129.6 (CHAr/Hetar), 124.7 (CHAr/Hetar), 123.2 (CAr), 
121.2 (q, 1J = 275.65 Hz, CF3), 119.8 (CAr), 101.7(q, 
3J = 4.13 Hz, CH-C-CF3); 
19F-
NMR (300 MHz, DMSO-d6): δ = -66.62 (ArCF3); IR (ATR, cm
-1): ṽ = 3253 (w), 3072 
(m), 2956 (m), 1633 (w), 1554 (s), 1508 (s), 1468 (s), 1419 (m), 1356 (m), 1298 (s), 
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1279 (s), 1194 (s), 1192 (s), 1149 (s), 1134 (s), 1109 (s), 1092 (s), 1059 (m), 889 (m), 
862 (s), 854 (s), 827 (s), 723 (s), 710 (m), 621 (m), 555 (s), 538 (s); MS (EI, 
70 eV): m/z (%) = 291 (M+, 100), 274 (6), 272 (7), 245 (13), 243 (19), 224 (16), 222 
(24), 196 (8), 194 (9), 184 (18), 164 (10), 115 (11), 88 (17), 87 (13), 75 (15), 69 (27), 63 
(19), 50 (10); HR-MS (ESI): m/z = calcd. for C10H5BrF3NO  [M+H]
+: 291.95794, 
found 291.95858, calcd. for C10H5
81BrF3NO  [M+H]
+: 293.95595 found: 293.9566,; 
Anal. calcd. for C10H5BrF3NO: C 40.84, H 2.40, N 4.76; found: C 40.53, H 2.44, N 
4.58.  
Procedure for the synthesis of 4,6-dibromo-2-(trifluoromethyl)quinoline (20a) 
An oven-dried round-bottom flask (250 mL) was charged with phosphorous 
oxybromide (1.1 equiv.; 4.994 mmol, 1.4306 g) and was warmed to 75 °C under stirring 
for 5 minutes. Afterwards,  quinolinone 19 (1 equiv.; 4.543 mmol, 1.3260 g) was added 
in one portion and the mixture was warmed to 150 °C under stirring for 2.5 h. 
Afterwards, it was cooled the reaction mixture to room temperature, ice-water was 
added carefully and the mixture was made basic by addition of NaOH solution (10 %). 
The Solids were filtered off and dried. 
4,6-dibromo-2-(trifluoromethyl)quinoline (20a): 
According to the procedure described above 20a was isolated as 
yellow solid; yield: 1.282 g (80 %); mp. 123 – 124 °C. 1H-NMR 
(CDCl3, 300 MHz): δ = 8.44 (d, 1H, 
4J = 2.08 Hz, CHAr/Hetar), 
8.10 (d, 1H 3J = 9.06 Hz, CHAr/Hetar), 8.04 (s, 1H, CHAr/Hetar), 7.95 (dd, 1H, 
3J = 9.06 Hz, 
4J = 2.08 Hz, CHAr/Hetar). 
13C-NMR (CDCl3, 75,46 MHz): δ = 147.9 (q, 
2J = 35.76 Hz, 
C-CF3), 146.2 (CAr), 135.4 (CHAr/Hetar), 134.5 (CAr), 132.2 (CHAr/Hetar), 129.6 (CAr), 
129.1 (CHAr/Hetar), 125.0 (q, 
1J = 274.89 Hz, CF3), 124.8 (CAr), 121.8 (q, 
3J = 2.29 Hz, 
CH-C-CF3); 
19F-NMR (300 MHz, CDCl3): δ = -67.60 (ArCF3); IR (ATR, cm
-1): 
ṽ = 3064 (w), 2980 (w), 1954 (w), 1603 (w), 1579 (w), 1450 (m), 1394 (w), 1335 (m), 
1313 (m), 1257 (w), 1191 (m), 1140 (s), 1093 (s), 1065 (s), 885 (m), 874 (s), 870 (s), 
825 (s), 768 (m), 706 (m), 681 (s), 594 (m), 530 (m); MS (EI, 70 eV): m/z (%) = 355 
(M+, 100), 353 (M+, 54), 276 (12), 274 (12), 207 (14), 205 (14), 126 (12), 100 (30), 99 
(28), 74 (18), 69 (10); HR-MS (ESI): m/z = calcd. for C10H4NBr2F3 [M]
+: 352.86571, 
found: 352.86595, calcd. for C10H4NBr 
81BrF3 : 354.86366, found 354.86414, calcd. for 
N
Br
Br
CF3
5. Experimental Section 
105 
 
C10H4N
81Br2F3: 356.86162, found 356.86181; Anal. calcd. for C10H4NBr2F3: C 33.84 , 
H 1.14, N 3.95; found: C 34.10, H 0.95, N 4.04. 
Procedure for the synthesis of 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
(20b) 
An oven-dried round-bottom flask (250 mL) was charged with phosphorous 
oxychloride (1.1 equiv.; 67.639 mmol, 6.19 mL) and warmed to 75 °C under stirring for 
5 minutes. Afterwards, quinolinone 19 (1 equiv.; 61.49 mmol, 17.959 g) was added in 
one portion and the mixture was warmed to 100 °C under stirring for 8 h. Afterwards, 
the mixture was cooled to room temperature, ice-water was added carefully and the 
mixture was made basic by addition of NaOH solution (10 %). The Solids were filtered 
off and dried. 
6-bromo-4-chloro-2-(trifluoromethyl)quinoline (20b): 
According to the procedure described above 20b was isolated as 
yellow solid; yield: 12.8 g (65 %); mp. 97 – 98 °C. 1H-NMR 
(CDCl3, 300 MHz): δ = 8.46 (d, 1H, 
4J = 2.08 Hz, CHAr/Hetar), 
8.11 (d, 1H, 3J = 8.88 Hz, CHAr/Hetar), 7.95 (dd, 1H, 
3J = 8.88 
Hz, 4J = 2.08 Hz, CHAr/Hetar), 7.85 (s, 1H, CHAr/Hetar). 
13C-NMR (CDCl3, 75,46 MHz): 
δ = 148.0 (q, 2J = 35.5 Hz, C-CF3), 146.5 (CAr), 143.5 (CAr), 135.4 (CHAr/Hetar), 132.1 
(CHAr/Hetar), 128.1 (CAr), 126.5 (CHAr/Hetar), 124.5 (CAr), 120.8 (q, 
1J = 275.38 Hz, CF3), 
118.0 (q, 3J = 2.20 Hz, CH-C-CF3); 
19F-NMR (300 MHz, CDCl3): δ = -67.71 (ArCF3); 
IR (ATR, cm-1): ṽ = 3061 (w), 2980 (w), 1741 (w), 1605 (w), 1578 (w), 1452 (m), 1398 
(w), 1340 (m), 1308 (w), 1257 (w), 1191 (m), 1138 (s), 1093 (s), 1066 (m), 987 (m), 
887 (m), 876 (m), 870 (s), 837 (s), 775 (m), 694 (s), 617 (m), 598 (m), 530 (m); MS (EI, 
70 eV): m/z (%) = 311 (M+, 100), 310 (9), 309 (M+, 83), 242 (25), 240 (19), 230 (13), 
180 (11), 13 (7), 161 (22), 126 (7), 100 (12), 99 (21), 74 (11); HR-MS (EI): 
m/z = calcd. for C10H4NBrClF3  [M]
+: 308.91623; found: 308.91614; calcd. for 
C10H4N
18BrClF3: 310.91418; found 310.91411; calcd. for C10H4N 
81Br37ClF3  
312.91123; found 312.91158; Anal. calcd. for C10H4NBrClF3: C 38.68, H 1.30, N 4.51; 
found: C 38.98, H1.10, N 4.60. 
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General procedure for the synthesis of compounds 21a–k 
An oven-dried, argon-flushed sealable glass tube was charged with 2-trifluoromethyl-
4,6-dibromoquinoline 20a (0.5 mmol, 177.5 mg), Palladium (II) acetate (5 mol%, 
5.6 mg), Tricyclohexylphosphine (10 mol%, 14.2 mg), the appropriate boronic acid 
(1.3 mmol) and K3PO4 (1.3 mmol, 276.0 mg) followed by anhydrous toluene (4.0 mL); 
The tube was sealed with a Teflon valve and stirred at 100 °C for 8 h. The cooled 
reaction mixture was diluted with water and extracted with CH2Cl2. The combined 
organic layers were dried with Na2SO4, filtered and concentrated in vacuum. The 
residue was purified by column chromatography (heptane/dichlormethan). 
2-(trifluoromethyl)-4,6-diphenylquinoline (21a):  
21a was synthesized according to general procedure using 2-
trifluoromethyl-4,6-dibromoquinoline 20a (0.5 mmol, 
177.5 mg) and phenylboronic acid (1.3 mmol, 158.5 mg) and 
was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 136 mg 
(78 %); mp. 164 - 165 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.38 (d, 1H, 
3J = 8.7 Hz, 
CHAr/Hetar), 8.18 (d, 1H, 
4J = 1.9 Hz, CHAr/Hetar), 8.10 (dd, 1H, 
3J = 8.8, 4J = 2.0 Hz, 
CHAr/Hetar), 7.72 (s, 1H, CHAr/Hetar), 7.55 - 7.66 (m, 7H, 7CHAr), 7.37-7.52 (m, 3H, 
3CHAr). 
13C-NMR (CDCl3, 75,46 MHz): δ = 150.9 (CAr/Hetar), 147.3(q, 
2J = 34.4 Hz, C-
CF3), 147.2 (CAr), 141.4 (CAr), 139.9 (CAr), 137.1 (CAr), 130.9 (CH), 130.4 (CH), 129.5 
(CH), 129.1 (CH), 129.0 (CH), 128.9 (CH), 128.1 (CH), 127.6 (CAr), 127.5 (CH), 121.7 
(q, 1J = 275.4 Hz, CF3), 123.4 (CH), 117.4 (q, 
3J = 2.2 Hz, CH-C-CF3); 
19F-NMR 
(300 MHz, CDCl3): -67.40 (ArCF3); IR (ATR, cm
-1): ṽ = 3062 (w), 2849 (w), 1620 (w), 
1576 (w), 1464 (m), 1444 (w), 1389 (m), 1367 (m), 1311 (w), 1279 (w), 1261 (s), 1184 
(s), 1176 (s), 1130 (s), 1092 (s), 1020 (m), 885 (s), 758 (s), 712 (s), 696 (s), 623 (s), 600 
(m), 582 (m), 528 (m); MS (EI, 70 eV): m/z (%) = 349 (M+, 100), 348 (18), 328 (10), 
278 (9), 252 (10), 202 (8), 77 (6); HR-MS (EI): m/z = calcd for C22H14NF3 [M]
+: 
349.10729; found: 349.10652; Anal. calcd. for C22H14NF3: C 75.64, H 4.04, N 4.01; 
found: C 75.87, H 4.10, N 3.62. 
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2-(trifluoromethyl)-4,6-di-p-tolylquinoline (21b):  
21b was synthesized according to general procedure 
using 2-trifluoromethyl-4,6-dibromoquinoline 20a 
(0.5 mmol, 177.5 mg) and 4-methylphenylboronic acid 
(1.3 mmol, 176.7 mg) and was purified via column 
chromatography (heptane/dichloromethane). Yellow 
solid; yield: 163 mg (86 %); mp. 126 – 127 °C. 1H-NMR 
(CDCl3, 300 MHz): δ = 8.36 (d,1H, 
3J = 8.7 Hz, CHAr/Hetar), 8.20 (d, 1H, 
4J = 1.9 Hz, 
CHAr/Hetar), 8.09 (dd, 1H, 
3J = 8.7, 4J = 2.0 Hz, CHAr/Hetar), 7.70 (s, 1H, CHAr/Hetar), 7.54 
(d, 2H, 3J = 8.1 Hz, 2CHAr), 7.49 (d, 2H, 
3J = 8.1 Hz, 2CHAr), 7.40 (d, 2H, 
3J = 7.8 Hz, 
2CHAr), 7.29 (d, 2H, 
3J = 7.9 Hz, 2CHAr), 2.51 (s, 3H, CH3), 2.42 (s, 3H, CH3). 
13C-
NMR (CDCl3, 75,46 MHz): δ = 150.9 (CAr/Hetar), 147.2 (q, 
2J = 34.4 Hz, C-CF3), 147.08 
(CAr), 141.2 (CAr), 139.1 (CAr), 138.0 (CAr), 137.1 (CAr), 134.3 (CAr), 130.8 (CH), 130.2 
(CH), 129.7 (CH), 129.6 (CH), 129.4 (CH), 127.7 (CAr), 127.3 (CH), 123.1(CH), 121.7 
(q, 1J = 275.4 Hz, CF3), 117.3 (q, 
3J = 2.2 Hz, CH-C-CF3), 21.3 (CH3), 21.1 (CH3);
 19F-
NMR (300 MHz, CDCl3): δ = - 67.40 (ArCF3); IR (ATR, cm
-1): ṽ = 3034 (w), 2920 
(w), 2854 (w), 1612 (w), 1570 (w), 1460 (m), 1362 (m), 1311 (w), 1279 (m), 1259 (s), 
1213 (w), 1178 (s), 1126 (s), 1093 (s), 1018 (m), 968 (m), 895 (s), 883 (s), 852 (m), 812 
(s), 791 (s), 725 (s), 698 (s), 677 (m), 608 (m), 581 (m), 559 (m), 544 (m); MS (EI, 
70 eV): m/z (%) = 377 (M+, 100), 362 (7), 91 (5); HR-MS (EI): m/z = calcd. for 
C24H18NF3  [M]
+: 377.13859; found: 377.13836; Anal. calcd. for C24H18NF3: C 76.38, H 
4.81, N 3.71; found: C 76.50, H 4.68, N 3.46.  
4,6-bis(4-chlorophenyl-2-(trifluoromethyl)quinoline (21c):  
21c was synthesized according to general procedure 
using 2-trifluoromethyl-4,6-dibromoquinoline 20a 
(0.5 mmol, 177.5 mg) and 4-chlorophenylboronic acid 
(1.3 mmol, 203.3 mg) and was purified via column 
chromatography (heptane/dichloromethane). White 
solid; yield: 74.0 mg (35 %); mp. 172 - 173 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.38 
(d, 1H, 3J = 9.4 Hz, CHAr/Hetar), 8.06 (m, 2H, CHAr/Hetar), 7.68 (s, 1H, CHAr/Hetar), 7.61 -
 7.43 (m, 8H, 8CHAr). 
13C-NMR (CDCl3, 75,46 MHz): δ = 149.6 (CAr/Hetar), 147.6 (q, 
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2J = 34.9 Hz, C-CF3), 147.2 (CAr), 140.4 (CAr), 135.5 (CAr), 135.4 (CAr), 134.5 (CAr), 
131.3 (CH), 130.8 (CH), 130.2 (CH), 129.3 (CH), 129.0 (CAr), 128.7 (CH), 128.2 (CH), 
127.4 (CAr), 122.9 (CH), 121.5 (q, 
1J = 275.4 Hz, CF3), 117.5 (q, 
3J = 3.3 Hz, CH-C-
CF3); 
19F-NMR (300 MHz, CDCl3): δ = -67.46 (ArCF3); IR (ATR, cm
-1): ṽ = 3065 (w), 
2850 (w), 1630 (w), 1593 (w), 1568 (w), 1458 (m), 1387 (m), 1360 (m), 1304 (w), 1259 
(s), 1188 (m), 1176 (s), 1136 (s), 1088 (s), 1012 (s), 969 (m), 893 (m), 822 (s), 793 (s), 
694 (m), 631 (m), 606 (m), 534 (m); MS (EI, 70 eV): m/z (%) = 417 (M+, 100), 382 (5), 
362 (6), 346 (8), 327 (8), 277 (14); HR-MS (EI): m/z = calcd for C22H12NCl2F3  [M]
+: 
417.02934, found: 417.02832, calcd for C22H12NCl 
37ClF3  [M]
+: 419.02639; found: 
419.02608; Anal. calcd. for C22H12NCl2F3: C 63.18, H 2.89, N 3.35; found: C 63.07, H 
2.87, N 3.14. 
2-(trifluoromethyl)-4,6-bis(4-methoxyphenyl)quinoline (21d):  
21d was synthesized according to general procedure 
using 2-trifluoromethyl-4,6-dibromoquinoline 20a 
(0.5 mmol, 177.5 mg) and 4-methoxyphenylboronic 
acid (1.3 mmol, 197.5 mg) and was purified via column 
chromatography (heptane/dichloromethane). Yellow 
solid; yield: 121.0 mg (59 %); mp. 107 - 108 °C. 1H-
NMR (CDCl3, 300 MHz): δ = 8.33 (d, 1H, 
3J = 8.9 Hz, CHAr/Hetar), 8.17 (d, 1H, 
4J = 1.9 Hz, CHAr/Hetar), 8.06 (dd, 1H, 
3J = 8.9 Hz, 4J = 2.1 Hz, CHAr/Hetar), 7.67 (s, 1H, 
CHAr/Hetar), 7.58 (d, 2H, 
3J = 8.9 Hz, 2CHAr), 7.53 (d, 2H, 
3J = 8.9 Hz, CHAr), 7.12 (d, 
2H, 3J = 8.9 Hz, 2CHAr), 7.01 (d, 2H, 
3J = 8.9 Hz, 2CHAr), 3.93 (s, 3H, OCH3), 3.87 (s, 
3H, OCH3). 
13C-NMR (CDCl3, 75,46 MHz): δ = 160.3 (C-OCH3), 159.8 (C-OCH3), 
150.4 (CAr/Hetar), 147.0 (q, 
2J = 34.4 Hz, C-CF3), 146.9 (CAr), 140.73 (CAr), 132.4 (CAr), 
130.8 (CH), 130.8 (CH), 129.9 (CH), 129.5 (CAr), 128.6 (CH), 127.8 (CAr), 121.7 (q, 
1J = 275.4 Hz, CF3), 122.6 (CH), 117.2 (q, 
3J = 1.7 Hz, CH-C-CF3), 114.5 (CH), 114.4 
(CH), 55.4 (OCH3), 55.4 (OCH3);
 19F-NMR (300 MHz, CDCl3): δ = -67.39 (ArCF3); IR 
(ATR, cm-1): ṽ = 3066 (w), 2933 (w), 2841(w), 1608 (m), 1574 (m), 1516 (m), 1458 
(m), 1385 (w), 1327 (w), 1290 (m), 1250 (s), 1174 (s), 1119 (s), 1095 (s), 1026 (s), 980 
(w), 891 (m), 824 (s), 814 (s), 787 (m), 768 (w), 698 (m), 631 (w), 609 (w), 555 (m); 
MS (EI, 70 eV): m/z (%) = 409 (M+, 100), 394 (19); HR-MS (EI): m/z = calcd for 
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C24H18 O2NF3  [M]
+: 409.12841; found: 409.12942; Anal. calcd. for C24H18 O2NF3:  C 
70.41, H 4.43, N 3.42; found: C 70.39, H 4.48, N 3.22.  
2-(trifluoromethyl)-4,6-bis(4-(trifluoromethoxy)phenyl)quinolone (21e):  
21e was synthesized according to general procedure 
using 2-trifluoromethyl-4,6-dibromoquinoline 20a 
(0.5 mmol, 177.5 mg) and 4-
(trifluoromethoxy)phenylboronic acid (1.3 mmol, 
267.7 mg) and was purified via column 
chromatography (heptane/dichloromethane). White 
solid; yield: 200.0 mg (77 %); mp. 135 - 136 °C. 1H-NMR (CDCl3, 300 MHz): 8.40 (d, 
1H, 3J = 9.25 Hz, CHAr/Hetar), 8.07 (m, 2H, 2CHAr/Hetar), 7.71 (s,1H, CHAr/Hetar), 7.64 (m, 
4H, 4CHAr), 7.47 (d, 2H, 
3J = 7.9 Hz, 2CHAr), 7.35 (d, 2H, 
3J = 7.9 Hz, 2CHAr). 
13C-
NMR (CDCl3, 75,46 MHz): δ = 149.9 (q, 
3J = 1.9 Hz, C-OCF3), 149.5 (CAr/Hetar), 149.4 
(q, 3J = 1.9 Hz, C-OCF3), 147.7 (q, 
2J = 34.7 Hz, C-CF3), 147.2 (CAr), 140.4 (CAr), 
138.5 (CAr), 135.5 (CAr), 131.4 (CH), 131.0(CH), 130.3 (CH), 128.9 (CH), 127.4 (CAr), 
123.1 (CH), 121.5 (CH), 121.5 (q, 1J = 275.4 Hz, CF3), 121.4 (CH), 120.5 (q, 
1J = 258.3 Hz, 2OCF3), 117.7 (q, 
3J = 1.7 Hz, CH-C-CF3); 
19F-NMR (300 MHz, 
CDCl3): δ = -67.51 (ArCF3); -57.82 (ArCF3); -57.69 (ArCF3); IR (ATR, cm
-1): ṽ = 3086 
(w), 2924 (w), 1608 (w), 1581 (w), 1514 (w), 1497 (m), 1462 (w), 1389 (w), 1319 (w), 
1281 (m), 1254 (s), 1211 (s), 1180 (s), 1149 (s), 1130 (s), 1093 (s), 1016 (m), 981 (m), 
947 (m), 893 (m), 829 (s), 810 (m), 791 (m), 685 (m), 631 (m), 606 (m), 559 (m), 543 
(m); MS (EI, 70 eV): m/z (%) = 517 (M+, 100), 448 (5), 432 (6), 69 (28); HR-MS (EI): 
m/z = calcd. for C24H12O2NF9 [M]
+: 517.07188; found: 517.07260; Anal. calcd. for 
C24H12 O2NF9: C 55.72, H 2.34, N 2.71; found: C 56.08, H 2.31, N 2.59. 
2-(trifluoromethyl)-4,6-bis(3-fluorophenyl)quinoline (21g):  
21g was synthesized according to general procedure using 2-
trifluoromethyl-4,6-dibromoquinoline 20a (0.5 mmol, 
177.5 mg) and 3-fluorophenylboronic acid (1.3 mmol, 
181.9 mg) and was purified via column chromatography 
(heptane/dichloromethane).White solid; yield: 91.0 mg 
(47 %); mp. 109 – 110 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.40 (dd, 1H, 
3J = 8.31 Hz, 
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4J = 1.13 Hz CHAr/Hetar), 8.09 (m, 2H, CHAr/Hetar), 7.72 (s, 1H, CHAr/Hetar), 7.60 (m, 1H, 
CHAr), 7.50–7.26 (m, 6 H, 6CHAr), 7.11 (m, 1 H, CHAr). 
13C-NMR (CDCl3, 
75,46 MHz): δ = 164.7 (d, 1J = 246.5 Hz, CAr), 161.6 (d,
 1J = 248.1 Hz, CAr), 149.6 
(CAr/Hetar), 147.6 (q, 
2J = 34.7 Hz, C-CF3), 147.3 (CAr), 142.1 (d,
 3J = 7.70 Hz, CAr), 
140.4 (CAr), 139.02 (d,
 3J = 7.70 Hz, CAr), 131.3 (CH), 130.7 (d, 
3J = 4.95 Hz, CAr), 
130.6 (d, 3J = 4.95 Hz, CAr), 130.3 (CH), 127.3 (CAr), 125.2 (d, 
4J = 3.30 Hz, CAr), 123.3 
(CH), 123.2 (d, 4J = 3.30 Hz, CAr), 121.5 (q, 
1J = 275.4 Hz, CF3), 117.6 (q, 
3J = 1.93 Hz, 
CH-C-CF3), 116.6 (d, 
2J = 22.56 Hz, CAr), 116.2 (d,
 2J = 21.46 Hz, CAr), 115.1 (d, 
2J = 21.46 Hz, CAr), 114.5 d, 
 2J = 22.01 Hz, CAr); 
19F-NMR (300 MHz, CDCl3): δ = -
112.24 (ArF); -111.52 (ArF); - 67.49 (ArCF3); IR (ATR, cm
-1): ṽ = 3064 (w), 2924 (w), 
2852 (w), 1614 (w), 1506 (m), 1470 (m), 1441 (m), 1383 (m), 1323 (m), 1279 (m), 
1267 (s), 1180 (s), 1163 (s), 1136 (s), 1120 (s), 1093 (s), 997 (m), 970 (w), 910 (m), 885 
(m), 835 (m), 798 (s), 783 (s), 768 (m), 712 (s), 673 (s), 611 (m), 538 (w); MS (EI, 
70 eV): m/z (%) = 385 (M+, 100), 364 (12), 316 (6), 314 (6), 220 (6); HR-MS (EI): 
m/z = calcd. for C22H12NF5  [M]
+: 385.08844; found: 385.08814; Anal. calcd. for 
C22H12NF5: C 68.57, H 3.14, N 3.63; found: C 68.56, H 3.042, N 3.24. 
2-(trifluoromethyl)-4,6-dio-tolylquinoline (21h):  
21h was synthesized according to general procedure using 2-
trifluoromethyl-4,6-dibromoquinoline 20a (0.5 mmol, 
177.5 mg) and 2-methylphenylboronic acid (1.3 mmol, 
176.7 mg) and was purified via column chromatography 
(heptane/dichloromethane).White solid; yield: 138.0 mg 
(73 %); mp. 153 - 154 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.25 (d, 1H, 
3J = 8.7 Hz, 
CHAr/Hetar), 7.72 (dd, 1H, 
3J = 8.67 Hz, 4J = 1.89 Hz, CHAr/Hetar), 7.55 (s, 1H, CHAr/Hetar), 
7.40 (d, 1H, 4J = 1.9 Hz, CHAr/Hetar), 7.32 - 7.11 (m, 8H, 8CHAr), 2.13 (s, 3H, CH3), 1.98 
(s, 3H, CH3). 
13C-NMR (CDCl3, 75,46 MHz): δ = 151.0 (CAr/Hetar), 147.5 (q, 
2J = 34.4 Hz, C-CF3), 146.5 (CAr), 142.4 (CAr), 140.6 (CAr), 136.5 (CAr), 135.8 (CAr), 
135.4 (CAr), 132.6 (CH), 130.5 (CH), 130.4 (CH), 130.1 (CH), 129.8 (CH), 129.4 (CH), 
128.9 (CH), 127.9 (CH), 127.8 (CAr), 121.7 (q, 
1J = 275.4 Hz, CF3), 125.9 (CH), 125.7 
(CH), 117.5 (q, 3J = 1.7 Hz, CH-C-CF3), 20.4 (CH3), 19.9 (CH3); 
19F-NMR (300 MHz, 
CDCl3): δ = -67.35 (ArCF3); IR (ATR, cm
-1): ṽ = 3068 (w), 2924 (w), 2864 (w), 1610 
(w), 1572 (w), 1454 (w), 1367 (w), 1319 (w), 1288 (w), 1259 (m), 1227 (w), 1182 (s), 
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1146 (s), 1134 (s), 1090 (s), 1024 (w), 899 (m), 841 (m), 791 (w), 731 (m), 725 (m), 
690 (m), 608 (m), 555 (w); MS (EI, 70 eV): m/z (%) = 377 (M+, 100), 376 (45), 362 
(18), 308 (8), 286 (5), 284 (7), 216 (5), 91 (6); HR-MS (EI): m/z = calcd. for C24H18NF3   
[M]+: 377.13859; found: 377.13809; Anal. calcd. for C24H18NF3: C 76.38, H 4.81, N 
3.71; found: C 76.14, H 4.79, N 3.64. 
2-(trifluoromethyl)-4,6-bis(4-fluorophenyl)quinoline (21i):  
21i was synthesized according to general procedure using 
2-trifluoromethyl-4,6-dibromoquinoline 20a (0.5 mmol, 
177.5 mg) and 4-fluorophenylboronic acid (1.3 mmol, 
181.9 mg) and was purified via column chromatography 
(heptane/dichloromethane).White solid; yield: 73.0 mg 
(38 %); mp. 173 – 174 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.26 (brd, 1H, 
3J = 9,4 Hz, 
CHAr/Hetar), 7.97 - 7.93 (m, 2H, 2CHAr/Hetar), 7.58 (s, 1H, CHAr/Hetar), 7.48 (m, 4H, 
4CHAr); 7.23 - 7.16 (m, 2H, 2CHAr), 7.10 - 7.03 (m, 2H, 2CHAr).
 13C-NMR (CDCl3, 75, 
46 MHz): δ = 163.3 (d, 1J = 249.8 Hz, CF), 162.9 (d, 1J = 248.14 Hz, CF), 149.8 
(CAr/Hetar), 147.2 (q, 
2J = 34.4 Hz, C-CF3), 147.1 (CAr), 140.6 (CAr), 135.9 (d, 
4J = 3.30 Hz, CAr), 133.0 (d, 
4J = 3.30 Hz, CAr), 131.3 (d, 
3J = 8.25 Hz 2(CAr)), 131.2 
(CH), 130.3 (CH), 129.2 (d, 3J = 8.25 Hz, 2(CAr) ), 127.6 (CAr), 122.9 (CH), 121.6 (q, 
1J = 275.4 Hz, CF3), 117.6 (q, 
3J = 1.7 Hz, CH-C-CF3), 116.1 (d, 
 2J = 22.01 Hz, 2 
(CAr)), 116.0 (d, 
2J = 21.46 Hz, 2 (CAr)); 
19F-NMR (300 MHz, CDCl3): δ = -113.88 
(ArF); -111.83 (ArF), -67.45 (ArCF3); IR (ATR, cm
-1): ṽ = 3074 (w), 2920 (w), 2850 
(w), 1605 (m), 1512 (m), 1462 (m), 1387 (m), 1325 (w), 1261 (m), 1221 (s), 1178 (m), 
1170 (m), 1159 (s), 1130 (s), 1095 (s), 982 (m), 960 (w), 895 (m), 847 (m), 825 (s), 820 
(s), 806 (s), 789 (m), 775 (m), 698 (m), 677 (m), 606 (m), 557 (s), 551 (s); MS (EI, 
70 eV): m/z (%) = 385 (M+, 100), 364 (10), 314 (7), 220 (5), 95 (2); HR-MS (EI): 
m/z = calcd for C22H12NF5  [M]
+: 385.08844; found: 385.08803; Anal. calcd. for 
C22H12NF5: C 68.57, H 3.14, N 3.63; found: C 68.71, H 3.09, N 3.44. 
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2-(trifluoromethyl)-4,6-bis(4-(trifluoromethyl)phenyl)quinoline (21j):  
21j was synthesized according to general procedure 
using 2-trifluoromethyl-4,6-dibromoquinoline 20a 
(0.5 mmol, 177.5 mg) and 4-
(trifluoromethyl)phenylboronic acid (1.3 mmol, 
246.9 mg) and was purified via column chromatography 
(heptane/dichloromethane).White solid; yield: 214.0 mg (88 %); mp. 138 - 139 °C. 1H-
NMR (CDCl3, 300 MHz): δ = 8.43 (d, 1H, 
3J = 8.9 Hz, CHAr/Hetar), 8.12 (dd, 1H, 
3J = 8.88 Hz, 4J = 2.08 Hz, CHAr/Hetar), 8.06 (d, 1H, 
4J = 1.70 Hz, CHAr/Hetar), 7.89 (s, 1H, 
CHAr/Hetar), 7.87 (s, 1H, CHAr), 7.77 - 7.70 (m, 7H, 7CHAr). 
13C-NMR (CDCl3, 
75,46 MHz): δ = 149.5 (CAr/Hetar), 147.9 (q, 
2J = 34.9 Hz, C-CF3), 147.4 (CAr), 143.3 
(CAr), 140.5 (CAr), 131.5 (q, 
2J = 32.74 Hz, CAr) 131.5 (CAr), 130.4 (q, 
2J = 32.74 Hz, 
CAr), 130.4 (CH), 129.9 (CH), 127.6 (q, 
1J = 272.35 Hz, CAr), 127.9(CH), 127.2 (CAr), 
126.1 (CH), 126.1 (q, 3J = 3.58 Hz, CAr), 126.0 (q, 
3J = 3.58 Hz, CAr), 123.5 (CH), 
121.5 (q, 1J = 275.4 Hz, CF3), 120.4 (q, 
1J = 272.35 Hz, CAr), 117.7 (q, 
3J = 1.7 Hz, CH-
C-CF3), 
19F-NMR (300 MHz, CDCl3): δ = -67.53 (ArCF3), -62.72 (ArCF3), -62.64 
(ArCF3); IR (ATR, cm
-1): ṽ = 3062 (w), 2929 (w), 1620 (w), 1464 (w), 1406 (w), 1321 
(s), 1165 (s), 1141 (s), 1126 (s), 1109 (s), 1093 (s), 1065 (s), 1016 (s), 845 (m), 827 (s), 
775 (w), 652 (w), 617 (m), 584 (w), 530 (w); MS (EI, 70 eV): m/z (%) = 485 (M+, 100), 
466 (13), 416 (10), 396 (11), 346 (6), 69 (6); HR-MS (EI): m/z = calcd. for C24H12NF9  
[M]+: 485.08205; found: 485.08163; Anal. calcd. for C24H12NF9: C 59.39, H 2.49, N 
2.89; found: C 59.95, H 2.73, N 2.69.  
General procedure for the synthesis of compounds 22a-b (Regioisomeric Mixtures)  
An oven-dried and argon-flushed pressure tube was charged with 2-trifluoromethyl-4,6-
dibromoquinoline 20a (0.5 mmol, 177.5 mg), Pd source (5 mol%), ligand (10 mol%), 
the appropriate boronic acid (1.0 equiv.; 0.5 mmol) and K3PO4 (2.6 equiv.; 1.3 mmol) 
followed by toluene (5.0 mL) or toluene/H2O (4:1) ; The tube was sealed with a Teflon 
valve and the reaction mixture was stirred at 100 or 50 °C for 8 h. The cooled reaction 
mixture was diluted with water and extracted with DCM. The combined organic layers 
were dried (Na2SO4), filtered and the filtrate was concentrated under vacuum. The 
residue was purified by column chromatography (heptane/dichlormethan). In all cases 
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were isolated inseparable mixtures of both 4- and 6-monoarylated isomers, in rtios of 
8:1up 9:1, corroborated by 19F-NMR and GC-MS analysis. 
General procedure for the synthesis of compounds 23a-g  
An oven-dried and argon-flushed pressure tube was charged with 6-bromo-4-chloro-2-
(trifluoromethyl)quinoline 20b (0.5 mmol, 155.3 mg), palladium(II) acetate (5 mol%, 
5.6 mg), tricyclohexylphosphine (10 mol%, 14.2 mg), the appropriate boronic acid (1.2 
equiv.; 0.6 mmol) and K3PO4 (2.6 equiv.; 1.3 mmol) followed by toluene (4.0 mL) and 
water (1 mL); The tube was sealed with a Teflon valve and the reaction mixture was 
stirred at 80 °C for 8 h. The cooled reaction mixture was diluted with water and 
extracted with DCM. The combined organic layers were dried (Na2SO4), filtered and the 
filtrate was concentrated under vacuum. The residue was purified by column 
chromatography (heptane/dichlormethan). 
4-Chloro-2-(trifluoromethyl)-6-p-tolylquinoline (23a):  
23a was synthesized according to general procedure 
using 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
20b (0.5 mmol, 155.3 mg) and 4-methylphenylboronic 
acid (0.6 mmol, 81.6 mg) and was purified via column 
chromatography (heptane/dichloromethane).White solid; yield: (72 %) 116.0 mg); mp. 
105 – 106 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.43 (d, 1H, 
4J = 1.89 Hz, CHAr/Hetar), 
8.29 (d, 1H, 3J = 8.69 Hz, CHAr/Hetar), 8.13 (dd, 1H, 
3J = 8.88 Hz, 4J = 2.08 Hz, 
CHAr/Hetar), 7.84 (s, 1H, CHAr/Hetar), 7.66 (d, 2H, 
3J = 8.12 Hz, CHAr), 7.35 (d, 2H, 
3J = 7.74 Hz, 2CHAr), 2.46 (s, 3H, CH3). 
13C-NMR (CDCl3, 75,46 MHz): δ = 147.2 (q, 
2J = 35.2 Hz, C-CF3), 147.2 (CAr/Hetar), 144.4 (CAr), 142.4 (CAr), 138.6 (CAr), 136.4 
(CAr), 131.3(CH), 130.9 (CH), 129.9 (CH), 127.4 (CH), 127.3 (CAr), 121.1 (CH), 121.1 
(q, 1J = 275.38 Hz, CF3), 117.5 (q, 
3J = 2.20 Hz, CH-C-CF3), 21.2 (CH3); 
19F-NMR 
(300 MHz, CDCl3): δ = -67.48 (ArCF3); IR (ATR, cm
-1): ṽ = 3027 (w), 2922 (w), 1589 
(w), 1570 (w), 1493 (m), 1462 (m), 1381 (w), 1348 (s), 1321 (m), 1250 (m), 1184 (s), 
1173 (s), 1138 (s), 1115 (s), 1095 (s), 897 (m), 851 (s), 812 (s), 773 (m), 719 (w), 700 
(s), 600 (m), 536 (m); MS (EI, 70 eV): m/z (%) = 321 (M+, 100), 320 (31), 300 (8), 216 
(7), 214 (8), 189 (10), 69 (18); HR-MS (EI): m/z = calcd. for C17H11NClF3  [M]
+: 
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321.05266; found: 321.05217; calcd. for C17H11N 
37ClF3: 323.04971; found 323.04977; 
Anal. calcd. for C17H11NClF3: C 63.46, H 3.45, N 4.35; found: C 63.86, H 3.33, N 4.28. 
4-Chloro-2-(trifluoromethyl)-6-(3-(trifluoromethyl)phenylquinoline (23b): 
23b was synthesized according to general procedure 
using 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
20b (0.5 mmol, 155.3 mg) and 3-
(trifluoromethyl)phenylboronic acid (0.6 mmol, 
114.0 mg) and was purified via column chromatography (heptane/dichloromethane). 
White solid; yield: 119.0 mg (63 %); mp. 130 – 131 °C. 1H-NMR (CDCl3, 300 MHz): 
δ = 8.48 (d, 1H, 4J = 1.89 Hz, CHAr/Hetar), 8.36 (d, 1H, 
3J = 8.69 Hz, CHAr/Hetar), 8.13 (dd, 
1H, 3J = 8.88 Hz, 4J = 2.08 Hz, CHAr/Hetar), 7.79–7.88 (m, 5H, CHAr/Hetar, 5CHAr). 
13C-
NMR (CDCl3, 75,46 MHz): δ = 147.6 (CAr/Hetar), 147.5 (q, 
2J = 35.1 Hz, C-CF3), 144.8 
(CAr/Hetar), 142.9 (CAr/Hetar), 141.0 (CAr), 131.4 (CH), 131.1 (CH), 130.1 (q, 
2J = 32.96 Hz, CAr), 128.0 (CH), 127.3 (CAr), 126.1 (q, 
3J = 3.66 Hz, 2(CAr)), 124.1 (q, 
1J = 276.95 Hz, CAr), 122.3 (CH), 120.9 (q, 
1J = 275.57 Hz, CF3), 117.8 (q, 
3J = 2.29 Hz, CH-C-CF3); 
19F-NMR (300 MHz, CDCl3): δ = -67.62 (ArCF3), -62.61 
(ArCF3); IR (ATR, cm
-1): ṽ = 3093 (w), 2935 (w), 1619 (w), 1583 (w), 1558 (w), 1462 
(w), 1402 (w), 1335 (s) 1325 (s), 1252 (m), 1173 (s), 1147 (s), 1113 (s), 1093 (s), 1070 
(s), 1012 (s), 951 (m), 897 (m), 847 (m), 820 (s), 770 (m), 739 (m), 694 (s), 625 (m), 
592 (m), 536 (w); MS (EI, 70 eV): m/z (%) = 375 (M+, 100), 356 (10), 371 (12), 201 
(7), 69 (14); HR-MS (EI): m/z = calcd. for C17H8NClF6 [M]
+: 375.02440; found: 
375.02417; calcd. for C17H8N
37ClF6: 377.02145; found 377.02160; Anal. calcd. for 
C17H8NClF6: C 54.35, H 2.15, N 3.73; found: C 54.78, H 2.03, N 3.54.  
4-chloro-2-(trifluoromethyl)-6-(4-methoxyphenyl)quinoline (23c):  
23c was synthesized according to general procedure 
using 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
20b (0.5 mmol, 155.3 mg) and 4-
methoxyphenylboronic acid (0.6 mmol, 91.2 mg) and 
was purified via column chromatography (heptane/dichloromethane). White solid; 
yield: 111.0 mg (66 %); mp. 121 – 122 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.38 (d, 
1H, 4J = 1.89 Hz, CHAr/Hetar), 8.27 (d, 1H, 
3J = 8.88 Hz, CHAr/Hetar), 8.11 (dd, 1H, 
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3J = 8.88 Hz, 4J = 2.08 Hz, CHAr/Hetar), 7.83 (s, 1H, CHAr/Hetar), 7.73 - 7.80 (m, 2H, 
2CHAr), 7.09-7.04 (m, 2H, 2CHAr), 3.90 (s, 3H, OCH3). 
13C-NMR (CDCl3, 
75,46 MHz): δ = 160.2 (COCH3), 147.0 (q, 
2J = 35.2 Hz, C-CF3), 146.9 (CAr/Hetar), 144.3 
(CAr/Hetar), 142.1 (CAr/Hetar), 131.7 (CAr), 131.2 (CH), 130.9 (CH), 128.7 (CH), 127.4 
(CAr), 121.1 (q, 
1J = 275.38 Hz, CF3), 120.6 (CH), 117.5 (q, 
3J = 2.20 Hz CH-C-CF3), 
114.6 (CH), 55.4 (OCH3); 
19F-NMR (300 MHz, CDCl3): δ = -67.47 (ArCF3); IR (ATR, 
cm-1): ṽ = 3036 (w), 2960 (w), 2937 (w), 2841 (w), 1608 (m), 1520 (w), 1464 (m), 1417 
(w), 1371 (w), 1358 (s), 1303 (w), 1247 (s), 1188 (s), 1173 (s), 1153 (s), 1115 (s), 1093 
(s) 1039 (m), 1022 (s), 897 (m), 864 (s), 852 (s), 825 (s), 816 (s), 773 (m), 729 (w), 700 
(s), 648 (m), 576 (m), 544 (m); MS (EI, 70 eV): m/z (%) = 337 (M+, 100), 322 (30), 296 
(11), 295 (7), 294 (38), 268 (8), 239 (7), 190 (8), 188 (7), 164 (8), 69 (13); HR-MS 
(EI): m/z = calcd. for C17H11ONClF3 [M]
+: 337.04758; found: 337.04760; calcd. for 
C17H11ON
37Cl1F3: 339.04463; found 339.04487; Anal. calcd. for C17H11ONClF3: C 
60.46, H 3.28, N 4.15; found: C 60.73, H 3.27, N 4.00. 
4-chloro-2-(trifluoromethyl)-6-(3,5-dimethylphenyl)quinoline (23d):  
23d was synthesized according to general procedure using 
6-bromo-4-chloro-2-(trifluoromethyl)quinoline 20b 
(0.5 mmol, 155.3 mg) and 3,5-dimethylphenylboronic 
acid (0.6 mmol, 90.0 mg) and was purified via column 
chromatography (heptane/dichloromethane). White solid; 
yield: 98.0 mg (58 %); mp. 121 – 122 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.43 (d, 1H, 
4J = 1.89 Hz, CHAr/Hetar), 8.29 (d, 1H, 
3J = 8.88 Hz, CHAr/Hetar), 8.13 (dd, 1H, 
3J = 8.88 Hz, 4J = 2.08 Hz, CHAr/Hetar), 7.85 (s, 1H, CHAr/Hetar), 7.36 (s, 2H, 2CHAr), 7.11 
(s, 1H), 2.45 (s, 6H, 2 CH3). 
13C-NMR (CDCl3, 75,46 MHz): δ = 147.2 (q, 
2J = 35.2 Hz, 
C-CF3), 147.2 (CAr/Hetar), 144.5 (CAr/Hetar), 142.8 (CAr/Hetar), 139.3 (CAr), 138.8 (CAr), 
131.6 (CH), 130.8 (CH), 130.2 (CH), 127.3 (CAr), 121.1 (q, 
1J = 275.38 Hz, CF3), 125.5 
(CH), 121.4 (CH), 117.5 (q, 3J = 2.20 Hz, CH-C-CF3), 21.4 (2(CH3)); 
19F-NMR 
(300 MHz, CDCl3): δ = -67.49 ArCF3); IR (ATR, cm
-1): ṽ = 3091 (w), 2914 (w), 2859 
(w), 1460 (m), 1348 (s), 1329 (m), 1306 (s), 1252 (m), 1184 (s), 1169 (s), 1132 (s), 
1095 (s), 849 (s), 825 (s), 754 (m), 712 (w), 696 (s), 648 (m), 598 (m), 569 (m), 528 
(m); MS (EI, 70 eV): m/z (%) = 335 (M+, 100), 334 (13), 320 (20), 300 (10), 285 (6), 
214 (11), 69 (13); HR-MS (EI): m/z = calcd. for C18H13NClF3  [M]
+: 335.06831; found: 
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335. 06803; calcd for C18H13N 
37ClF3: 337.06536; found 337.06571; Anal. calcd. for 
C18H13NClF3: C 64.39, H 3.90, N 4.17; found: C 64.53, H 3.94, N 4.03. 
4-chloro-2-(trifluoromethyl)-6-o-tolylquinoline (23e):  
23e was synthesized according to general procedure using 6-
bromo-4-chloro-2-(trifluoromethyl)quinoline 20b (0.5 mmol, 
155.3 mg) and 2-methylphenylboronic acid (0.6 mmol, 
81.6 mg) and was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 106.0 mg (66 %); mp. 98 – 99 °C. 1H-
NMR (CDCl3, 300 MHz): δ = 8.31 (d, 1H, 
3J = 8.7 Hz, CHAr/Hetar), 8.26 (d, 1H, 
4J = 1.70 Hz, CHAr/Hetar), 7.90 (dd, 1H, 
3J = 8.8 Hz, 4J = 2.08 Hz, CHAr/Hetar); 7.87 (s, 1H, 
CHAr/Hetar), 7.39 – 7.33 (m, 4H, 4CHAr), 2.34 (s, 3H, CH3). 
13C-NMR (CDCl3, 
75,46 MHz): δ = 147.6 (q, 2J = 35.2 Hz, C-CF3), 147.0 (CAr/Hetar), 144.54 (CAr/Hetar), 
143.7 (CAr/Hetar), 140.2 (CAr), 135.4 (CAr), 133.6 (CH), 130.7 (CH), 130.2 (CH), 129.9 
(CH), 28.3 (CH), 126.9 (CAr), 121.1 (q, 
1J = 275.38 Hz, CF3), 126.2 (CH), 123.9 (CH), 
117.5 (q, 3J = 2.20 Hz, CH-C-CF3), 20.5 (CH3); 
19F-NMR (300 MHz, CDCl3): δ = -
67.51 (ArCF3); IR (ATR, cm
-1): ṽ = 3064 (w), 3016 (w), 2976 (w), 1583 (w), 1572 (w), 
1487 (m), 1460 (m), 1379 (w), 1344 (s), 1321 (m), 1250 (m), 1184 (s), 1171 (s), 1151 
(s), 1126 (s), 1117 (s), 1093 (s), 895 (s), 862 (s), 847 (s), 814 (m), 754 (s), 723 (s), 696 
(s), 685 (s), 654 (m), 611 (m), 554 (m), 532 (m); MS (EI, 70 eV): m/z (%) = 321 (M+, 
100), 320 (80), 306 (17), 302 (16), 300 (28), 286 (11), 285 (10), 266 (6), 265 (9), 216 
(11), 214 (21), 189 (14), 69 (29); HR-MS (EI): m/z = calcd. for C17H11NClF3  [M]
+: 
321.05266; found: 321.05193; calcd for C17H11N
37ClF3: 323.04971; found 323.04963; 
Anal. calcd. for C17H11NClF3: C 63.46, H 3.45, N 4.35; found: C 63.54, H 3.41, N 4.13.  
4-chloro-2-(trifluoromethyl)-6-(3-fluorophenyl)quinoline (23f):  
23f was synthesized according to general procedure using 
6-bromo-4-chloro-2-(trifluoromethyl)quinoline 20b 
(0.5 mmol, 155.3 mg) and 3-fluorophenylboronic acid 
(0.6 mmol, 84.0 mg) and was purified via column 
chromatography (heptane/dichloromethane). White solid; yield: 90.0 mg (55 %); mp. 
96 – 97 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.44 (d, 1H, 
4J = 2.08 Hz, CHAr/Hetar), 8.32 
(d, 1H, 3J = 8.88 Hz, CHAr/Hetar), 8.10 (dd, 1H, 
3J = 8.88 Hz, 4J = 2.08 Hz, CHAr/Hetar), 
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7.86 (s, 1H, CHAr/Hetar), 7.56 – 7.43 (m, 3H, 3CHAr), 7.20 - 7.13 (m, 1H, CHAr). 
13C-
NMR (CDCl3, 75,46 MHz): δ = 163.3 (d, 
1J = 247.04 Hz, CAr), 147.8 (q, 
2J = 35.2 Hz, 
C-CF3), 147.5 (CAr/Hetar), 144.7 (CAr/Hetar), 141.6 (d, 
3J = 7.7 Hz, CAr), 141.2 (d, 
4J = 2.20 Hz, CAr), 140.1 (CAr), 131.2 (CH), 131.1 (CH), 130.7 (d, 
3J = 8.25 Hz, CAr), 
127.3 (CAr), 120.9 (q, 
1J = 275.38 Hz, CF3), 121.8 (CH), 117.7 (q, 
3J = 2.20 Hz, CH-C-
CF3), 115.4 (d, 
2J = 22.01 Hz, CAr), 114.6 (d, 
2J = 22.01 Hz, CAr); 
19F-NMR (300 MHz, 
CDCl3): δ = -67.58 (ArCF3), -112.06 (ArCF); IR (ATR, cm
-1): ṽ = 3068 (w), 2926 (w), 
2850 (w), 1606 (w), 1508 (m), 1470 (m), 1344 (s), 1311 (m), 1259 (m), 1190 (s), 1174 
(s), 1153 (s), 1126 (s), 1093 (s), 974 (m), 964 (m), 893 (m), 860 (s), 835 (s), 783 (s), 
771 (s), 698 (s), 685 (s), 650 (s), 581 (m), 527 (m); MS (EI, 70 eV): m/z (%) = 325 (M+, 
100), 221 (16), 194 (7), 69 (16); HR-MS (EI): m/z = calcd for C16H8NClF4  [M]
+: 
325.02759; found: 325.02749; calcd for C16H8N 
37ClF4: 327.02464; found 327.02498; 
Anal. calcd. for C16H8NClF4: C 59.00, H 2.48, N 4.30; found: C 59.11, H 2.34, N 4.13.  
4-chloro-6-(4-ethoxyphenyl)-2-(trifluoromethyl)quinoline (23g):  
23g was synthesized according to general procedure 
using 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
20b (0.5 mmol, 155.3 mg) and 4-ethoxyphenylboronic 
acid (0.6 mmol, 99.6 mg) and was purified via column 
chromatography (heptane/dichloromethane). White solid; yield: 107.0 mg (61 %); mp. 
138 – 139 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.38 (d, 1H, 
4J = 1.70 Hz, CHAr/Hetar), 
8.27 (d, 1H, 3J = 8.88 Hz, CHAr/Hetar), 8.11 (dd, 1H, 
3J = 8.88 Hz, 4J = 2.08 Hz, 
CHAr/Hetar), 7.83 (s, 1H, CHAr/Hetar), 8.70 (d, 2H, 
3J = 8.88 Hz, 2CHAr), 7.06 (d, 2H, 
3J = 8.69 Hz, 2CHAr), 4.13 (q, 2H, 
3J = 6.99 Hz, CH2), 1.48 (t, 3H, 
3J = 6.99 Hz, CH3). 
13C-NMR (CDCl3, 75,46 MHz): δ = 159.6 (C-OC2H5), 147.0 (q, 
2J = 35.2 Hz, C-CF3), 
146.9 (CAr/Hetar), 144.3 (CAr/Hetar), 142.1 (CAr/Hetar), 131.5 (CAr), 131.2 (CH), 130.9 (CH), 
128.7 (CH), 127.4 (CAr), 121.1 (q, 
1J = 275.38 Hz, CF3), 120.5 (CH), 117.5 (q, 
3J = 2.20 Hz, CH-C-CF3), 115.1 (CH), 63.6 (CH2), 14.8 (CH3); 
19F-NMR (300 MHz, 
CDCl3): δ = -67.47 (ArCF3); IR (ATR, cm
-1): ṽ = 3063 (w), 2983 (w), 2929 (w), 2885 
(w), 1606 (m), 1518 (w), 1462 (m), 1419 (w), 1394 (w), 1354 (s), 1325 (m), 1309 (w), 
1244 (s), 1188 (m), 1182 (s), 1167 (s), 1140 (s), 1117 (s), 1097 (s), 1047 (s), 899 (m), 
874 (s), 835 (s), 827 (s), 810 (s), 779 (m), 729 (m), 700 (s), 683 (s), 650 (m), 559 (m), 
527 (m); MS (EI, 70 eV): m/z (%) = 351 (M+, 57), 325 (33), 324 (23), 323 (100), 322 
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(14), 294 (12), 239 (7), 219 (8), 190 (9), 189 (6), 164 (7), 163 (7), 69 (7), 29 (28); HR-
MS (EI): m/z = calcd. for C18H13ONClF3  [M]
+: 351.06323; found: 351.06317; calcd for 
C18H13ON 
37Cl1F3: 353.06028; found 353.06093; Anal. calcd. C18H13ONClF3: C 61.46, 
H 3.73, N 3.98; found: C 61.57, H 3.74, N 3.76. 
General procedure for the synthesis of compounds 24a–g 
An oven-dried and argon-flushed pressure tube was charged with 6-bromo-4chloro-2-
(trifluoromethyl)quinoline 20b (0.5 mmol, 155.3 mg), palladium(II) acetate (5 mol%, 
5.6 mg), tricyclohexylphosphine (10 mol%, 14.2 mg), the corresponding 4-
methylphenylboronic acid or 4-methoxyphenylboronic acid (1.2 equiv.; 0.6 mmol) and 
K3PO4 (2.6 equiv.; 1.3 mmol) followed by toluene (4.0 mL) and water (1 mL); The tube 
was sealed with a Teflon valve and the reaction mixture was stirred at 80 °C for 8 h. 
Afterwards the appropriate second boronic acid (1.2 equiv.; 0.6 mmol) was added. The 
tube was sealed with a Teflon valve again and stirred at 100 °C for 8 h. The cooled 
reaction mixture was diluted with water and extracted with DCM. The combined 
organic layers were dried (Na2SO4), filtered and the filtrate was concentrated under 
vacuum. The residue was purified by column chromatography (heptane/dichlormethan). 
2-(trifluoromethyl)-4-(4-methoxyphenyl)-6-p-tolylquinoline (24a):  
24a was synthesized according to general procedure 
using 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
20b (0.5 mmol, 155.3 mg) with 4-methylphenylboronic 
acid (0.6 mmol, 81.6 mg) and later it was added 4-
methoxyphenylboronic acid (0.6 mmol, 91.2 mg) as 
second boronic acid. The compound 24a was purified 
via column chromatography (heptane/dichloromethane). White solid; yield: 121.0 mg 
(62 %); mp. 104 – 105 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.32 (d, 1H, 
3J = 8.88 Hz, 
CHAr/Hetar), 8.18 (d, 1H, 
4J = 1.89 Hz, CHAr/Hetar), 8.05 (dd, 1H, 
3J = 8.88 Hz, 
4J = 2.08 Hz, CHAr/Hetar), 7.65 (s, 1H, CHAr/Hetar), 7.49 - 7.53 (m, 4H, 4CHAr), 7.26 (d, 
2H, 3J = 9.06 Hz, 2CHAr), 7.06 - 7.10 (m, 2H, 2CHAr), 3.90 (s, 3H, OCH3), 2.39 (s, 3H, 
CH3). 
13C-NMR (CDCl3, 75,46 MHz): δ = 160.3 (C-OCH3), 150.6 (CAr/Hetar), 147.1 
(CAr/Hetar), 147.0 (q, 
2J = 34.4 Hz, C-CF3), 141.1 (CAr), 138.1 (CAr), 137.1 (CAr), 130.8 
(CH), 130.2 (CH), 129.7 (CH), 129.5 (CAr), 127.8 (CAr), 127.3 (CH), 123.1 (CH), 121.7 
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(q, 1J = 275.10 Hz, CF3), 117.2 (q, 
3J = 2.20 Hz, CH-C-CF3), 114.4 (CH), 55.4 (OCH3), 
21.1 (CH3); 
19F-NMR (300 MHz, CDCl3): δ = -67.38 (ArCF3); IR (ATR, cm
-1): 
ṽ = 3016 (w), 2947 (w), 2920 (w), 2843 (w), 1608 (m), 1514 (m), 1469 (m), 1387 (s), 
1300 (m) 1265 (s), 1250 (s), 1174 (s), 1122 (s), 1093 (s), 1038 (s) 1028 (s), 893 (s), 835 
(s), 814 (s), 787 (s), 721 (m), 698 (s), 642 (m), 608 (m), 571 (s), 554 (m), 527 (m); MS 
(EI, 70 eV): m/z (%) = 393 (M+, 100), 378 (6), 91(4); HR-MS (EI): m/z = calcd. for 
C24H18ONF3  [M]
+: 393.13350; found: 393.13322; Anal. calcd. for C24H18ONF3: C 
73.27, H 4.61, N 3.56; found: C 73.39, H 4.77, N 3.17. 
4-(4-ethoxyphenyl)-2-(trifluoromethyl)-6-p-tolylquinoline (24b):  
24b was synthesized according to general procedure 
using 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
20b (0.5 mmol, 155.3 mg) with 4-methylphenylboronic 
acid (0.6 mmol, 81.6 mg) and later it was added 4-
ethoxyphenylboronic acid (0.6 mmol, 99.6 mg) as 
second boronic acid. The compound 24b was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 120.0 mg (59 %); mp. 92 – 93 °C. 1H-
NMR (CDCl3, 300 MHz): δ = 8.24 (d, 1H, 
3J = 8.88 Hz, CHAr/Hetar), 8.11 (d, 1H, 
4J = 1.51 Hz, CHAr/Hetar), 7.98 (dd, 1H, 
3J = 8.88 Hz, 4J = 2.08 Hz, CHAr/Hetar), 7.57 (s, 
1H, CHAr/Hetar), 7.43 (m, 4H, 4CHAr), 7.18 (d, 2H, 
3J = 8.12 Hz, 2CHAr), 7.00 (d, 2H, 
3J = 8.50 Hz, 2CHAr), 4.06 (q, 2H, 
3J = 6.99 Hz, CH2), 2.32 (s, 3H, CH3), 1.40 (t, 3H, 
3J = 6.99 Hz, OCH2-CH3). 
13C-NMR (CDCl3, 75,46 MHz): δ = 159.7 (C-OC2H5), 150.7 
(CAr/Hetar), 147.2 (q, 
2J = 34.4 Hz, C-CF3), 147.2 (CAr/Hetar), 141.1 (CAr), 138.1 (CAr), 
137.1 (CAr), 130.8 (CH), 130.1 (CH), 129.7 (CH), 129.3 (CAr), 127.8 (CAr), 127.3 (CH), 
123.1 (CH), 121.8 (q, 1J = 275.39 Hz, CF3), 117.2 (q, 
3J = 1.83 Hz, CH-C-CF3), 114.9 
(CH), 63.7 (CH2), 21.1 (CH3), 14.8(OCH2-CH3); 
19F-NMR (300 MHz, CDCl3): δ = -
67.40 (ArCF3); IR (ATR, cm
-1): ṽ = 3031(w), 2980 (w), 2929 (w), 2899 (w), 1608 (m), 
1514 (m), 1460 (m), 1385 (m), 1296 (m), 1261 (s), 1254 (s), 1176 (s), 1128 (s), 1117 
(s), 1093 (s), 1039 (m), 1018 (m), 897 (m), 833 (s), 804 (s), 781 (s), 733 (m), 704 (m), 
646 (w), 600 (s), 575 (m), 528 (m); MS (EI, 70 eV): m/z (%) = 407 (M+, 100), 380 (14), 
379 (56), 378 (18), 334 (5), 264 (5), 91 (5), 29 (20); HR-MS (EI): m/z = calcd. for 
C25H20ONF3  [M]
+: 407.14915; found: 407.14909; Anal. calcd. for C25H20ONF3: C 
73.70, H 4.95, N 3.44; found : C 73.56, H 4.93, N 3.53. 
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2-(trifluoromethyl)-4-(4-(trifluoromethyl)phenyl)-6-p-tolylquinoline (24c):  
24c was synthesized according to general procedure 
using 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
20b (0.5 mmol, 155.3 mg) with 4-methylphenylboronic 
acid (0.6 mmol, 81.6 mg) and later it was added 4-
(trifluoromethyl)phenylboronic acid (0.6 mmol, 
114.0 mg) as second boronic acid. The compound 24c was purified via column 
chromatography (heptane/dichloromethane). White solid; yield: 122.0 mg (57 %); mp. 
139 – 140 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.38(d, 1H, 
3J = 8.7 Hz, CHAr/Hetar), 
8.12 (dd, 1H, 3J = 8.88 Hz, 4J = 2.08 Hz, CHAr/Hetar), 8.03 (d, 1H, 
4J = 2.08 Hz, 
CHAr/Hetar), 7.87 (d, 2H, 
3J = 8.50 Hz, 2CHAr), 7.69-7.72 (m, 3H, 3CHAr), 7.52 (d, 2H, 
3J = 8.0 Hz, 2CHAr), 7.30 (d, 2H, 
3J = 8.0 Hz, 2CHAr), 2.42 (s, 3H, CH3). 
13C-NMR 
(CDCl3, 75,46 MHz): δ = 149.1 (CAr/Hetar), 147.2 (q, 
2J = 34.4 Hz, C-CF3), 147,0 
(CAr/Hetar), 141.9 (CAr/Hetar), 140.8 (CAr), 138.4 (CAr), 136.8 (CAr), 131.7 (q, 
2J = 32.46 Hz, CAr), 131.0 (CH), 10.7 (CH), 129.9 (CH), 129.8 (CH), 127.4 (CH), 127.2 
(CAr), 125.9 (q, 
3J = 3.58 Hz, CAr), 123.9 (q, 
1J = 272.35 Hz, CAr), 122.4 (CH), 121.6 (q, 
1J = 275.38 Hz, CF3), 117.4 (q, 
3J = 2.20 Hz, CH-C-CF3), 21.1 (CH3); 
19F-NMR 
(300 MHz, CDCl3): δ = -67.42 (ArCF3), -62.67 (ArCF3); IR (ATR, cm
-1): ṽ = 3068 (w), 
3026 (w), 2920 (w), 2852 (w), 1618 (w), 1462 (m), 1406 (w), 1387 (m), 1363 (w), 1323 
(s), 1263 (m), 1180 (s), 1157 (m), 1128 (s), 1119 (s), 1109 (s), 1093 (s), 1065 (s), 1016 
(m), 847 (s), 837 (s), 816 (s), 783 (m), 766 (m), 710 (m), 677 (m), 652 (m), 617 (m), 
596 (m), 552 (m), 540 (m); MS (EI, 70 eV): m/z (%) = 431 (M+, 100), 430 (19), 412 
(7), 91 (5), 69 (7); HR-MS (EI): m/z = calcd. for C24H15NF6  [M]
+: 431.11032; found: 
431.11042; Anal. calcd. for C24H15NF6: C 66.82, H 3.50, N 3.25; found: C 66.60, H 
3.24, N 3.68.  
4-(4-chlorophenyl)-2-(trifluoromethyl)-6-p-tolylquinoline (24d):  
24d was synthesized according to general procedure 
using 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
20b (0.5 mmol, 155.3 mg) with 4-methylphenylboronic 
acid (0.6 mmol, 81.6 mg) and later it was added 4-
chlorophenylboronic acid (0.6 mmol, 93.8 mg) as second 
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boronic acid. The compound 24d was purified via column chromatography 
(heptane/dichloromethane). White solid; yield: 91.0 mg (46 %); mp. 156 – 157 °C. 1H-
NMR (CDCl3, 300 MHz): δ = 8.36 (d, 1H, 
3J = 8.7 Hz, CHAr/Hetar), 8.08 - 8.12 (m, 2H, 
2CHAr/Hetar), 7.67 (s, 1H, CHAr/Hetar), 7.59 - 7.51 (m, 6H, 6CHAr), 7.30 (d, 2H, 
3J = 8.12 Hz, 2CHAr), 2.43 (s, 3H, CH3). 
13C-NMR (CDCl3, 75,46 MHz): δ = 149.5 
(CAr/Hetar), 147.2 (q, 
2J = 34.7 Hz, C-CF3), 147.0 (CAr/Hetar), 141.6 (CAr), 138.3 (CAr), 
136.9 (CAr), 135.6 (CAr), 135.4 (CAr), 130.9 (CH), 130.8 (CH), 1130.5 (CH), 129.8 
(CH), 129.2 (CH), 127.4 (CAr), 127.3 (CH), 122.6 (CH), 121.6 (q, 
1J = 275.38 Hz, CF3), 
117.3 (q, 3J = 2.20 Hz, CH-C-CF3), 21.1 (CH3); 
19F-NMR (300 MHz, CDCl3): δ = -
67.39 (ArCF3); IR (ATR, cm
-1): ṽ = 3066 (w), 3030 (w), 2920 (w), 1595 (m), 1570 (w), 
1489 (m), 1460 (m), 1387 (m), 1325 (m), 1257 (m), 1182 (s), 1126 (s), 1088 (s), 895 
(s), 831 (s), 816 (s), 779 (m), 729 (m), 667 (m), 606 (m), 540 (m); MS (EI, 70 eV): m/z 
(%) = 397 (M+, 100), 396 (15), 91 (7), 69 (4); HR-MS (EI): m/z = calcd. for 
C23H15NClF3  [M]
+: 397.08396; found: 397.08374; calcd. for C23H15N
37ClF3: 
399.08101; found 399.08155; Anal. calcd. for C23H15NClF3: C 69.44, H 3.80, N 3.52; 
found: C 69.80, H 3.95, N 3.43. 
2-(trifluoromethyl)-6-(4-methoxyphenyl)-4-p-tolylquinoline (24e):  
24e was synthesized according to general procedure 
using 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
20b (0.5 mmol, 155.3 mg) with 4-
methoxyphenylboronic acid (0.6 mmol, 91.2 mg) and 
later it was added 4-methylphenylboronic acid 
(0.6 mmol, 81.6 mg) as second boronic acid. The 
compound 24e was purified via column chromatography (heptane/dichloromethane). 
White solid; yield: 90.0 mg (46 %); mp. 130 - 131 °C. 1H-NMR (CDCl3, 300 MHz): 
δ = 8.34 (d, 1H, 3J = 8.88 Hz, CHAr/Hetar), 8.16 (d, 1H, 
4J = 1.89 Hz, CHAr/Hetar); 8.06 
(dd, 1H, 3J = 8.88 Hz, 4J = 2.08 Hz, CHAr/Hetar), 7.68 (s, 1H, CHAr/Hetar), 7.58 (d, 2H, 
3J = 8.88 Hz, 2CHAr), 7.49 (d, 2H, 
3J = 7.96 Hz, 2CHAr), 7.40 (d, 2H, 
3J = 7.93 Hz, 
2CHAr), 7.01 (d, 2H, 
3J = 8.88 Hz, 2CHAr), 3.87 (s, 3H, OCH3), 2.50 (s, 3H, CH3). 
13C-
NMR (CDCl3, 75,46 MHz): δ = 159.8 (C-OCH3), 150.8 (CAr/Hetar), 147.0 (q, 
2J = 34.4 Hz, C-CF3), 146.9 (CAr/Hetar), 140.8 (CAr), 139.1 (CAr), 134.0 (CAr), 132.4 
(CAr), 130.8 (CH), 130.0 (CH), 129.6 (CH), 129.4 (CH), 128.5 (CH), 127.8 (CAr), 122.6 
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(CH), 121.7 (q, 1J = 275.38 Hz, CF3), 117.3 (q, 
3J = 2.20 Hz, CH-C-CF3), 114.5 (CH), 
55.4 (OCH3), 21.3 (CH3); 
19F-NMR (300 MHz, CDCl3): δ = -67.36 (ArCF3); IR (ATR, 
cm-1): ṽ = 3055 (w), 2997 (w), 2928 (w), 2839 (w), 1605 (s), 1524 (m), 1495 (s), 1460 
(m), 1387 (m) 1327 (m), 1259 (s) 1248 (s), 1180 (s), 1120 (s), 1095 (s), 1039 (m), 1022 
(m), 897 (m), 847 (m), 816 (s), 785 (m), 723 (m), 698 (m), 636 (m), 608 (m), 575 (m), 
554 (m), 540 (m); MS (EI, 70 eV): m/z (%) = 394 (25), 393 (M+, 100), 378 (20), 334 
(4), 308 (3), 284 (5), 264 (5), 214 (2), 189 (2), 139 (2), 91(2), 69 (3), 65 (2), 39 (2); 
HR-MS (EI): m/z = calcd. for C24H18ONF3  [M]
+: 393.13350; found: 393.13351; Anal. 
calcd. for C24H18ONF3: C 73.27, H 4.61, N 3.56; found: C 73.62, H 4.73, N 3.61. 
2-(trifluoromethyl)-4-(4-(trifluoromethyl)phenyl)-6-(4-methoxyphenyl)quinoline 
(24f): 
24f was synthesized according to general procedure 
using 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
20b (0.5 mmol, 155.3 mg) with 4-
methoxyphenylboronic acid (0.6 mmol, 91.2 mg) and 
later it was added 4-(trifluoromethyl)phenylboronic 
acid (0.6 mmol, 114.0 mg) as second boronic acid. The 
compound 24f was purified via column chromatography (heptane/dichloromethane).  
White solid; yield: 103.0 mg (46 %); mp. 127 – 128 °C. 1H-NMR (CDCl3, 300 MHz): 
δ = 8.36 (d, 1H, 3J = 8.88 Hz, CHAr/Hetar), 8.10 (dd, 1H, 
3J = 8.88 Hz, 4J = 2.08 Hz, 
CHAr/Hetar), 7.99 (d, 1H, 
4J = 1.89 Hz, CHAr/Hetar), 7.87 (d, 2H, 
3J = 8.12 Hz, 2CHAr), 
7.72 (d, 2H, 3J = 7.93 Hz, 2CHAr), 7.68 (s, 1H, CHAr/Hetar), 7.57 (dd, 2H, 
3J = 8.88 Hz, 
4J = 2.08 Hz, 2CHAr); 7.02 (dd, 2H, 
3J = 8.88 Hz, 
4J = 2.08 Hz, 2CHAr), 3.87 (s, 3H, 
OCH3). 
13C-NMR (CDCl3, 75,46 MHz): δ = 159.9 (C-OCH3), 148.9 (CAr/Hetar), 147.0 
(q, 2J = 34.4 Hz, C-CF3), 146.9 (CAr/Hetar), 141.5 (CAr/Hetar), 140.9 (CAr), 132.0 (CAr), 
131.2 (q, 2J = 33.01 Hz, CAr), 131.0 (CH), 130.5 (CH), 129.9 (CH), 128.6 (CH), 128.1 
(q, 1J = 272.35 Hz, CAr), 127.3 (CAr), 125.9 (q, 
3J = 3.85 Hz, CAr), 121.8 (CH), 121.6 (q, 
1J = 275.39 Hz, CF3), 117.4 (q, 
3J = 1.65 Hz, CH-C-CF3), 114.6 (CH), 55.4 (OCH3); 
19F-NMR (300 MHz, CDCl3): δ = -67.40 (ArCF3), -62.65 (ArCF3); IR (ATR, cm
-1): 
ṽ = 3001 (w), 2956 (w), 2835 (w), 1608 (m), 1587 (w), 1495 (s), 1464 (m), 1406 (w), 
1323 (s), 1265 (m), 1171 (s), 1136 (s), 1111 (s), 1095 (s), 1065 (s), 1016 (m), 895 (m), 
845 (m), 833 (s), 806 (s), 766 (m), 748 (m), 710 (s), 675 (m), 615 (s), 596 (m), 552 (m), 
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527 (m); MS (EI, 70 eV): m/z (%) = 447 (M+, 100), 432 (20), 428 (7), 404 (6), 334 (9), 
224 (5), 158 (5); HR-MS (EI): m/z = calcd. for C24H15ONF6  [M]
+: 447.10523; found: 
447.10491; Anal. calcd. for C24H15 ONF6: C 64.43, H 3.38, N 3.13; found: C 64.26, H 
3.47, N 3.22. 
2-(trifluoromethyl)-6-(4-methoxyphenyl)-4-phenylquinoline (24g):  
24g was synthesized according to general procedure 
using 6-bromo-4-chloro-2-(trifluoromethyl)quinoline 
20b (0.5 mmol, 155.3 mg) with 4-
methoxyphenylboronic acid (0.6 mmol, 91.2 mg) and 
later it was added phenylboronic acid (0.6 mmol, 
73.2 mg) as second boronic acid. The compound 24g was purified via column 
chromatography (heptane/dichloromethane).  White solid; yield: 106.0 mg (56 %); mp. 
102 – 103 °C. 1H-NMR (CDCl3, 300 MHz): δ = 8.35 (d, 1H, 
3J = 8.80 Hz, CHAr/Hetar); 
8.12 (d, 1H, 4J = 1.70 Hz, CHAr/Hetar); 8.07 (dd, 1H, 
3J = 8.69 Hz, 4J = 2.08 Hz, 
CHAr/Hetar), 7.69 (s, 1H, CHAr/Hetar), 7.55 - 7.59 (m, 7H, 7CHAr), 6.99 - 7.02 (m, 2H, 
2CHAr), 3.86 (s, 3H, OCH3). 
13C-NMR (CDCl3, 75,46 MHz): δ = 159.8 (C-OCH3), 
150.7 (CAr/Hetar), 147.0 (q, 
2J = 34.4 Hz, C-CF3), 146.9 (CAr/Hetar), 140.9 (CAr), 137.3 
(CAr), 132.3 (CAr), 130.8 (CH), 130.1 (CH), 129.5 (CH), 129.0 (CH), 128.8 (CH), 128.6 
(CH), 127.7 (CAr), 122.5 (CH), 121.7 (q, 
1J = 275.38 Hz, CF3), 117.4 (q, 
3J = 1.65 Hz, 
CH-C-CF3), 114.5 (CH), 55.4 (OCH3); 
19F-NMR (300 MHz, CDCl3):δ = -67.36 
(ArCF3); IR (ATR, cm
-1): ṽ = 3039 (w), 2929 (w), 2833 (w), 1606 (m), 1500 (m), 1462 
(m), 1365 (m), 1315 (w), 1240 (s), 1178 (s), 1165 (s), 1122 (s), 1117 (s), 1093 (s), 1039 
(s), 1022 (m), 893 (m), 825 (s), 806 (s), 792 (m), 712 (s), 698 (s), 677 (m), 606 (m), 584 
(m), 554 (m), 528 (m); MS (EI, 70 eV): m/z (%) = 379 (M+, 100), 364 (25), 266 (8), 
265 (5), 133 (7), 119 (6); HR-MS (EI): m/z = calcd. for C23H16ONF3  [M]
+: 379.11785; 
found: 379.11721; Anal. calcd. for C23H16ONF3: C 72.82, H 4.25, N 3.69; found: C 
73.02, H 4.23, N 3.46. 
3-bromo-4-iodoquinoline (25) was prepared according to a three-step procedure 
reported by Bogányi et al.103 
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Procedure for the synthesis of 3-bromo-4-(2-bromophenyl)quinoline (26) 
An oven-dried, argon-flushed sealable glass tube was charged with 3-bromo-4-
iodoquinoline 25 (0.3 mmol, 100 mg), Pd(PPh3)4 (5 mol%, 17.3 mg), 2-
bromophenylboronic acid (0.42 mmol, 84.3 mg) and Na2CO3 (0.60 mmol, 63.5 mg) 
followed by a mixture of DMF/ water (10:1, 1.01 mL); The tube was sealed with a 
Teflon valve and stirred at 100 °C for 24 h. The cooled reaction mixture was diluted 
with water and extracted with ethyl acetate. The combined organic layers were dried 
with Na2SO4, filtered and concentrated in vacuum. The residue was purified by column 
chromatography using heptane/ ethyl acetate as eluent.  
3-bromo-4-(2-bromophenyl)quinoline (26):  
According to the procedure described above 26 was isolated as a white 
solid; yield: 66 mg (61 %); mp. 130 - 131 °C. 1H-NMR (300 MHz, 
CDCl3): δ = 9.09 (s, 1H, CHHetar), 8.19 (d, 
3J = 8.50 Hz, 1H, 
CHAr/Hetar), 7.81 - 7.73 (m, 2H, CHAr/Hetar), 7.55 - 7.48 (m, 2H, 
CHAr/Hetar), 7.45 - 7.39 (m, 1H, CHAr), 7.33 (dd, 
3J = 8.50 Hz, 
4J = 0.76 Hz, 1H, CHAr), 7.25 (dd, 
3J = 7.55 Hz, 4J = 1.70 Hz, 1H, CHAr). 
13C-NMR 
(75.0 MHz, CDCl3): δ = 151.8 (CHAr/Hetar), 146.5 (CAr/Hetar), 146.5 (CAr/Hetar), 137.8 
(CAr), 133.1 (CHAr), 130.7 (CHAr), 130.4 (CHAr), 129.7 (CHAr), 129.6 (CHAr), 128.2 
(CAr/Hetar), 127.9 (CHAr), 127.7 (CHAr), 125.7 (CHAr), 122.9 (CAr), 118.8 (CAr/Hetar). IR 
(ATR, cm-1): ṽ = 3054 (w), 1570 (m), 1467 (m), 1427 (m), 1104 (m), 1047 (m), 1025 
(m), 918 (m), 759 (s), 728 (s) 709 (m), 604 (s), 595 (m).  MS (EI, 70 eV): m/z 
(%) = 365 (M+, 15), 363 (M+, 30), 361 (M+, 15), 284 (12), 282 (12), 204 (16), 203 
(100), 202 (13), 176 (17), 175 (11). HR-MS (EI): m/z = calcd. for C15H9Br2N 
360.90963 found: 360.90888; calcd. for C15H9Br
81BrN 362.90758 found 362.90688 
calcd. for C15H9 
81Br2N 364.90553 found 364.90517. 
General procedure for the Synthesis of tne compounds 27a-m 
An oven-dried, argon-flushed sealable glass tube was charged with 3-bromo-4-(2-
bromophenyl)quinoline 26 (0.28 mmol, 100 mg), Pd2(dba)3 (5 mol%, 12.6 mg), rac-
BINAP (10 mol%, 18.3 mg), the appropriate amine, (0.41 mmol) and KOtBu 
(0.67 mmol, 74.2 mg) followed by toluene (3 mL). The tube was sealed with a Teflon 
valve and stirred at 100 °C for 24 h. The cooled reaction mixture was diluted with water 
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and extracted with ethyl acetate. The combined organic layers were dried with Na2SO4, 
filtered and concentrated in vacuum. The residue was purified by column 
chromatography using heptane/ ethyl acetate as eluent. 
7-p-tolyl-7H-indolo[2,3-c]quinoline (27a):  
27a was synthesized according to general procedure using 
3-bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 
100 mg) and 4-methylaniline (0.41 mmol, 44.3 mg) and 
was purified via column chromatography (heptane/ ethyl 
acetate). Yellow solid; yield: 80 mg (94 %); mp. 137 - 138 °C. 1H-NMR (300 MHz, 
CDCl3): δ = 9.13 (s, 1H, CHHetar), 8.80 (dd, 
3J = 8.31 Hz, 4J = 1.13 Hz, 1H, CHAr/Hetar), 
8.67 (d, 3J = 7.93 Hz, 1H, CHAr/Hetar), 8.35 (dd, 
3J = 8.12 Hz, 4J = 1.13 Hz, 1H, 
CHAr/Hetar), 7.82 - 7.69 (m, 2H, CHAr/Hetar), 7.63 - 7.56 (m, 2H, CHAr), 7.52 - 7.46 (m, 
5H, CHAr), 2.46 (s, 3H, CH3). 
13C-NMR (75.0 MHz, CDCl3): δ = 142.8 (CAr/Hetar), 141.1 
(CAr/Hetar), 138.6 (CAr), 136.9 (CHAr/Hetar), 133.6 (CAr/Hetar), 133.6 (CAr), 130.8 (2CHAr), 
130.0 (CHAr/Hetar), 127.4 (CHAr/Hetar), 127.3 (CHAr/Hetar), 127.2 (2CHAr), 126.0 
(CHAr/Hetar), 124.6 (CAr/Hetar), 123.4 (2CHAr/Hetar), 122.1(CAr/Hetar), 121.7 (CAr/Hetar), 121.4 
(CHAr/Hetar),111.3 (CHAr/Hetar), 21.3 (CH3). IR (ATR, cm
-1): ṽ = 3081 (w), 3035 (w), 
2960 (w), 2918 (w), 2854 (w), 1606 (m), 1511 (s), 1454 (m), 1329 (s), 813 (m), 756 (s), 
733 (s), 681 (m), 513 (m), 427 (s).  MS (EI, 70 eV): m/z (%) = 309 (23), 308 (M+, 100), 
307 (19), 306 (6), 292 (6), 190 (6), 146 (6). HR-MS (EI): m/z = calcd. for C22H16N2 
308.13080 found: 308.13063. 
7-(4-methoxyphenyl)-7H-indolo[2,3-c]quinoline (27b):  
27b was synthesized according to general procedure 
using 3-bromo-4-(2-bromophenyl)quinoline 26 
(0.28 mmol, 100 mg) and 4-methoxyaniline (0.41 mmol, 
50.9 mg) and was purified via column chromatography 
(heptane/ ethyl acetate). Yellow solid; yield: 85 mg 
(95 %); mp 141 - 142 °C. 1H-NMR (300 MHz, CDCl3): δ = 9.09 (s, 1H, CHHetar), 8.79 
(dd, 3J = 8.31Hz, 4J = 1.32 Hz, 1H, CHAr/Hetar), 8.66 (d, 
3J = 7.93 Hz, 1H, CHAr/Hetar), 
8.34 (dd, 3J = 8.50Hz, 4J = 1.32 Hz, 1H, CHAr/Hetar), 7.81 - 7.76 (m, 1H, CHAr/Hetar), 7.73 
- 7.68 (m, 1H, CHAr/Hetar), 7.62 - 7.58 (m, 1H, CHAr/Hetar), 7.55 - 7.46 (m, 4H, CHAr), 
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7.18 (d, 3J = 9.06 Hz, 2H, CHAr), 3.96 (s, 3H, OCH3). 
13C-NMR (75.0 MHz, CDCl3): 
δ = 159.6 (C-OCH3), 142.9 (CAr/Hetar), 141.3 (CAr/Hetar), 137.0 (CHAr/Hetar), 133.8 
(CAr/Hetar), 130.2 (CHAr/Hetar), 128.9 (CAr/Hetar), 128.7 (2CHAr), 127.3 (CHAr/Hetar), 127.2 
(CHAr/Hetar), 125.9 (CHAr/Hetar), 124.6 (CAr), 123.3 (CHAr/Hetar), 123.3 (CHAr/Hetar), 122.0 
(CAr/Hetar), 121.4 (CAr/Hetar), 121.2 (CHAr/Hetar), 115.3 (2CHAr), 111.2 (CHAr/Hetar), 55.7 
(OCH3). IR (ATR, cm
-1): ṽ = 3041 (w), 3002 (w), 2930 (w), 2835 (w), 1611 (m), 1510 
(s), 1456 (m), 1239 (s), 1186 (m), 1031 (m), 821 (s), 757 (s), 735 (s), 427 (m). MS (EI, 
70 eV): m/z (%) = 325 (24), 324 (M+, 100), 309 (26), 280 (17), 279 (16), 140 (8). HR-
MS (EI): m/z = calcd. for C22H16ON2 324.12571 found: 324.12608.  
7-(4-fluorophenyl)-7H-indolo[2,3-c]quinoline (27c):  
27c was synthesized according to general procedure using 3-
bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 
100 mg) and 4-fluoroaniline (0.41 mmol, 39.0 µL) and was 
purified via column chromatography (heptane/ ethyl 
acetate). Yellow solid; yield: 81 mg (95 %); mp. 119 - 120 °C. 1H-NMR (300 MHz, 
CDCl3): δ = 9.09 (s, 1H, CHHetar), 8.79 (dd, 
3J = 8.12Hz, 4J = 1.13 Hz, 1H, CHAr/Hetar), 
8.68 - 8.65 (m, 1H, CHAr/Hetar), 8.35 (dd, 
3J = 8.12Hz, 4J = 1.13 Hz, 1H, CHAr/Hetar), 
7.82 - 7.69 (m, 2H, CHAr/Hetar), 7.64 - 7.57 (m, 3H, CHAr), 7.53 - 7.48 (m, 2H, CHAr), 
7.42 - 7.34 (m, 2H, CHAr). 
13C-NMR (75.0 MHz, CDCl3): δ = 162.3 (d, 
1JCF = 249.24 Hz, CF), 143.1 (CAr/Hetar), 141.0 (CAr/Hetar), 136.6 (CHAr/Hetar), 133.6 
(CAr/Hetar), 132.3 (d,
 4JCF = 3.30 Hz, CAr), 130.16 (CHAr/Hetar), 129.4 (CHAr/Hetar), 129.2 
(CHAr/Hetar), 127.5 (2CHAr/Hetar), 126.2 (CHAr/Hetar), 124.5 (CAr/Hetar), 123.4 (d, 
3JCF = 8.25 Hz, 2CHAr), 122.2 (CAr/Hetar), 121.8 (CAr/Hetar), 121.6 (CHAr/Hetar), 117.3 (d, 
2JCF = 22.56 Hz, 2CHAr), 110.9 (CHAr/Hetar).
 19F-NMR (282 MHz, CDCl3): δ = -111.98 
(ArCF). IR (ATR, cm-1): ṽ = 3039 (w), 2919 (w), 1613 (m), 1510 (s), 1453 (m), 1330 
(m), 1219 (m), 1157 (m), 818 (m), 800 (m), 755 (m), 730 (s), 571 (m), 518 (m), 421 
(m). MS (EI, 70 eV): m/z (%) = 313 (22), 312 (M+, 100), 311 (31), 310 (9); 190 (6), 156 
(7). HR-MS (EI): m/z = calcd. for C21H13N2F 312.10573 found: 312.10531.  
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7-(4-chlorophenyl)-7H-indolo[2,3-c]quinoline (27d):  
27d was synthesized according to general procedure using 
3-bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 
100 mg) and 4-chloroaniline (0.41 mmol, 52.7 mg) and was 
purified via column chromatography (heptane/ ethyl 
acetate). White solid; yield: 72 mg (80 %); mp. 143 - 144 °C. 1H-NMR (300 MHz, 
CDCl3): δ = 9.11 (s, 1H, CHHetar), 8.79 (dd, 
3J = 8.51 Hz, 4J = 1.10 Hz, 1H, CHAr/Hetar), 
8.67 (d, 3J = 7.88 Hz, 1H, CHAr/Hetar), 8.35 (dd, 
3J = 8.35 Hz, 4J = 1.42 Hz, 1H, 
CHAr/Hetar), 7.83 - 7.72 (m, 2H, CHAr/Hetar), 7.70 - 7.64 (m, 2H, CHAr/Hetar), 7.62 - 7.48 
(m, 5H, CHAr). 
13C-NMR (75.0 MHz, CDCl3): δ = 143.0 (CAr/Hetar), 140.8 (CAr/Hetar), 
136.5 (CHAr/Hetar), 134.9 (CAr), 134.3 (CAr/Hetar), 132.3 (CAr/Hetar), 130.5 (2CHAr), 130.1 
(CHAr/Hetar), 128.7 (2CHAr), 127.6 (CHAr/Hetar), 127.5(CHAr/Hetar), 126.3 (CHAr/Hetar), 
124.4 (CAr/Hetar), 123.5 (CHAr/Hetar), 123.4 (CHAr/Hetar) 122.3 (CAr), 122.1 (CAr/Hetar), 121.7 
(CHAr/Hetar), 110.9 (CHAr/Hetar). IR (ATR, cm
-1): ṽ = 3074 (w), 3051 (w), 2950 (w), 2916 
(w), 1594 (m), 1495 (s), 1453 (m), 1375 (m), 1325 (m), 1092 (m), 1049 (m) 754 (s), 740 
(s), 726 (s), 682 (m), 516 (m), 426 (m). MS (EI, 70 eV): m/z (%) = 330 (M+, 32), 329 
(29), 328 (M+, 100), 327 (17), 292 (16), 190 (29), 188 (13), 164 (16), 163 (16), 111 
(23), 75 (39). HR-MS (EI): m/z = calcd. for C21H13N2Cl 328.07618 found: 328.07671; 
calcd. for C21H13N2
37Cl 330.07323 found 330.07397.  
7-(4-ethylphenyl)-7H-indolo[2,3-c]quinoline (27e):  
27e was synthesized according to general procedure using 
3-bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 
100 mg) and 4-ethylaniline (0.41 mmol, 51.0 µL) and was 
purified via column chromatography (heptane/ ethyl 
acetate). Yellow solid; yield: 80 mg (90 %); mp. 103 - 104 °C. 1H-NMR (300 MHz, 
CDCl3): δ = 9.14 (s, 1H, CHHetar), 8.80 (dd, 
3J = 8.35 Hz, 4J = 1.10 Hz, 1H, CHAr/Hetar), 
8.67 (d, 3J = 7.88 Hz, 1H, CHAr/Hetar), 8.36 (dd, 
3J = 8.51 Hz, 4J = 1.42 Hz, 1H, 
CHAr/Hetar), 7.82 - 7.67 (m, 2H, CHAr/Hetar), 7.60 - 7.57 (m, 2H, CHAr/Hetar), 7.56 - 7.46 
(m, 5H, CHAr), 2.85 (q,
 3J = 7.57 Hz, 2H, CH2), 1.40 (t, 
3J = 7.57 Hz, 3H, CH3). 
13C-
NMR (75.0 MHz, CDCl3): δ = 144.8 (CAr/Hetar), 142.9 (CAr/Hetar), 141.1 (CAr), 136.9 
(CHAr/Hetar), 133.8 (CAr), 133.6 (CAr/Hetar), 130.0 (CHAr/Hetar), 129.6 (2CHAr/Hetar), 127.3 
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(CHAr/Hetar), 127.3 (CHAr/Hetar), 127.2 (2CHAr), 126.0 (CHAr/Hetar), 124.6 (CAr/Hetar), 123.4 
(2CHAr), 122.1 (CAr/Hetar), 121.7 (CAr/Hetar), 121.3 (CHAr/Hetar), 111.3 (CHAr/Hetar), 28.6 
(CH2), 15.5 (CH3). IR (ATR, cm
-1): ṽ = 3047 (w), 2965 (w) 2926 (w), 2873 (w), 1607 
(m), 1512 (m), 1454 (m), 1382 (m), 1331 (m), 1052 (m), 756 (m), 734 (s), 683 (m), 424 
(m). MS (EI, 70 eV): m/z (%) = 323 (27), 322 (M+, 100), 307 (37), 306 (14), 305 (15), 
217 (13), 190 (15), 89 (14), 77 (10). HR-MS (EI): m/z = calcd. for C23H18N2 322.14645 
found: 322.14655. 
7-(4-ethoxyphenyl)-7H-indolo[2,3-c]quinoline (27f):  
27f was synthesized according to general procedure using 
3-bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 
100 mg) and 4-ethoxyaniline (0.41 mmol, 53.0 µL) and 
was purified via column chromatography (heptane/ ethyl 
acetate). Yellow solid; yield: 71 mg (76 %); mp. 152 - 153 °C. 1H-NMR (300 MHz, 
CDCl3): δ = 9.09 (s, 1H, CHHetar), 8.79 (dd,
 3J = 8.31 Hz, 4J = 1.32 Hz, 1H, CHAr/Hetar ), 
8.66 (d, 3J = 7.93 Hz, 1H, CHAr/Hetar), 8.35 (dd, 
3J = 8.31 Hz, 4J = 1.13 Hz, 1H, 
CHAr/Hetar), 7.82 - 7.68 (m, 2H, CHAr/Hetar), 7.62 - 7.48 (m, 5H, CHAr), 7.17 (d,
 
3J = 8.88 Hz, 2H, CHAr), 4.19 (q,
 3J = 7.0 Hz, 2H,CH2), 1.53 (t,
 3J = 7.0 Hz, 3H,CH3). 
13C-NMR (75.0 MHz, CDCl3): δ = 159.0 (C-OC2H5), 142.7 (CAr/Hetar), 141.4 (CAr/Hetar), 
136.9 (CHAr/Hetar), 133.8 (CAr/Hetar), 129.9 (CHAr/Hetar), 128.7 (2CHAr), 128.6 (CAr/Hetar), 
127.4 (CHAr/Hetar), 127.3 (CHAr/Hetar), 126.0 (CHAr/Hetar), 124.6 (CAr), 123.4 (CHAr/Hetar), 
123.3 (CHAr/Hetar), 121.9 (CAr/Hetar), 121.6 (CAr/Hetar), 121.3 (CHAr/Hetar), 115.8 (2CHAr), 
111.2 (CHAr/Hetar), 63.9 (CH2), 14.8 (CH3). IR (ATR, cm
-1): ṽ = 3079 (w), 3038 (w), 
2975 (w), 2874 (w), 1161 (m), 1509 (s), 1456 (m), 1393 (m), 1381 (m), 133 (m), 1231 
(s), 1114 (m), 1045 (m), 923 (m), 816 (m), 755 (m), 734 (s), 526 (m), 425 (m). MS (EI, 
70 eV): m/z (%) = 339 (23), 338 (M+, 100), 310 (28), 309 (48), 281 (12), 280 (28), 279 
(29), 29 (36). HR-MS (EI): m/z = calcd. for C23H18ON2 338.14136 found: 338.14116.  
7-phenyl-7H-indolo[2,3-c]quinoline (27g):   
27g was synthesized according to general procedure using 3-
bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 100 mg) 
and aniline (0.41 mmol, 38.0 µL) and was purified via column 
chromatography (heptane/ ethyl acetate). Yellow solid; yield: 
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71 mg (88 %); mp 108 - 109 °C. 1H-NMR (300 MHz, CDCl3): δ = 9.15 (s, 1H, CHHetar), 
8.81 (dd, 3J = 8.35 Hz, 4J = 1.10 Hz, 1H, CHAr/Hetar) 8.68 (d, 
3J = 7.88 Hz, 1H, 
CHAr/Hetar), 8.36 (dd, 
3J = 8.04 Hz, 4J = 0.95 Hz, 1H, CHAr/Hetar), 7.83 - 7.68 (m, 3H, 
CHAr/Hetar), 7.67 - 7.48 (m, 7H, CHAr). 
13C-NMR (75.0 MHz, CDCl3): δ = 140.9 
(CAr/Hetar), 136.9 (CHAr/Hetar), 136.3 (CAr/Hetar), 133.4 (CAr), 130.2 (2CHAr), 130.1 
(CHAr/Hetar), 128.5 (CHAr/Hetar), 127.4 (4 CHAr), 126.1 (CHAr/Hetar), 124.5 (CAr/Hetar), 123.4 
(CHAr/Hetar), 123.4 (CHAr/Hetar), 122.2 (CAr/Hetar), 121.9 (CAr/Hetar), 121.5 (CHAr/Hetar), 118.9 
(CAr/Hetar), 111.2 (CHAr/Hetar). IR (ATR, cm
-1): ṽ = 3039 (w), 2921 (w), 2851 (w), 1593 
(m), 1497 (m), 1449 (m), 1378 (m), 1330 (m), 756 (s), 734 (s), 702 (s), 678 (m), 607 
(m), 513 (m), 426 (m). MS (EI, 70 eV): m/z (%) = 29 (24), 294 (M+, 100), 293 (30), 
292 (11), 190 (21), 163 (10), 77 (33), 51 (24). HR-MS (EI): m/z = calcd. for C21H14N2 
294.11515 found: 294.11480.  
7-(3,5-dimethoxyphenyl)-7H-indolo[2,3-c]quinoline (27h):  
27h was synthesized according to general procedure using 
3-bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 
100 mg) and 3,5-dimethoxyaniline (0.41 mmol, 63.3 mg) 
and was purified via column chromatography (heptane/ 
ethyl acetate). Yellow solid; yield: 94 mg (96 %); mp. 
105 - 106 °C. 1H-NMR (250 MHz, CDCl3): δ = 9.23 (s, 1H, CHHetar), 8.80 (dd,
 
3J = 8.35 Hz, 4J = 1.10 Hz, 1H, CHAr/Hetar), 8.67 (d,
 3J = 7.88 Hz, 1H, CHAr/Hetar), 8.38 
(dd, 3J = 8.04 Hz, 4J = 0.95 Hz, 1H, CHAr/Hetar), 7.84 - 7.58 (m, 4H, CHAr/Hetar), 7.54 -
 7.47 (m, 1H, CHAr/Hetar), 6.77 (d, 
4J = 2.36 Hz, 2H, 2CHAr), 6.67 (t, 
4J = 2.36 Hz, 1H, 
CHAr), 3.88 (s, 6H, 2OCH3). 
13C-NMR (75.0 MHz, CDCl3): δ = 161.9 (2C-OCH3), 
142.4 (CAr/Hetar), 140.9 (CAr/Hetar), 137.8 (CAr/Hetar), 136.6 (CHAr/Hetar), 133.2 (CAr/Hetar), 
129.7 (CHAr/Hetar), 127.6 (CHAr/Hetar), 127.5 (CHAr/Hetar), 126.3 (CHAr/Hetar), 
124.5(CAr/Hetar), 123.4 (CHAr/Hetar), 123.4 (CHAr/Hetar), 122.2 (CAr/Hetar), 122.1 (CAr/Hetar), 
121.6 (CHAr/Hetar), 111.5 (CHAr/Hetar), 105.5 (2CHAr), 100.6 (CHAr), 55.7 (2OCH3). IR 
(ATR, cm-1): ṽ = 3048 (w), 3004 (w), 2933 (w), 2839 (w), 1591 (s), 1452 (m), 1426 
(m), 1336 (m), 1284 (m), 1203 (m), 1156 (s), 1042 (m), 825 (m), 730 (s), 679 (m), 609 
(m), 426 (m). MS (EI, 70 eV): m/z (%) = 355 (23), 354 (M+, 100), 267 (11), 190 (11), 
63 (9). HR-MS (EI): m/z = calcd. for C23H18O2N2 354.13628 found: 354.13563.  
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7-(3,4-dimethoxyphenyl)-7H-indolo[2,3-c]quinoline (27i):  
27i was synthesized according to general procedure using 
3-bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 
100 mg) and 3,4-dimethoxyaniline (0.41 mmol, 63.3 mg) 
and was purified via column chromatography (heptane/ 
ethyl acetate). White solid; yield: 88 mg (90 %); mp. 122 - 123 °C. 1H-NMR 
(300 MHz, CDCl3): δ = 9.13 (s, 1H, CHHetar), 8.79 (d, 
3J = 7.93 Hz, 1H, CHAr/Hetar), 8.67 
(d, 3J = 7.93 Hz, 1H, CHAr/Hetar), 8.34 (d, 
3J = 8.31 Hz, 1H, CHAr/Hetar), 7.81 - 7.68 (m, 
2H, CHAr/Hetar), 7.63 - 7.47 (m, 3H, CHAr/Hetar), 7.19 (dd, 
3J = 8.50 Hz. 4J = 2.27 Hz 1H, 
CHAr), 7.16 - 7.09 (m, 2H, CHAr), 4.04 (s, 3H, OCH3), 3.92 (s, 3H, OCH3). 
13C-NMR 
(75.0 MHz, CDCl3): δ = 150.1 (C-OCH3), 149.2(C-OCH3), 143.0 (CAr/Hetar), 141.3 
(CAr/Hetar), 137.1 (CHAr/Hetar), 133.8 (CAr/Hetar), 130.2 (CHAr/Hetar), 129.0 (CAr), 127.3 
(CHAr/Hetar), 127.3 (CHAr/Hetar), 125.9 (CHAr/Hetar), 124.5 (CAr/Hetar), 123.4 (2CHAr/Hetar), 
122.0 (CAr/Hetar), 121.5 (CAr/Hetar), 121.3 (CHAr/Hetar), 119.9 (CHAr), 111.8 (CHAr), 111.2 
(CHAr), 110.8 (CHAr/Hetar), 56.2 (OCH3), 56.2 (OCH3). IR (ATR, cm
-1): ṽ = 3047 (w), 
2991 (w), 2957 (w), 2832 (w), 1512 (s), 1460 (m), 1326 (m), 1257 (s), 1238 (s), 1024 
(s), 803 (m), 759 (s), 738 (m), 676 (m), 577 (m). MS (EI, 70 eV): m/z (%) = 355 (25), 
354 (M+, 100), 339 (12), 311 (11), 309 (10), 295 (12),  279 (11), 267 (14), 217 (16), 79 
(11), 51 (14). HR-MS (EI): m/z = calcd. for C23H18O2N2 354.13628 found: 354.13620. 
 7-(4-methylbenzyl)-7H-indolo[2,3-c]quinoline (27j):  
27j was synthesized according to general procedure using 
3-bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 
100 mg) and p-Methylbenzylamine (0.41 mmol, 53.0 µL) 
and was purified via column chromatography (heptane/ 
ethyl acetate). White solid; yield:  82 mg (92 %); mp. 176 -
 177 °C. 1H-NMR (300 MHz, CDCl3): δ = 9.22 (s, 1H, CHHetar), 8.76 (dd, 
3J = 8.31 Hz, 
4J = 1.32 Hz, 1H, CHAr/Hetar), 8.64 (d, 
3J = 8.12 Hz, 1H, CHAr/Hetar), 8.33 (dd, 
3J = 8.31 Hz, 4J = 1.13 Hz, 1H, CHAr/Hetar), 7.80 - 7.67 (m, 2H, CHAr/Hetar), 7.62 - 7.59 
(m, 2H, CHAr/Hetar), 7.50 - 7.43 (m, 1H, CHAr/Hetar), 7.09 (d,
 3J = 8.31 Hz, 2H, CHAr),  
7.05 (d, 3J = 8.50 Hz, 2H, CHAr), 5.71 (s, 2H, CH2), 2.29 (s, 3H, CH3). 
13C-NMR 
(75.0 MHz, CDCl3): δ = 142.5 (CAr/Hetar), 140.5 (CAr/Hetar), 137.7 (CAr/Hetar), 136.1 
(CHAr/Hetar), 133.3 (CAr), 133.0 (CHAr/Hetar), 130.0 (CAr), 129.6 (2CHAr), 127.3 
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(CHAr/Hetar), 127.2 (CHAr/Hetar), 126.3 (2CHAr), 125.9 (CHAr/Hetar), 124.6 (CAr/Hetar), 123.5 
(CHAr/Hetar), 123.2 (CHAr/Hetar), 122.0 (CAr/Hetar), 121.5 (CAr/Hetar), 120.8 (CHAr/Hetar), 110.4 
(CHAr/Hetar), 46.8 (CH2), 21.0 (CH3). IR (ATR, cm
-1): ṽ = 3051 (w), 3025 (w), 2918 (w), 
2851 (w), 1612 (m), 1515 (m), 1330 (m), 757 (m), 745 (s), 734 (s), 677 (m), 604 (m), 
593 (m), 514 (m), 426 (m). MS (EI, 70 eV): m/z (%) = 322 (M+, 29), 218 (11), 217 
(34), 216 (10), 190 (17), 105 (100), 103 (13), 79 (17), 77 (20). HR-MS (EI): 
m/z = calcd. for C23H18N2 322.14645 found: 322.14599. 
7-(4-methoxybenzyl)-7H-indolo[2,3-c]quinoline (27k):  
27k was synthesized according to general procedure using 
3-bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 
100 mg) and 4-methoxybenzylamine (0.41 mmol, 
54.0 µL) and was purified via column chromatography 
(heptane/ ethyl acetate). Yellow solid; yield: 66 mg 
(71 %); mp. 132 - 133 °C. 1H-NMR (300 MHz, CDCl3): δ = 9.23 (s, 1H, CHHetar), 8.74 
(dd, 3J = 8.31 Hz, 4J = 1.32 Hz, 1H, CHAr/Hetar), 8.63 (d, 
3J = 8.12 Hz, 1H, CHAr/Hetar), 
8.33 (dd, 3J = 8.12 Hz, 4J = 1.32 Hz, 1H, CHAr/Hetar), 7.79 - 7.66 (m, 2H, CHAr/Hetar), 
7.62 - 7.59 (m, 2H, CHAr/Hetar), 7.50 - 7.42 (m, 1H, CHAr/Hetar), 7.10 (d, 
3J = 8.88 Hz, 2H, 
CHAr), 6.80 (d, 
3J = 8.88 Hz, 2H, CHAr), 5.68 (s, 2H, CH2), 3.74 (s, 3H, OCH3). 
13C-
NMR (75.0 MHz, CDCl3): δ = 159.3 (C-OCH3), 142.6 (CAr/Hetar), 140.4 (CAr/Hetar), 136.2 
(CHAr/Hetar), 132.9 (CAr/Hetar), 130.1 (CHAr/Hetar), 128.4 (CAr/Hetar), 127.7 (2CHAr), 127.3 
(CHAr/Hetar), 127.2 (CHAr/Hetar), 125.8 (CHAr/Hetar), 124.6 (CAr), 123.5 (CHAr/Hetar), 123.2 
(CHAr/Hetar), 122.0 (CAr/Hetar), 121.4 (CAr/Hetar), 120.8 (CHAr/Hetar), 114.4 (2CHAr), 110.4 
(CHAr/Hetar), 55.2 (OCH3), 46.5 (CH2). IR (ATR, cm
-1): ṽ = 3051 (w), 300 (w), 2935 
(w), 2835 (w), 1612 (m), 1512 (s), 1470 (m), 1288 (m), 1243 (s), 1180 (m), 1038 (m), 
760 (s), 727 (s), 606 (m), 424 (m). MS (EI, 70 eV): m/z (%) = 338 (M+, 19), 217 (29), 
190 (15), 121 (100), 78 (17), 77 (14). HR-MS (EI): m/z = calcd. for C23H18ON2 
338.14136 found: 338.14124.  
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7-(4-fluorobenzyl)-7H-indolo[2,3-c]quinoline (27l):   
27l was synthesized according to general procedure using 3-
bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 
100 mg) and 4-fluorobenzylamine (0.41 mmol, 47.0 µL) 
and was purified via column chromatography (heptane/ 
ethyl acetate). Yellow solid; yield: 80 mg (89 %); mp. 129 -
 130 °C. 1H-NMR (300 MHz, CDCl3): δ = 9.20 (s, 1H, CHHetar), 8.75 (dd, 
3J = 8.31 Hz, 
4J = 1.32 Hz, 1H, CHAr/Hetar), 8.64 (d, 
3J = 8.12 Hz, 1H, CHAr/Hetar), 8.33 (dd, 
3J = 8.12 Hz, 4J = 1.13 Hz, 1H, CHAr/Hetar), 7.80 - 7.70 (m, 2H, CHAr/Hetar), 7.68 - 7.56 
(m, 2H, CHAr/Hetar), 7.50 - 7.45 (m, 1H, CHAr/Hetar), 7.14 - 7.09 (m, 2H, CHAr), 6.99 -
 6.93 (m, 2H, CHAr), 5.72 (s, 2H, CH2). 
13C-NMR (75.0 MHz, CDCl3): δ = 162.3 (d, 
1JCF = 246.49 Hz, CF), 142.7 (CAr/Hetar), 140.3 (CAr/Hetar), 135.9 (CHAr/Hetar), 132.9 
(CAr/Hetar), 132.1 (d, 
4JCF = 3.30 Hz, CAr), 130.1 (CHAr/Hetar), 128.0 (d, 
3JCF = 8.25 Hz 
2CHAr), 127.4 (CHAr/Hetar), 127.3 (CHAr/Hetar), 126.0 (CHAr/Hetar), 124.6 (CAr), 123.6 
(CHAr/Hetar), 123.2 (CHAr/Hetar), 122.1 (CAr/Hetar), 121.6 (CAr/Hetar), 121.0 (CHAr/Hetar), 115.9 
(d, 2JCF = 22.01 Hz, 2CHAr), 110.2 (CHAr/Hetar), 46.3 (CH2). 
19F-NMR (282 MHz, 
CDCl3): δ = -114.13 (Ar-F). IR (ATR, cm
-1): ṽ = 3047 (w), 2928 (w), 1602 (m), 1507 
(m), 1330 (m), 1217 (m), 1152 (m), 820 (m), 756 (s), 733 (s), 682 (m), 605 (m), 483 
(m), 423 (m). MS (EI, 70 eV): m/z (%) = 326 (M+, 26), 217 (24), 190 (12), 109 (100), 
83 (16). HR-MS (EI): m/z = calcd. for C22H15N2F 326.12138 found: 326.12116.  
7-cyclopentyl-7H-indolo[2,3-c]quinoline (27m):  
27m was synthesized according to general procedure using 3-
bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 100 mg) 
and cyclopentyl amine (0.41 mmol, 41.0 µL) and was purified 
via column chromatography (heptane/ ethyl acetate). Yellow 
solid; yield: 72 mg (91 %); mp. 56 - 57 °C. 1H-NMR (300 MHz, CDCl3): δ = 9.39 (s, 
1H, CHHetar), 8.77 (dd, 
3J = 8.31 Hz, 4J = 1.32 Hz, 1H, CHAr/Hetar), 8.65 (d, 
3J = 8.12 Hz, 
1H, CHAr/Hetar), 8.33 (dd, 
3J = 8.31 Hz, 4J = 1.32 Hz, 1H, CHAr/Hetar), 7.78 - 7.60 (m, 4H, 
CHAr/Hetar), 7.44 (ddd, 
3J = 8.12 Hz, 3J = 6.99 Hz, 4J = 1.13 Hz, 1H, CHAr/Hetar), 5.39 
(quin, 3J = 9.06 Hz. 1H, CH;alkyl), 2.51 - 2.41 (m, 2H, CH2;alkyl), 2.38 - 2.29 (m, 2H, 
CH2;alkyl), 2.26 - 2.13 (m, 2H, CH2;alkyl), 2.01 - 1.87 (m, 2H, CH2;alkyl). 
13C-NMR 
N
N
F
N
N
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(75.0 MHz, CDCl3): δ = 141.9 (C), 139.6 (C), 136.6 (CH), 132.3 (C), 129.9 (CH), 127.2 
(CH), 126.7 (CH), 125.7 (CH), 124.8 (C), 123.7 (CH), 123.1 (CH), 122.2 (C), 121.6 
(C), 120.4 (CH), 111.2 (CH), 56.2 (CH;alkyl), 30.5 (2CH2;alkyl), 25.4 (2CH2;alkyl). IR 
(ATR, cm-1): ṽ = 3049 (w), 2919 (s), 2850 (m), 1612 (m), 1512 (m), 1460 (m), 1331 
(m), 1295 (m), 1165 (m), 760 (s), 746 (s), 685 (m), 610 (m), 427 (m). MS (EI, 70 eV): 
m/z (%) = 287 (14), 286 (M+, 58), 257 (10), 219 (16), 218 (100), 217 (61), 216 (18), 
191 (11), 190 (37), 189 (13), 188 (12), 164 (12), 163 (11), 69 (29), 41 (50), 39 (16). 
HR-MS (EI): m/z = calcd. for C20H18N2 286.14645 found: 286.14619. 
General procedure for the Synthesis of tne compounds 27n-o 
An oven-dried, argon-flushed sealable glass tube was charged with 3-bromo-4-(2-
bromophenyl)quinoline 26 (0.28 mmol, 100 mg), Pd2(dba)3 (5 mol%, 12.6 mg), rac-
BINAP (10 mol%, 18.3 mg), the appropriate amine, (0.41 mmol) and KOtBu 
(0.67 mmol, 74.2 mg) followed by xylene (isomeric mixture) (3 mL). The tube was 
sealed with a Teflon valve and stirred at 140 °C for 24 h. The cooled reaction mixture 
was diluted with water and extracted with ethyl acetate. The combined organic layers 
were dried with Na2SO4, filtered and concentrated in vacuum. The residue was purified 
by column chromatography using heptane/ ethyl acetate as eluent. 
7-n-hexyl-7H-indolo[2,3-c]quinoline (27n):  
27n was synthesized according to general procedure using 3-
bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 100 mg) 
and n-hexylamine (0.41 mmol, 55.0 µL) and was purified via 
column chromatography (heptane/ ethyl acetate). Yellow solid; 
yield: 71 mg (85 %); mp. 113 - 114 °C. 1H-NMR (300 MHz, 
CDCl3): δ = = 9.28 (s, 1H, CHHetar), 8.74 (dd, 
3J = 8.20 Hz, 4J = 0.95 Hz, 1H, 
CHAr/Hetar), 8.61 (d, 
3J = 8.20 Hz, 1H, CHAr/Hetar), 8.33 (dd, 
3J = 8.20 Hz, 4J = 0.95 Hz, 
1H, CHAr/Hetar), 7.77 - 7.73 (m, 1H, CHAr/Hetar), 7.70 - 7.66 (m, 1H, CHAr/Hetar), 7.64 -
 7.61(m, 2H, CHAr/Hetar), 7.46 - 7.43 (m, 1H, CHAr/Hetar), 4.54 (t,
 3J = 7.25 Hz, 2H, CH2), 
2.0 - 1.94 (m, 2H, CH2), 1.36 - 1.25 (m, 6H,3CH2), 0.86 (t,
 3J = 7.25 Hz, 3H, CH3). 
13C-
NMR (75.0 MHz, CDCl3): δ = 142.5 (C), 140.1 (C), 136.1 (CH), 132.9 (C), 130.1 
(CH), 127.2 (CH), 126.9 (CH), 125.6 (CH), 124.7 (C), 123.5 (CH), 123.2 (CH), 121.9 
(C), 120.9 (C), 120.5 (CH), 110.2 (CH), 43.5 (CH2), 31.5 (CH2), 29.7 (CH2), 26.9 
N
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(CH2), 22.5 (CH2), 13.9 (CH3). IR (ATR, cm
-1): ṽ = 3053 (w), 2950 (m), 2923 (m), 
2853 (m), 1613 (m), 1560 (m), 1513 (m), 1513 (m), 1459 (m), 1379 (m), 1331 (m), 755 
(m), 743 (s), 730 (s), 602 (m), 422 (m). MS (EI, 70 eV): m/z (%) = 302 (M+, 50), 232 
(18), 231 (100), 217 (6), 190 (5), 176 (6). HR-MS (EI): m/z = calcd. for C21H22N2 
302.17775 found: 302.17760. 
7-n-butyl-7H-indolo[2,3-c]quinoline (27o):  
 
27o was synthesized according to general procedure using 3-
bromo-4-(2-bromophenyl)quinoline 26 (0.28 mmol, 100 mg) and 
 n-butylamine (0.41 mmol, 55.0 µL) and was purified via column 
chromatography (heptane/ ethyl acetate). Yellow solid; yield: 
66 mg (88 %); mp. 103 - 104 °C. 1H-NMR (300 MHz, CDCl3): δ = 9.28 (s, 1H, 
CHHetar), 8.73 (dd, 
3J = 8.31 Hz, 4J = 1.32 Hz, 1H, CHAr/Hetar), 8.61 (d, 
3J = 8.12 Hz, 1H, 
CHAr/Hetar), 8.32 (dd, 
3J = 8.31 Hz, 4J = 1.32 Hz, 1H, CHAr/Hetar), 7.78 - 7.67 (m, 2H, 
CHAr/Hetar), 7.66 - 7.60 (m, 2H, CHAr/Hetar), 7.47 - 7.41 (m, 1H, CHAr/Hetar), 4.55 (t,
 
3J = 7.18 Hz, 2H, CH2), 2.01 - 1.91 (m, 2H, CH2), 1.48 - 1.36 (m, 2H, CH2), 0.96 (t, 
3J = 7.36 Hz, 3H, CH3). 
13C-NMR (75.0 MHz, CDCl3): δ = 142.6 (C), 140.6 (C), 136.2 
(CH), 132.9 (C), 130.2 (CH), 127.1 (CH), 126.8 (CH), 125.6 (CH), 124.7 (C), 123.5 
(CH), 123.2 (CH), 121.9 (C), 120.9 (C), 120.4 (CH), 110.1 (CH), 43.2 (CH2), 31.8 
(CH2), 20.5 (CH2), 13.8 (CH3). IR (ATR, cm
-1): ṽ = 3056 (w), 2950 (w), 2926 (w), 
2867 (w), 1613 (m), 1561 (m), 1513 (m), 1469 (m), 1437 (m), 1513 (m), 1469 (m), 
1381 (m), 1348 (m), 1332 (s), 1293 (m), 1250 (m), 1151 (m), 757 (m), 742 (m), 729 
(m),4223 (m). MS (EI, 70 eV): m/z (%) = 274 (M+, 44), 232 (17), 231 (100), 217 (8), 
190 (6), 176 (7). HR-MS (EI): m/z = calcd. for C19H18N2 274.14645 found: 274.14637. 
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5.3. Crystallographic Data 
 
Crystal data and structure refinement for 4-bromo-2,3,5-trichloro-6-iodopyridine (3) 
  is_lo002n 
Crystal data 
Chemical formula  0.87(C5BrCl3IN)·0.13(C5BrCl4N)  
Mr 375.56 
Crystal system, space group Tetragonal, P41212 
Temperature (K) 123 
a, c (Å) 5.4082 (3), 30.402 (2) 
V (Å3) 889.22 (12) 
Z 4 
Radiation type Mo Kα 
µ (mm−1) 8.52 
Crystal size (mm) 0.16 × 0.09 × 0.04 
Data collection 
Diffractometer Bruker Apex Kappa-II-CCD- 
diffractometer 
Absorption correction Multi-scan  
(SADABS; Sheldrick, 2004) 
Tmin, Tmax 0.564, 0.746 
No. of measured, independent and 
observed [I > 2σ(I)] reflections 
9706, 1470, 1318  
Rint 0.063 
(sin θ/λ)max (Å
−1) 0.735 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.048, 0.089, 1.28 
No. of reflections 1470 
No. of parameters 57 
Δρmax, Δρmin (e Å
−3) 0.70, −1.10 
Absolute structure Refined as an inversion twin.  
Absolute structure parameter 0.05 (4) 
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Crystal data and structure refinement for 4-bromo-2,3,5-trichloro-6-(4-chlorophenyl) 
pyridine  (4k) 
 is_r25 
Crystal data 
Chemical formula C11H4BrCl4N  
Mr 371.86 
Crystal system, space group Monoclinic, P21/c 
Temperature (K) 123 
a, b, c (Å) 3.8934 (2), 25.7303 (14), 12.1698 (7) 
β (°) 95.006 (2) 
V (Å3) 1214.50 (11) 
Z 4 
Radiation type Mo Kα 
µ (mm−1) 4.24 
Crystal size (mm) 0.99 × 0.02 × 0.02 
Data collection 
Diffractometer Bruker D8 QUEST  
diffractometer 
Absorption correction Multi-scan  
(SADABS; Sheldrick, 2004) 
Tmin, Tmax 0.603, 0.746 
No. of measured, independent and 
observed [I > 2σ(I)] reflections 
35706, 2924, 2436  
Rint 0.243 
(sin θ/λ)max (Å
−1) 0.661 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.055, 0.128, 1.10 
No. of reflections 2924 
No. of parameters 154 
H-atom treatment H-atom parameters constrained 
Δρmax, Δρmin (e Å
−3) 1.25, −0.97 
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Crystal data and structure refinement for 2-(4-methoxyphenyl)-3,5-diphenyl-4,6-di-p-
tolylpyridine (11a) 
 is_r266 
Crystal data 
Chemical formula C38H31NO  
Mr 517.64 
Crystal system, space group Monoclinic, P21/c 
Temperature (K) 123 
a, b, c (Å) 9.9547 (5), 15.7621 (8), 18.305 (1) 
β (°) 92.577 (3) 
V (Å3) 2869.3 (3) 
Z 4 
Radiation type Mo Kα 
µ (mm−1) 0.07 
Crystal size (mm) 0.40 × 0.12 × 0.12 
Data collection 
Diffractometer Bruker Apex Kappa-II-CCD- 
diffractometer 
Absorption correction Multi-scan  
(SADABS; Sheldrick, 2004) 
Tmin, Tmax 0.678, 0.746 
No. of measured, independent and 
observed [I > 2σ(I)] reflections 
42507, 7621, 5721  
Rint 0.045 
(sin θ/λ)max (Å
−1) 0.682 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.046, 0.121, 1.02 
No. of reflections 7621 
No. of parameters 395 
No. of restraints 45 
H-atom treatment H-atom parameters constrained 
Δρmax, Δρmin (e Å
−3) 0.30, −0.23 
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Crystal data and structure refinement for 2-(trifluoromethyl)-4,6-diphenylquinoline (21a) 
 is_rp3-1 
Crystal data 
Chemical formula C22H14F3N  
Mr 349.34 
Crystal system, space group Monoclinic, P21/c 
Temperature (K) 173 
a, b, c (Å) 9.7957 (4), 6.7048 (2), 25.3358 (9) 
β (°) 98.093 (2) 
V (Å3) 1647.44 (10) 
Z 4 
Radiation type Mo Kα 
µ (mm−1) 0.11 
Crystal size (mm) 0.20 × 0.11 × 0.11 
Data collection 
Diffractometer Bruker-Nonius Apex X8-CCD- 
diffractometer 
Absorption correction Multi-scan  
(SADABS; Sheldrick, 2004) 
Tmin, Tmax 0.709, 0.746 
No. of measured, independent and 
observed [I > 2σ(I)] reflections 
20385, 4151, 2804  
Rint 0.050 
(sin θ/λ)max (Å−1) 0.671 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.060, 0.113, 1.10 
No. of reflections 4151 
No. of parameters 299 
No. of restraints 19 
H-atom treatment H-atom parameters constrained 
Δρmax, Δρmin (e Å−3) 0.29, −0.22 
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Crystal data and structure refinement for 2-(trifluoromethyl)-4-(4-
(trifluoromethyl)phenyl)-6-p-tolylquinoline (24c) 
Identification code                  is_rp413 
Crystal data 
Chemical formula C24H15F6N 
Mr 431.37 
Crystal system, space group Triclinic, P  
Temperature (K) 173 
a, b, c (Å) 10.4516 (2), 12.8402 (3), 16.7333 (3) 
α, β, γ (°) 106.412 (1), 94.990 (1), 112.592 (1) 
V (Å3) 1939.75 (7) 
Z 4 
Radiation type Mo Kα 
µ (mm−1) 0.13 
Crystal size (mm) 0.44 × 0.25 × 0.23 
Data collection 
Diffractometer Bruker Apex Kappa II-CCD- 
diffractometer 
Absorption correction Multi-scan  
(SADABS; Sheldrick, 2004) 
Tmin, Tmax 0.720, 0.746 
No. of measured, independent and 
observed [I > 2σ(I)] reflections 
58961, 11306, 8706  
Rint 0.021 
(sin θ/λ)max (Å−1) 0.703 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.055, 0.158, 1.02 
No. of reflections 11306 
No. of parameters 636 
No. of restraints 38 
H-atom treatment H-atom parameters constrained 
Δρmax, Δρmin (e Å−3) 0.73, −0.41 
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